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ABSTRACT
Outbreaks of hepatitis A amongst hemophiliacs receiving solvent detergent treated factor 
v m  in Europe and the USA have recently caused concern to blood product 
manufacturers and control agencies. In this study, the use of terminal dry heat treatment 
to inactivate HAV (strains HM175A.2 and HM175/18f) in spiked factor Vm was 
assessed using tissue culture based HAV assays, including a novel cytopathic microtitre 
plate assay, and a quantitative RT-PCR assay. The infectivity of HAV was quickly 
destroyed by heating to 80 ®C. However, it was not until samples were heated to 100 ®C 
for 8 hr that PCR positivity was lost. The use of nucleic acid amplification techniques in 
blood transfusion virology is increasing due to the lack of suitable cell culture assays for 
viruses such as HCV and parvovirus B19. This study shows that ability to detect viral 
genome in blood products does not necessarily imply the presence of infectious virus 
after the use of virucidal treatments. The relationship between PCR positivity and 
infectivity of HAV was further assessed in a time course study of cytopathic HAV 
HM175A.2 replication in BS-C-1 cells. Titres of released HAV RNA were similar to that 
of infectious virus with a ratio of 2 genome equivalents per infectious unit, whereas 19 
genome equivalents per infectious unit were found associated with the cell. The 
infectious titre of contaminating HAV in blood products prior to viral inactivation was 
similar to that of HAV RNA. Comparison of infectious titres with genome copies of 
HAV during the time course demonstrated that little viral RNA was available for 
replication in the early stages of infection due to efficient encapsidation. The uptake and 
replication of the less cytopathic strain, HM175/18f, was slower than that of HM175A.2, 
however similar RNA titres were reached. The ability of HAV to cause cytopathology 
may be related to rate of replication. The attenuation of HM175A.2 and HM175/18f was 
studied in a tamarin model. HAV HM175/18f showed a degree of attenuation compared 
to wild type HM175 and HM175A.2 appeared to be completely attenuated. There was no 
difference in time of seroconversion between strains. HAV HM175A.2 may prove to be a 
suitable vaccine strain.
ACKNOWLEDGEMENTS
I wish to express my gratitude to Dr J. Saldanha for his helpful advice and 
encouragement throughout my studentship. I am also thankful to Dr D. Wood and Dr P: 
Minor their guidance during the project and in the preparation of this manuscript. I 
would like to thank Dr M. Taylor for performing the in situ hybridization, Mr G. Bevan 
for histological processing, Ms L. Young for maintenance of cell lines, Mr A. Heath for 
statistical help and Mr A. Davies and Mr R. Longuehaye for the photographs. Special 
thanks to my husband, Paul, for his encouragement and emotional support. I would also 
like to thank my family, friends and colleagues for their care and friendship. Finally, I 
would like to thank the National Biological Standards Board for financial support.
. %
PUBLISHED WORK
The following publication has arisen from work presented in this manuscript;
Beales, L. P., Wood, D. J., Minor, P. D. and Saldanha, J. A. (1996) A novel cytopathic 
microtitre plate assay for hepatitis A virus and anti-hepatitis A neutralizing antibodies, J. 
Virol M etk, 59: 147-154.
A
LIST OF FIGURES
Page
1.1 Genome structure of HAV. 21
1.2 Post translational processing of HAV proteins. 27
1.3 The process of reverse transcription and PCR. 46
2.1 Protein dot blot of fractions from large scale purification of HAV 54
HM175A.2.
2.2 Comparison ofRNA and cDNA PCR titrations. 60
3.1 Cytopathology of HAV HM175A.2 and HM175/18f in BS-C-1 63
cells.
3.2 Effect of cell concentration on the cytopathic microtitre plate 66
assay for HAV.
3.3 Effect of PCS concentration on the cytopathic microtitre plate 67
assay for HAV.
3.4 Effect of sodium chloride concentration on the cytopathic 68
microtitre plate assay for HAV.
3.5 Cytopathic microtitre plate assay of HAV HM175A.2. 69
3.6 Cytopathic microtitre plate assay of HAV HM175/18f 70
3.7 Assay of WHO immune serum globulin standard for HAV 73
neutralising antibodies.
3.8 Neutralisation of HAV HM175A.2 cytopathology by pooled 74
human sera and mouse sera from vaccine potency tests.
3.9 Comparison of proteinase K / SDS RNA extraction with the 75
QIAmp viral RNA kit
3.10 Optimisation of RT-PCR for HAV RNA. 78
3.11 Map of pGEM-T vector 80
3.12 Purification of amplification products. 81
3.13 Restriction enzyme digestion of products from small scale 83
plasmid preparations.
3.14 Restriction enzyme digestion of product from large scale 85
preparation of plasmid pGEM-HAV5.
3.15 Estimation of size of restriction enzyme digestion products. 85
Page
3.16 . In vitro transcribed HAV RNA. 88
3.17 RT-PCR of ten fold dilutions of In vitro transcribed HAV RNA. 91
3.18 Example PCR titration of in vitro transcribed RNA 92
4.1 Terminal dry heat inactivation of HAV in spiked factor VDI 100
(SNBTS).
4.2 Example quantitative PCR titration of HAV spiked factor VOX 101
4.3 Terminal dry heat inactivation of HAV in spiked factor Vm 104
(BPL).
4.4 Reverse transcription and PCR primers. 105
4.5 Non specific priming of reverse transcription. 106
4.6 Analysis of the integrity of heat treated HAV in spiked factor 110
vm.
4.7 Elimination of HAV by monoclonal affinity purification of 112
spiked factor Vm.
4.8 Half life of RNA integrity during dry heat inactivation 115
5.1 Immunofiuorescent staining of HAV HM175A.2 infected BS-C-1 126.
cells.
5.2 In situ hybridisation of HAV HM175A.2 infected BSC-1 cells. 128
5.3 Accumulation and release of HM175A.2 infectious particles and 130
genome in BS-C-1 cells.
5.4 Total HM175A.2 infectious particles and genome in BS-C-1 131
cells.
5.5 Example quantitative RT-PCR assay of cell associated 133
HM175A.2.
5.6 Accumulation and release of HM175/18f RNA in BS-C-1 cells. 135
5.7 Comparison of RNA replication of HAV HM175A.2 and 142
HM175/18fin BS-C-1 cells.
6.1 Enzymatic reactions involved in the measurement of ALT levels. 147
6.2 Faecal shedding of HAV HM175/wt. 152
6.3 Example quantitative RT-PCR assay of HAV in tamarin faeces. 153
6.4 Faecal shedding of HAV HM175/18f.
Page
155
6.5 Serum ALT levels in Group 1 tamarins (HM175/wt). 160
6.6 Serum ALT levels in Group 2 tamarins (HMl 75/18f). 161
6.7 Serum ALT levels in Group 3 tamarins (HM175A.2). 162
6.8 Histological analysis of tamarin liver biopsies. 164
6.9 Immunohistochemical staining of HAV antigen of tamarin liver 
biopsies.
172
6.10 Replication and virulence of HAV HM175/wt in tamarins. 181
6.11 Replication and virulence of HAV HMl 75/18f in tamarins. 182
LIST OF TABLES
Page
1.1 Prevalence of anti-HAV antibodies in adult populations 17
1.2 Geographic localisation of human HAV genotypes 18
1.3 Comparison of characteristics of the genera of picomaviruses 20
1.4 HAV non-structural proteins 24
1.5 Cell culture adapted cytopathic strains of HAV 28
1.6 Common nucleotide changes occurring during adaptation of HAV to 30
growth in tissue culture
2.1 Variants of HAV HMl 75 used in this study 48
3.1 Optimisation of cell concentration 65
3.2 Optimisation of assay conditions 65
3.3 Example of endpoint titratioA 70
3.4 Repeat assays of HAV HM175A.2 preparation 13 71
3.5 Variation between assays 71
3.6 Restriction analysis of pGEM^HAV5 86
3.7 Composition of transcribed RNA 90
3.8 Assay of transcribed RNA 90
4.1 Terminal dry heat treatment of HAV spiked factor VQI (SNBTS) 100
4.2 Terminal dry heat treatment of HAV spiked replenate factor VTU 103
(BPL)
4.3 Reverse transcription and PCR primer sequences 105
4.4 Prevention of non-specific priming during reverse transcription of 108
HAV RNA
5.1 Oligonucleotide probes 124
5.2 Levels of cell and medium associated HAV HM175A.2 tissue culture 132 
infectious particles following infection of BS-C-1 cells
5.3 Levels oJTcell and medium associated HAV HM175A.2 RNA 135
following infection of BS-C-1 cells -
6.1 Inoculation of tamarins
Page
144
6.2 Collection of samples from tamarins 144
6.3 Excretion of HAV RNA 154
6.4 HAV viraemia in Group 1 tamarins (HM175/wt) 156
6.5 Performance of Murex HAV VK38 assays 157
6.6 Detection of total anti-HAV in inoculated tamarins 158
6.7 Levels of Serum ALT in inoculated tamarins 159
6.8 Histological analysis of liver biopsies from inoculated tamarins 170
6.9 Immunohistochemical analysis of liver biopsies from inoculated 
tamarins
178
6.10 Amino acid alterations in the PI region of HM175 pl6 and 180
HM175/18f
Chapter 1 
INTRODUCTION
1.1 HISTORY
Symptoms of liver disease were documented as early as 5^ century BC in the Babylonian 
Talmud which describes the common appearance of jaundice in the population. In Greek 
and Roman literature of the same era the epidemic nature of some liver conditions was 
noted. Hippocrates (460-375 BC) classified an epidemic form of jaundice as the ‘fourth 
kind of jaundice’, however, contemporary understanding of the nature of epidemic 
diseases was based on the four humours which included yellow bile as a common source 
of fever. In the 8* century AD, in a letter to St. Boniface, Archbishop of Mainz, Pope 
Zacharias encouraged the separation of jaundiced individuals fi-om others due to the 
contagious nature of the disease.
Sporadic outbreaks of epidemic jaundice were not commonly noted until the 18^ century 
when written accounts reported several epidemics which occurred throughout Europe 
(reviewed by Achemknecht, 1968). Epidemic jaundice has been a particular problem 
amongst the military during wars fi-om the Middle Ages and therefore became known as 
‘campaign jaundice'. Extremely large epidemics of hepatitis were recorded during both 
the First and Second world wars. This campaign jaundice was usually characterised by 
transient fever, malaise, headache, anorexia, nausea, abdominal discomfort and 
eventually, the appearance of jaundice (Macpherson et al, 1921).
The common view during the 19* century was that jaundice was due to swelling and 
obstruction of the hepatic duct or the common bile duct, rather than disease of the liver 
itself, giving rise to the terms obstructive or catarrhal jaundice (MacCallum, 1972). 
However, several clinicians at that time suspected the liver to be the site of primary 
pathology and that infection had a role in the aetiology of jaundice. In 1912, Cockayne 
described epidemic jaundice as infectious hepatitis, postulating that the pathogen reaches 
the liver via the blood being transmitted by the aerosol route. A popular belief at this
time, as expressed by McDonald (1908) was that an infectious agent caused necrosis of a 
previously damaged liver. Both Cockayne and McDonald proposed that the pathogen 
may be a virus due to the epidemic nature of the disease and the inability to isolate a 
bacterial agent. This view soon gained support (Martin, 1915; Stokes et al., 1920; 
Findlay et al., 1931). In a report on outbreaks of epidemic hepatitis in the USA between 
1918 and 1922, Blumer (1923) established the occurrence of infectious hepatitis, now 
known as infectious hepatitis type A. It was not until during and after the Second World 
War when human volunteer studies were performed that the viral aetiology of hepatitis 
was finally established (reviewed by MacCallum et al., 1951; Havens, 1947; 1963).
The earliest report of jaundice being transmitted via serum was in 1883 amongst 
shipyard workers of Bremen (reviewed by MacCallum, 1947). After vaccination against 
smallpox with glycerated human lymph, 191 of 1289 vaccinated employees became 
jaundiced within 6 months. It was discovered that workers inoculated with a different 
batch of lymph did not develop symptoms of hepatitis. Early in the 20* century, the use 
of long needles in Salvarsen therapy administered by venepuncture in the treatment of 
syphilis brought about reports of outbreaks of jaundice occurring at many venereal 
disease clinics (Bigger, 1948). Due to the high numbers of patients at these clinics, there 
was not time to sterilise needles between each patient. Outbreaks of jaundice were also 
attributed to thé use of shared needles in administration of insulin to diabetics and gold 
injections to sufferers of rheumatoid arthritis (MacCallum, 1943). After an outbreak of 
41 cases of jaundice and subsequently 8 deaths following immunisation against measles 
using a convalescent human serum, a report by MacNalty for the Ministry of Health 
(1938) classified this type of jaundice as serum hepatitis. The spread of this disease after 
administration of otiier human serum based immunotherapies and on transfusion of 
serum, plasma or whole blood became a recognised risk.
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Epidemiological observations led to the classification of infectious hepatitis and serum 
hepatitis into 2 distinct groups based mainly on length of incubation period and route of 
transmission. In 1947, MacCallum proposed the names hepatitis type A for infectious 
hepatitis and hepatitis type B for serum hepatitis which were adopted in 1973 by the 
Scientific Group on Viral Hepatitis of the World Health Organisation.
Between 1956 and 1973 studies were carried out by Krugman and co-workers (Krugman 
et al., 1967; Krugman and Giles, 1970) at an institution for the mentally handicapped in 
New York which confirmed that there were 2 distinct groups of viral hepatitis. 
Epidemics of hepatitis were fi-equent at this institution and the majority of children 
acquired the illness within the first 6-12 months after admission. Using subjects at the
school, it was shown that by about 4 weeks after inoculation with serum MS-1, children
(
became ill with a type of hepatitis that was highly transmissible by contact, typical of 
hepatitis A. Children inoculated with another serum, MS-2 did not develop symptoms as 
quickly (Incubation period > 3 months) and did not generally pass on the virus by 
contact. The immunoreactivity of the MS-1 strain was impaired by heating to 98 ®C for 
1 minutes whereas that of MS-2 was unaffected (Krugman et a l, 1970). The MS-1 agent 
was subsequently classified as a type A hepatitis virus and MS-2 as type B hepatitis virus. 
When adult volunteers were inoculated with MS-1 agent, they developed the same 
symptoms as the inoculated children (Boggs et a l, 1970). The pathogen was extracted 
from the stools of these patients and identified as a virus-like agent by immune electron 
microscopy by Feinstone et a/.(1973).
After many finstrated attempts by several groups, Provost and Hilleman (1979) 
demonstrated infection of primary marmoset liver cell cultures and foetal rhesus monkey 
kidney cells with hepatitis A virus strain CR326 which had been serially passaged in
11
marmosets (Mascoli et a l, 1973). Despite the long history of HAV infection, acquisition 
of knowledge about the biology of the virus has been extremely difficult. The slow 
growth and inability to produce high titres of HAV in tissue culture have particularly 
hindered attempts to study the virus.
1.2 PATHOGENESIS
Hepatitis A virus is transmitted via oral and percutaneous routes, usually by ingestion of 
food or drink contaminated with faeces containing the virus. The main site of viral 
replication and pathogenesis is the liver, however, the early events of infection in which 
the virus travels via the gastrointestinal tract to the liver remained little understood. 
Attempts to demonstrate primary extrahepatic replication of HAV have been 
inconclusive. Detection of HAV in the saliva of both humans (Purcell et a l, 1984) and 
experimentally inoculated chimpanzees (Cohen et a l, 1989) suggested that the virus 
replicates in the salivary glands however replication at this site has not been shown. 
Lemon (1985) suggested that the HAV may have been detected in the saliva due to 
contamination with viraemic blood.
The incubation period for HAV in humans is usually between 15-50  days with a mean 
of 30 days. A transient viraemic phase lasting up to 2 weeks occurs before thé onset of 
disease symptoms. Purcell and co-workers (1984) found the maximum titre of HAV 
detected in peripheral blood to be 10^  chimpanzee infectious units per ml. Faecal 
shedding also commences towards the end of the incubation period and is at a peak 
immediately prior to the onset of early disease symptoms. In the above study, viral titres 
of up to 10^  chimpanzees infectious units per gram were detected in human stool 
samples. By the time jaundice is apparent, HAV is usually no longer detectable in the 
faeces.
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The pathological changes seen in HAV infection are similar to those caused by HBV 
(Dienstag et al., 1975; Ishak, 1976). Acute hepatitis is characterised by ‘spotty liver 
necrosis’ and intralobular and portal lymphohistiocytic (involving infiltration by 
lymphocytes and macrophages) inflammation. Perivenular lytic necrosis and a randomly 
distributed eosinophilic type of necrosis are also observed. A picture of lobular disarray 
is formed by the coexistence of degeneration and regeneration of hepatocytes. 
Degeneration of these cells is distinguished by the appearance of swelling, indistinct 
plasma membranes, enlarged nuclei and featureless cytoplasm. Cellular debris and 
necrotic cells migrate into the sinusoids via the spaces of Disse where they are digested 
by the phagocytic Kupffer cells. As the Kupffer cells in the sinusoids and macrophages in 
the portal ducts become activated, both the size and number of cells in these structures 
increase. Enlargement of the portal tracts also results from oedema and cellular 
infiltration involving lymphocytes and, to a lesser extent, neutrophils and eosinophils. As 
the patient recovers, regeneration is characterised by mitosis and multinucleated cells. 
Inflammatory cells begin to recede and the hepatic tissue is usually restored within 8-12 
weeks.
The specific events that occur upon infection of the liver with HAV and lead to 
inflammation and necrosis have not yet been clarified. HAV antigen has been 
demonstrated in up to 100 % of hepatocytes and also in Kupffer cells of experimentally 
inoculated non-human primates. It was thought that the virus may be directly cytotoxic to 
hepatocytes, thereby facilitating the release of virions, however, maximal virus shedding 
occurs prior to the appearance of widespread cytopathology in the liver (Keenan at a l, 
1984; Karayiannis et al., 1986). When cultivated in BSC-1 cells (Afiican green monkey 
kidney cells) or FRhK-4 cells (Foetal rhesus kidney cells), HAV was demonstrated by
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electron microscopy to be located in vesicular structures (Asher et al., 1988). When liver 
biopsies from infected marmosets were examined by electron microscopy, similar 
structures were observed both in hepatocytes and Kupffer cells (Shimitzu et al., 1978). 
The virus containing vesicles also appeared to be released from these cells into the blood 
and biliary system. The inability of wild type HAV to cause cytopathic effect in vitro also 
tends to suggest that this virus is unlikely to be directly cytotoxic in vivo.
Alternatively, the pathogenesis of the liver seen upon infectipn with HAV may be due to 
the immune responses of the host towards the pathogen. Pathological damage of the 
liver temporally coincides with the appearance of anti-HAV IgM in the serum. However, 
Slusarczyk et al (1985) showed that anti-HAV antibodies with or without complement 
are not responsible for hepatocyte destruction and Gabriel et al (1986) failed to detect 
cytotoxic antibodies in HAV infection. The cell mediated immune response was 
implicated in the destruction of infected cells by in vitro studies (Kurane et al., 1985; 
Vallbracht et al, 1984; Baba et a l, 1993). In these studies HAV infected cells were 
lysed by natural killer cells and cytolytic T cells.
The role of inflammatory cytokines and chemokines in the pathogenesis of HAV 
infection has not yet been established. Infiltration of the liver by T-lymphocytes and 
neutrophils upon infection with HAV suggests a role of chemotactic cytokines. Studies 
of chemokine response in respiratory syncytial virus (RSV) infection of respiratory 
epithelial cells showed the a potent neutrophil and T-lymphocyte attractant interleukin 8 
(IL8), was produced by these cells (Noah and Becker, 1993). This IL8 secretion 
appeared to be stimulated by tumour necrosis factor (TNF) and ILl excreted from RSV 
infected epithelial cells (Arnold et a l, 1994). Similar findings resulted from the study of 
cytokine release in rhinovirus infection (Subauste et a l, 1995). HTV infected alveolar
14
macrophages secrete the chemokine macrophage inflammatory protein 1 a  (MEP-la) 
resulting in an influx of cytotoxic T cells (Denis and Ghadirian, 1994). Infection of 
hepatocytes and Kuppfer cells may result in the secretion of such chemokines and 
thereby cause the infiltration of immune cells seen.
1.3 CLINICAL SYMPTOMS
The result of infection with HAV is extremely variable. In under 2 year olds, the course 
of infection usually remains asymptomatic. A study of children at day care centres 
suspected of transmitting the virus to older siblings, indicated that only 4-16% of pre­
school children presented with symptoms upon infection with HAV. The majority of 
adults develop overt disease.
Symptoms of HAV infection are similar to those found with the other types of viral 
hepatitis and the course of illness may be divided into four clinical phases: (i) the 
incubation period before disease symptoms are apparent, (ii) the preicteric or prodromal 
phase, (iii) the icteric phase and (iv) the convalescent period. At the prodromal stage the 
first symptoms of infections with HAV are seen. The occurrence and severity of disease 
symptoms vary considerably between patients. The most common manifestations are 
fatigue (52-91 %), anorexia (42-90 %), abdominal pain (37-65 %), fever (32-73 %), 
nausea, vomiting (26-87 %), headache (26-73 %), myalgia (15-32 %), arthralgia (11-40 
%), and rash (1-14 %) (Friedman and Dienstag, 1984). The occurrence of diarrhoea in 
20% of infected adults and 60% of children implies that HAV replicates in the gut 
(Lemon, 1985). However the diarrhoea has been shown in some cases to be caused by 
another enteric infection acquired firom the same source (Dismukes et a l, 1969). The 
onset of these symptoms occurs very quickly, often taking only 24 hours for an infected
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individual to regress from apparent healthiness to acute illness. Serum levels of hepatic 
enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) become, 
elevated several days after the onset of symptoms.
The icteric phase usually begins within 10 days of the commencement of disease 
symptoms. As levels of serum bilirubin increase to 5 -15 mg /100 ml serum, the urine 
becomes darkened indicating biUrubinuria followed by pale stools and the yellow 
jaundiced appearance of skin, mucous membranes, sclerae and conjunctivae. The liver 
may enlarge and become sensitive to palpation. In extreme cases (<1.5% of hospitalised 
icteric patients) the extent of necrosis may be so extensive that the function of the liver 
becomes severely impaired. Symptoms of this fulminant hepatitis' are sudden high fever, 
severe abdominal pain and vomiting. Patients may suffer seizures and become comatosed 
due to hepatic encephalopathy which leads to the death of 70-90% of those who develop 
the fulminant disease.
1.4 EProEMIOLOGY
The prevalence of hepatitis A correlates with hygiene and sanitary conditions. Table 1.1 
shows the world wide prevalence of anti-HAV antibodies in the adult population. A 
decline in the prevalence of HAV in northern and western Europe and North America 
correlates with the development and related improvement in the sanitary conditions in 
these areas over the past several decades (Hadler, 1991). A similar pattern has been noted 
in other areas such as Australia, Japan and Hong Kong (Purcell, 1994). In developing 
countries where HAV is endemic, the virus is usually contracted during childhood and 
symptoms are usually mild whereas in the more industrialised areas that have a higher 
level of sanitation, infection usually occurs in adults. A modem risk of HAV infection is 
travel from low-prevalence areas to high-prevalence countries. A recent study showed 
geographical variation of age specific antibody prevalence to HAV and current incidence
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of HAV infection in England (Gay et a l, 1994). Incidence of HAV infection as estimated 
by both seroprevalence and notification rates appears to be higher in Yorkshire and the 
North West than in the South East Thames region. This difference is thought to result 
from geographical variation in socio-economic status. The prevalence of anti-HAV 
antibodies in UK adult populations varies from 29 % in 20-24 year olds to 90 % in those 
over 60 years. ^
Table 1.1. Prevalence of anti-ElAV antibodies in adult populations (Melnick, 1995)
Country of origin
Sweden 
Japan 
Netherlands
% positive
13
Poland
Senegal
Taiwan
Yugoslavia
The use of conventional immunological methods in the study of HAV with regard to the 
spread of individual epidemics is limited as this species of virus consists of only 1 
serotype. The advent of gene amplification, molecular cloning and sequencing 
technologies has recently made comparison of different strains at the genome level 
possible (Jansen et a l, 1990). Sequence analysis revealed a variable region comprising of 
168 bases at the putative junction of regions VPl and 2A of the HAV genome 
(nucleotides 3024-3191) . When 171 individual isolates of HAV were examined, 4 
distinct 'genotypes' (I-IH and VU) of human HAV and 3 genotypes of simian derived 
HAV (IV-Vl) emerged which differed from each other at >15% of base positions in this 
region (Table 1.2, Robertson et à l, 1991). Genotypes I and m  have also been divided
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into subgenotypes A and B. There do not appear to be any differences in the biological 
activities of the different genotypes of human HAV, however, the simian genotypes, 
isolated in Old World monkeys do not appear to cause disease in chimpanzees which are 
susceptible to human genotypes, whereas the human isolates do not routinely establish 
infection in Old World monkeys. The biological relevance of the different genotypes is 
therefore unclear.
Table 1.2. Geographic localisation of human HAV genotypes.
Area Number of 
isolates
lA IB n niA m B v n
North America 16 15 - - 1 - -
Central / South 
Americas
8 7 1 - - - -
Europe 22 7 5 1 8 1 -
U.S.S.R 3 3 - - - - -
China 6 6 - - - - -
Southeast Asia, 
India, Japan
41 32 - - 4 5 -
Australia, Africa, 
Middle East
8 1 6 - , - - 1
1.5 VACCEVATIUIN
From 1944 (Stokes and Neef, 1945) until recently, prevention from HAV infection has 
been achieved by passive immunisation with a heterologous preparation of human 
immune serum globulin (ISO) which was shown to contain significant amounts of 
antibodies to HAV. Passive immunisation with ISG is generally recommended for 
travellers to endemic countries and close contacts in HAV outbreaks (Deinhardt, 1992). 
The major disadvantage of ISG immunisation is the duration of protection. A large dose 
of ISG (0.05-0.06 ml / kg) provides protection for 4 - 6 months (Conrad and Lemon, 
1987; Weilland et al., 1981). The concentration of HAV in ISG preparations varies 
according to the incidence of HAV among donors (Stapleton, 1992). The titre of anti- 
HAV found in commercial preparations ranges between 1:500 and 1:4000 by RIA (80- 
600 lU ml‘^ ). A reduction of the incidence of HAV infection in developed countries
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resulting in a reduction in the titre of anti-HAV in ISG has recently caused concern that 
the effectiveness of this prophylactic treatment may decline (Stapleton, 1992). The first 
inactivated hepatitis A vaccine (Havrix, Smithkline Beecham Biologicals, Belgium) was 
introduced in Switzerland in 1991 and was subsequently licensed in several European 
countries (Andre et al., 1992). The vaccine is derived from the HM175 strain of HAV 
adapted to growth in human diploid cells (MRC-5) and is inactivated by formaldehyde 
treatment. The recommended dose of this vaccine is well tolerated and produces almost 
100 % seroconversion in healthy adults. To ensure long-term protection, a booster dose is 
administered 6 months to 1 year after the initial immunisation.
1.6 CLASSIFICATION
Biochemical and biological study of hepatitis A virus indicaW that this virus should be 
classified as a picomavirus. The family picomaviridae consists of five genera, 
aphthoviruses, cardioviruses, enteroviruses, hepatoviruses and rhinoviruses. Hepatitis A 
virus has recently been designated the prototype of the new hepatovirus genera which 
also includes simian hepatitis virus (Minor, 1991). Previously, HAV was classified as an 
enterovirus since the primary route of transmission of this genera is the oral-faecal 
route. The new genera ‘hepatoviruses’ was suggested (Siegl and Lemon, 1990) due to 
differences in the thermal stability, nucleotide sequence, response to antiviral 
compounds, and behaviour in tissue culture of HAV when compared to other members of 
the family picomaviridae (Table 1.3).
1.7 BIOPHYSICAL PROPERTIES
The hepatitis A virion is a non-envelpped, icosahedral particle with a diameter of 28nm 
(Feinstone et a l, 1973), a density of between 1.32 and 134 g / ml in caesium chloride and 
a sedimentation coefficient of 156-160 S in neutral sucrose solutions. The capsid is
k
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composed of multiple copies of 4 different proteins, and contains a 7.48 kb single 
stranded RNA genome.
Table 13. Comparison of characteristics of the 5 genera of picomaviruses 
(Adapted from HoUinger and Ticehnrst, 1990).
Hepatovirus Enterovirus Aphthovirus Cardiovirus Rhinovirus
Prototype virus HAV
(HM175/wt)
Poliovirus type 1 Foot and mouth 
disease virus A12
Encephalo-
myocarditis
virus
Rhinovirus 14
Serotypes 1 (^13 strains) >70 7 (^ 3  subtypes) 2
(^6 strains)
>130
Primaiy hosts Humans, oth^ 
primates
Humans, otho- 
mammals
Cloven footed, 
other mammals
Mice, other 
mammals
Humans, other 
mammals
Primary habitat Liver Gut Generalised CNS, heart Upper
respiratory
tract
Sensitivity
Acid (pH3) Stable Stable Labile Stable Labile
Heat
(60 °C, 60 mh^ 
Guanidine
Stable
Resistant
Labile
Sensitive
Labile
Resistant
Labile
Resistant
Labile 
. Sensitive
Disoxaril Resistant Sensitive Resistant Resistant Sensitive
Biophysical properties
Buoyant depsity 1.32-1.34 
(g/cm  ^in CsCl)
1.34 1.43-1.45 1.34 1.39-1.42
Sedimentation 
coefficient (S)
156-160 156-160 142-146 156 149
Genome
Length 7.48 7.44 8.4 7.84 7.21
%G + C 38 47 43 50 40
Poly C tract - - + -
PolyC+U + - - - -
Structural Proteins (Mr xlO“^
VPl 33.2 33.5 23.3 31.7 32.4
VP2
VP3
24.8
27.8
30.0
26.4
24.7
24.3
29.0
25.1
28.5
26.2
VP4 >2 5 7.4 8.5 7.2 7.2
VPg 2.4 2.3 2.6-27 2.2 2.4
Protein cleavage’
Proteases 3C only 2A + 3C 2A+3C + L 2A + 3C 2A + 3C
Primary cleavage 
site
2A/2B
junction
VP 1/2A junction 2A/2B
junction
2A/2B
junction
VP1/2A
junction
Enzyme 3C 2A 2A 2A 2A
*Ref: Ti&etai, 1993; Schultheisse/o/., 1994;Martine/a/., 1995.
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1.7.1 Genome
Provost et a l (1975) proposed HAV virions contained an RNA genome due to the 
cytoplasmic location of the virus and the effects of ribonuclease combined with heat 
treatment on infectivity. Electron microscopy (Siegl and Frôsner, 1978a; 1978b) and 
centrifugation of radio-iodinated HAV nucleic acid molecules in sucrose gradients 
(Coulepis et a l, 1981) indicated that the genome is linear with a molecular weight of 
2.25 X 10^ . The ability to infect cultured cells with naked HAV RNA (Locamini et a l, 
1981; Gauss-Müller et a l, 1984) suggested that the genome is positive sense. More 
detailed analysis was made possible by the cloning of (lie HAV genome by Ticehurst and 
co-workers (1983). Subsequent sequence analysis revealed the typical genome 
organisation of the picomavirus family (Najaran et a l, 1985; Cohen et a l, 1987), 
comprising of 3 regions: (i) an untranslated re^on (5’ UTR) of 735 nucleotides at the 5’ 
terminus, (ii) a large, single open reading frame of 6681 nucleotides encoding a 
polypeptide of 2227 amino acids and (iii) a 63 nucleotide 3’ terminal untranslated region 
(3* UTR) which includes a poly-adenosine tail (frg 1.1).
Figure 1.1 Genome structure of HAV (Adapted from Weitz and Siegl, 1993)
0 1 2 3 4 5 6 7  xlO^basœ
735
I
5’UTR lA
PI
30261 P2
5000 P3
36
O
.%v
VP4 VP2 VP3 VPl 
 ^Dotzauer et al., 1995
7416
3TJTR
IB 1C ID 2A 26 2C 3A 3C 3D —AAAAA
^  y  *4---------- -—►
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The 5’ UTR is essential for HAV replication and translation. Analysis of the 5* UTR 
revealed a highly ordered secondary structure which allows binding of ribosomes at an 
internal ribosomal entry site (1RES) between nucleotides 161-734, adjacent to a 
translation initiation codon (AUG) and directs cap-independent initiation of viral 
translation (Brown et a l, 1991; 1994; Glass and Summers, 1992). The majority of 
eukaryotic messenger RNA is translated after recognition of a 5’ tenninal cap structure 
by a translation initiation factor (eIF-4F) which allows binding of the 40s ribosomal 
subunit (Hershey, 1991). In enteroviruses and rhinoviruses, the 2A protein cleaves elF- 
4F, thus terminating host cell protein synthesis whilst allowing viral translation to 
continue without competition for translational requirements (Krâusslich et a l, 1987; 
Lamphear et a l, 1993).
The 5’ UTR contains two polypyrimidine tracts (C + U). The first is found between 
nucleotides 100-139 and the second near the initiation codon, nucleotides 706 to 726. 
Both of these polypyrimidine tracts appear to be involved in the initiation of tianslation 
(Silveira Cameiro er a/., 1995).
The region(s) within the 5’ UTR responsible for RNA replication have not yet been 
defined (Jia et a l, 1996). Recently Kusov et a l (1996), after analysis of interactions of 
the 3’UTR with host cell proteins, suggested that a putative psuedoknot structure in this 
region together with the 3D region encoding the viral RNA polymerase may be essential 
for the formation of a replication complex which initiates minus strand synthesis.
The coding region of the HAV genome can be divided into 3 regions (Figure 1.1). The
four structural protein encoding sequences are found in region PI adjacent to the 5’
UTR Region P2 encodes 3 non-structural proteins , 2A, 2B and 2C and P3 encodes non-
structural proteins 3A, 3Ç md 3D and a further structural protein, 3B (VPg).
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1.7.2 Structural proteins
The HAV capsid consists of multiples of 4 different proteins, VPl (33 kDa), VP2 (25 
kDa), VP3 (28 kDa), and VP4 (2.5 kDa). The presence of VP4 is assumed from 
comparison of the nucleotide sequence with that of other picomaviruses, however this 
protein has not yet been detected in HAV virions (Tesar et al., 1993). The tertiary 
stmcture of the capsid proteins and their alignment in the capsid is unclear. The thermal 
stability of HAV suggests that the stmcture of the particle differs from that of the other 
members of the picomavirus family (Table 1.3). Analysis of the thermal stability of 
empty HAV capsids revealed them to have similar characteristics to those of poliovirus 
which infers that in HAV, the presence of RNA improves HAV particle stability (Ruchti 
et al., 1991). A fifth stmctural protein is encoded in the P3 region of the genome. VPg 
(3B) is a small protein (2.4 KD) found to be covalently attached to HAV RNA in the 
capsid which may fimction in the initiation of negative strand RNA synthesis.
1.7.3 Non-structural proteins
Again, the non stmctural proteins have been classified on die basis of comparison of the 
genome sequence with that of other picomaviruses. The sizes and putative functions of 
these proteins are shown in Table 1.4
Table 1.4. HAV non-structural proteins
Protein Size(KD) Function
2A 10.0 Unknown
2B 12.0 Transcription?
2C 38.4 Transcription?
3A 8.0 Unknown
3C 24.1 Protease
3D 56.3 Polymerase
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1.8 VIRAL REPLICATION
1.8.1 CeU attachment, entry and uncoating
The first stage in viral infection is attachment of the virus to a specific cellular receptor 
located in the plasma membrane of the host cell. Once bound, the cell receptor mediates 
the internalisation and uncoating of the virus. The ability of a particular virus to infect a 
cell is partly determined by the expression of the corresponding receptor. HAV has been 
demonstrated to associate with several host cell macromolecules (Seelig et a l, 1984; 
Lemon and Binn, 1985; Margolis and Nainan, 1990; Zajac et a l, 1991), however it was 
not until recently that the probable fimctional receptor for HAV was finally identified in 
African Green Monkey Kidney cells and named HAVcr-1 (Kaplan et a l, 1996). 
Characterisation of the molecule showed HAVcr-1 to be a novel major 
histocompatibility complex (MHC) class I integral membrane molecule with an 
extracellular globular first domain and an extended mucin-like structure. On the basis of 
known binding of other picomaviruses to their host cell receptors, the authors suggested 
that HAV may bind to the first domain. The normal fimction of this receptor is unknown 
but may be involved in cell-cell signalling. A similar mucin-like receptor which appears 
to induce HAV attachment has also been identified on S.la/Ve-1 cells, a hybrid between 
marmoset liver cells and Vero cells (Ashida and Hamada, 1997). The in vivo and in vitro 
distribution of these putative receptors has yet to be determined Several studies have 
shown that in order to infect cells in culture, HAV requires calcium ions Wiich may 
interact with either the host cell receptor or the receptor binding domain of HAV, 
facilitating receptor-virus binding.
The process by which the receptor bound virus undergoes internalisation and uncoating 
is unclear. Early studies showed that interaction between poliovirus and it’s cellular 
receptor altered the stmcture of the viral capsid abolishing infectivity (Joklik and
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Darnell, 1961; Fenwick and Cooper, 1962). The ‘A particle’ thus formed is now 
considered to be a destabilised intermediate in cell entry (Fricks and Hogle, 1990). 
Formation of this particle is achieved by the loss of VP4 and externalisation of the N 
terminus VPl. Little is known about the events which occur during internalisation of 
HAV and the presence of VP4 in the capsid has not yet been conclusively established. 
Further study of HAV-receptor interactions are required to elucidate the mechanism by 
which the naked viral genome appears in the cytoplasm of infected cells.
1.8.2 RNA synthesis
The initial step in the replication of the genome of picomaviruses is transcription of the 
positive strand RNA to form negative strand RNA. From this template, multiple copies 
of the genome can be synthesised. Studies of poliovirus replication (Lama et al., 1994; 
Giachetti et al., 1992) have shown that proteins involved in the synthesis of negative 
strand picomaviral RNA include viral proteins 3D^\ 3CD, VPg (3B) and its precursor 
3AB, as well as at least one host cell protein factor (p36) The replication complexes 
comprise proteins interacting with a 3’ terminal RNA cloverleaf stmcture of poliovirus 
and are associated with smooth membrane in the cytoplasm (Caliguiri and Tamm, 1970). 
VPg or a polyurydylated form.of its precursor 3AB may act as a primer in the initiation 
of polymerisation by 3D^* (Takeda, et al., 1986; Takegami et al., 1983) . Protein 3AB 
has also been demonstrated to activate 3D^^ (Lama, et al., 1995). Negative strand RNA 
is readily detectable in poliovirus infected cells whereas this replicative intermediate has 
not been convincingly demonstrated upon HAV infection of cultured cells, hence little 
information is available regarding the mechanisms involved in HAV RNA replication.
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1.83 Translation and polyprotein processing
As with all picomaviruses, the HAV genome is translated in a single open reading frame 
to potentially form a single, large polypeptide. However, cleavage of the nascent 
polypeptide precludes the formation of the complete molecule. All cleavages of the HAV 
polypeptide are thought to be catalysed by the viral encoded protease 3C. Unlike 
enteroviruses and rhinoviruses, the primary cleavage of the HAV polyprotein is thought 
to occur at the 2A/2B junction releasing a molecule of 98.5 kDa composed of the 4 
stmctural proteins and non-stmctural protein 2A (Jia et al., 1993; Schultheiss et al., 
1994; Martin et al., 1995). Borovec and Anderson (1993) proposed a model for the 
synthesis and assembly of HAV stmctural proteins based on the results of pulse-chase 
experiments (Figure 1.2). After the initial cleavage of the HAV polyprotein at the 2A:2B 
junction, the P12A polyprotein rapidly form a 13 S pentamer. Each polypeptide in the 
pentamer is then cleaved by 3C in tram at the VP2:VP3 and VP3:VP1 junctions to form 
a 14 S pentamer containing VPO (VP4 and VP2), VP3 and PX (VPl and 2A). RNA is 
then incorporated and the polyprotein PX is cleaved to release protein 2A and a 150 S 
provirion is formed. A mature 160 S virion is formed when VPO is cleaved by protein 3C 
to give VP4 and VP2. Study of the synthesis of non-stmctural proteins revealed the 
cleavage of proteins 2B, 2C and 3D, but the processing of the remaining 3ABC 
polyprotein has yet to be elucidated (Jurgensen et al., 1993; Schultheiss et al., 1995). The 
cleavage of 3D from the P3 polyprotoin tends to suggest that unlilce that of poliovirus, 
the precursor 3CD is not formed and therefore is not involved in the synthesis of HAV 
negative strand RNA or cleavage of the stmctural proteins. However, these conclusions 
are drawn from in vitro translation studies and therefore may not strictly represent the 
events that occur in vivo.
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Figure 1*2. Post translational processing of HAV proteins (Adapted from Borovec
and Anderson, 1993; Jurgensen et ai., 1993; Schultheiss et aL, 1995)
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1.9 REPUCATION IN TISSUE CULTURE
HAV differs most strikingly from the other members of the picomavirus family in its 
ability to replicate in tissue culture. Picomaviruses typically replicate rapidly in tissue 
culture showing cytopathic effects and can produce up to 10  ^ infectious particles per cell 
within 5-10 hr of infection (Baltimore et al., 1966). Despite the long history of HAV, 
successful propagation of the virus in tissue culture was not achieved until 1979 when 
Provost and Hilleman (1979) demonstrated the replication of HAV in primary hver cell 
culture and foetal rhesus kidney cells. No cytopathology was seen in the infected cells 
and immunofiuorescent detection was necessary to demonstrate replication of the virus. 
HAV has subsequently been propagated in a small variety of cells including those 
derived from African green monkey kidney (BSC-1, Vero and BGMK), foetal rhesus 
kidney (FRhK4, FRhK6 and Frp/3) and human hepatoma (PLC/PRF/5), human diploid
27
lung (MRC5) as well as primary African green monkey kidney cells and primary human 
fibroblasts (Frôsner et a l, 1979; Flehmig, 1980; Daemer et al, 1981; Flehmig et a l, 
1981; Gauss-Müller et a l, 1981; Locamini et a l, 1981; Siegl et a l, 1984; Vallbracht et 
a l, 1984; Binn et a l, 1984). Isolation of HAV from clinical specimens may take several 
months and serial passage is required before the virus becomes progressively more 
adapted to growth in vitro (Wheeler et a l, 1986). The majority of these tissue culture 
adapted variants establish persistent infection of cells following 4-8 days of logarithmic 
growth and show very little effect on host cell morphology or protein synthesis (De 
Chastoney and Siegl, 1987). Electron microscopy revealed accumulation of multilayered 
membranes and virus containing vesicles in the cytoplasm of infected cells (Kieman et 
a l, 1987, Asher et a l, 1987; 1988). The majority of virus remains cell associated
Table 1.5. Cell culture adapted, cytopathic strains of HAV
Strain Origin Passages in 
cril culture
Cell line Plaque
purification
Reference
HM175/18f HM175/wt^ 16 passages 
+1 year 
persistent 
in&ction
BSC-1 Lemon e/nr/., 1991
HM175A2 HM175Avt 35 BSC-1 3 rounds Anderson et al, 
1987
Andeison, 1987
pHM175 HMÏ75/^^ 10
-38
AGMK  ^
primary ceils 
BSC-1 cells 2 rounds
Cromeans et al., 
1987; 1989
FG FG (Italy) 3 Frp/3 - Morace et al, 1993
SIO SIO (Italy) 3 Frp/3 - Moracee/o/., 1993
^HM17$ wild type + 6 mannoset passages 
^African grçen mpnkey kidney ceUs
Cytopathic variants of HAV have been isolated by repeated subculture of persistently 
infected cells, acute passage of vims and plaque purification (Table 1.5). These
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cytopathic variants replicate a little faster than other cell culture adapted strains but still 
produce low yields of virus. Infection of cells with cytopathic HAV variants does not 
cause shut down of host cell protein synthesis as observed with many other cytopathic 
picomaviruses. The cytopathic effects seen include pyknosis, aggregation of cells and 
detachment from the surface of the flask and includes the majority of infected cells.
1.9.1 Adaptation of HAV to growth in cell culture
The genome changes required for improved growth of HAV in tissue culture have been 
studied for several cell culture adapted variants. Mutations in the P2 (proteins 2B and 
2C), P3 and 5’ untranslated regions of the of HM175/wt resulted in a cytopathic, rapidly 
replicating variant, HM175/18f (Zhang et a l, 1995). Mutations in only the P3 and 5' 
UTR regions of HM175 did not cause cytopathology but when placed on a background of 
the P2 mutations, larger foci of cytopathology were observed. Zhang and co-workers 
proposed that interactions between proteins 2B and 2C and the 5' UTR of HAV may 
occur in the formation of a membrane-bound HAV replication complex. Again, changes 
in proteins 2B and 2C as well as in the 5' UTR and P3 region (particularly protein 3A) 
resulted in the adaptation of several strains of HAV to growth in cultured monkey 
kidney cells and MRC-5 cells (Graff et a l, 1994a and 1994b; Emerson et a/.,1992; 
Morace, et a l, 1993; Day et a l, 1992; Funkhouser et a l, 1994). Several of the mutations 
seen are present in a variety of cell culture adapted strains regardless of origin or cell 
culture system (Table 1.6).
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Table 1.6. Common nucleotide changes occurring during adaptation of HAV to 
growth in tissue culture.
Genome
region
Nucleotide
position
wild
type^
HM175
pl6^
HM175
18f
HAV/?' GBM/
FRhK4^
FG'^
P2(2B) 3889 Ala Yai YÛ y g
P2(2C) 4426 Lys Ik Lys Lys Ik Ik
P3 (3A) 5010-5012 Asp Asp dsi Asp Asp del
P3(3A) 5013-5015 Asp Asp Asp Asp dsi dsi
P3 (3A) 5016-5018 Asp Asp Asp Asp dsi dsi
P3(VPg) 5232 His His His Ixr ly r His
* Based on HM175 and (fflM wild type nucleotide sequences 
^Ref: Zhang et al., 1994 
^ef; G nffe ta i, 1994a
Morace et al, 1993, Beneduce et al,, 1995
Despite many studies, the mechanisms hampering the replication of HAV in tissue 
culture have yet to be clarified It has been suggested that asynchronous uncoating and 
replication of HAV causes the appearance of slow replication in vitro ( Wheeler et a l, 
1986; Cromeans et a l \ 1989 Cho and Ehrenfeld, 1991). Alternatively, Anderson et al 
(1988) showed highly efficient packaging of HAV RNA into virions and proposed that 
the number replicative intermediates available for further replication was therefore 
diminished at an early stage in the growth cycle. Further study implied that due to low 
levels of viral RNA replication early in the growth cycle of HAV, structural proteins 
form empty capsids. However, later in infection, levels of 3C protease increase 
concurrently with viral RNA. High levels of the protease lead to cleavage of capsid 
proteins prior to formation of 13 S pentamers instead producing 5 S monomers which 
cannot self assemble into virions and are degraded (Borovec and Anderson, 1993).
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1.10 ANIMAL MODELS
Since the 1950's, there have been many attempts to transmit HAV to non-human primates 
such as chimpanzees, macaques, sooty mangabeys, African green monkeys, baboons and 
gibbons (reviewed by Gust and Feinstone, 1988). The early studies were hampered by the 
techniques then available for analysis of infection, the acquisition of animals from the 
wild and subsequent unhygienic conditions and the limited understanding of the animals 
used. None of these studies convincingly showed reproducible transmission of the virus 
to the animals. A large investigation of viral hepatitis in 37 chimpanzees gave an 
indication that these primates were susceptible to HAV (Deinhardt et al., 1962). 
Although the study was complicated by the possible presence of both HAV and HBV in 
the inocula making the results inconclusive, valuable information regarding the normal 
liver function of chimpanzees was obtained. During the early 1960’s, colonies of white- 
lipped {Saguintis nigricollis} and cotton topped (S. oedipus) marmosets were established 
by Deinhardt and Deinhardt (1966). The lise of these colonies allowed selection of 
experimental animals with a known medical history. In 1967, Deinhardt and colleagues 
reported the transmission of the virus from serum or plasma of patients with hepatitis 
during the acute phase of illness to the white-lipped marmosets. Of the five sera 
inoculated, one, designated GB was found to be highly infectious to tamarins and could 
not be neutralised by post hepatitis A convalescent serum. Two distinct infectious agents 
were isolated from infected tamarins (GBV-A and GBV-B). Based on nucleotide and 
amino acid sequencing, these viruses have been classified as flaviviruses and may 
possibly be related to hepatitis G virus (Simons et al., 1995; Schlauder et al., 1995). In a 
cross challenge study using the MS-1 agent isolated during studies at the Willowbrook 
state school (Knigman et a l, 1967) and the GB agent, animals which were pre­
inoculated with the MS-1 agent were susceptible to infection when inoculated with GB 
sera and vice versa. The ability to infect marmosets with the MS-1 agent was
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subsequently confînned (Lorenz et al., 1970). Mascoli and co-workers (1973) 
successfully inoculated tamarins (marmosets, S. mystax and S. nigricollis) with blood 
from a Costa Rican patient inducing hepatitis as characterised by increased enzyme 
levels and liver histopathology within 25-55 days of inoculation. The detection of HAV 
strain MS-1 in stools of infected patients by immune electron microscopy (Feinstone et 
a l, 1973) provided Dienstag and colleagues (1975) with a more specific method of 
demonstrating infection of the chimpanzees {Pan troglodytes) with HAV. Transmission 
of HÀV to other non-human primates including lesser bushbabies {Galago senegalensis, 
Grabow and Prozesky, 1975), red bellied tamarins ( S. labiatus, Purcell and Dienstag, 
1978; Peterson et a l, 1979), stump-tailed monkeys (Macaca speciosa, Mao et a l, 1981), 
owl monkeys {Aotus trivirgatus. Lemon et a l, 1982; LeDuc et a l, 1983) and cotton 
eared marmosets {Callithrix jacchus, Shibayama, 1985) has now been achieved.
The most extensively studied animal models for HAV infection are tamarins and 
chimpanzees as infection is highly reproducible and follows a similar course to that of 
man Infection of lesser bushbabies with HAV resulted in a similar response to that seen 
in man, chimpanzees and tamarins, however, this, response was not seen in all infected 
animals suggesting that these primates are less susceptible to HAV (Grabow et a l, 1981). 
Both stump tailed and owl monkeys are susceptible to infection with HAV. Again, 
experimental infection in these animals results in a milder form of the disease than seen 
in man.
1.10.1 Experimental hepatitis A in tamarins and chimpanzees
Tamarins {Saguinus spp.) may be productively infected with HAV via parenteral or oral 
inoculation, the most susceptible species being S. mystax, S. labiatus (nfiventer) and S. 
fuscicollis. The resulting disease is generally milder than that seen in man and is 
comparable to that of chimpanzees {Pan troglodytes). Clinical features of HAV infection
32
of non-human primates include anorexia, lassitude, ruffled hair and diarrhoea, but these 
are unreliable markers of disease (Dienstag et al., 1975; Margolis et al., 1988). 
Biochemical and histopathological analysis is required in studies involving these 
animals. The incubation period usually ranges from 17-28 days. HAV antigen or 
infectious particles may be detected in the faeces several days before the serum enzyme 
levels begin to rise (Krawczynski et al., 1981; Maynard et al., 1975; Schulman et al., 
1976). The onset of faecal shedding is usually sudden and reaches a maximum level 
when histological changes associated with acute hepatitis become , apparent and then 
begins to decline rapidly (Dienstag et al., 1975; Ticehurst et al., 1987). Viraemia 
generally occur at the same time as faecal shedding but the titres of HAV detected in 
serum are several fold lower than those in the faeces (Lemon et al, 1988; Cohen et al.,
1989). The dose of virus administered does not appear to affect the severity of disease, 
but a linear correlation between the titre of the inoculum and the incubation period has 
been demonstrated (Gust and Feinstone, 1988).
Biochemical analysis reveals elevations in liver enzyme activity in the serum of infected 
animals with peak activity coinciding with the detection of HAV antigen in the liver. The 
enzymes generally assayed are isocitrate dehydrogenase (ICD), aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT). However, since elevations 
of ICD and AST are noted in other illnesses, assay of serum ALT is regarded as being 
more informative. In two studies, Karayiannis and co-workers (1986; 1990) found the 
baseline serum ALT to range between 8 and 18 l U / 1 in tamarins whereas in a study of 
chimpanzees the mean pre-incubation level was found to be 38 lU / ml (Karron et al., 
1988). Serum ALT levels rise to a maximum of between 120-275 lU / 1, however 
occasionally much higher levels are detected (Karron et al., 1988; Margolis et al., 1988; 
Karayiannis et al., 1986; 1990; Emerson et al., 1992). There does not appear to be any 
difference between chimpanzees and tamarins in peak ALT levels, but interpretation of
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the available data is difficult as slight alteration of assay temperature has a profound 
effect on the results obtained. Therefore, comparison of data from different studies may 
not be satisfactory.
Histological analysis of liver from HAV infected animals show similar changes to that of 
human patients. Whilst the livers of these primates are generally damaged to a lesser 
degree compared with the changes observed in human liver, occasionally severe necrosis 
is noted. The most prominent feature in diseased liVers is mononucleocytic, periportal 
infiltration. Hepatocyte degeneration is milder than that seen in humans and is often 
limited to the periphery of lobules. As the disease progresses, cells in the bile ductules 
proliferate and mononuclear cells infiltrate the duct walls. An iron pigment may 
accumulate in sinusoidal lining cells, particularly macrophages in the portal tracts. As 
recovery begins, the characteristic signs of regeneration seen are mitotic and 
multinucleated cells. Electron microscopy reveals aggregated HAV particles within 
vesicles associated with multiple myelin-like membranes in the cytoplasm and the 
formation of dense heterochromatic granules in the nuclei of hepatocytes. Shimizu and 
colleagues (1978) counted between 10 and 80 virus particles in infected hepatocytes and 
also noted particles in sinusoidal cells. Immunofluorescence also demonstrated the 
presence of HAV antigen in these cells (Mathieson et a l, 1980; Krawczynski et a l, 
1981).
Karayiannis and co-workers (1986) studied the host immune response to HAV in 
tamarins (5. labiatus ). Circulating anti-HAV IgM was detected within 3 weeks of 
inoculation, coinciding with the peak of serum ALT activity. The IgM response was 
maximal at 4-5 weeks post inoculation and then decreased rapidly. By the seventh week 
when anti-HAV IgM was no longer detectable an IgG response to the virus could be 
measured.
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1.11 TRANSMISSION OF HEPATITIS A VIRUS VIA BLOOD PRODUCTS
Until recently, transmission of HAV via blood or blood products has been extremely rare 
(Barbara et al., 1982; HoUinger et al., 1983; Weisfuse et al., 1990). The viraemic period
for HAV is transient, only lasting up to 2 weeks and the risk of transmission by this route
/
had been considered to be negligible. It was therefore surprising when in 1992 an 
outbreak of hepatitis A amongst patients with haemophilia was attributed to a factor VQI 
preparation used to treat their illness (Maimucci, 1992). A total of 52 patients visiting 12 
haemophilia centres throughout Italy contracted the disease between 1989 and 1992. AU 
but one of these patients suffered with severe haemophilia A and required regular high 
quantity infusion of clotting factor. They had each been infused, within 2 months of 
onset of symptoms, with a factor Vffi concentrate (Emclot Octa VI) which had been 
manufactured in Italy by AIMA Derivati from plasma pools collected from paid plasma 
donors in the United States. Prior to fractionation, the plasma had been tested for 
hepatitis B antigen, anti-HIV and raised ALT levels. The concentrated clotting factor was 
also treated with a mixture of lipid solvent (tri-(n-butyl) -phosphate) and detergent 
(Polysorbate 80) in order to inactivate any contaminating viruses. Subsequent detailed 
study of 29 of these patients compared with 71 randomly chosen control patients with 
haemophilia indicated that HAV had been transmitted via factor VQI and the authors 
proposed that patients with haemophilia be vaccinated against HAV (Mannucci et al., 
1994). PCR analysis of 9 lots of the factor VQI thought to be responsible for transmission 
of HAV to 4 patients revealed that 4 lots contained HAV genomic sequences and that 
each of the patients had been transfused with contaminated material. The sequences of 
the VP3 region of HAV RNA amplified from the different lots of clotting factor were 
96-99% homologous and sequences amplified from the serum of each of the 4 patients 
were identical to that in the contaminated lot of factor VQI that they received. This was 
confirmed by amplification and sequencing of the VP1/2A junction of HAV isolated
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from one of the patients and from the contaminated factor VIII preparation received by 
that patient (Purcell et a l, 1994). Further reports of transmission of HAV to 
haemophiliacs throughout Europe soon emerged (reviewed by Vermylen and Peerlink, 
1994).
Gerritzen and co-workers (1992) reported acute hepatitis A in patients with haemophilia 
in Bonn, Germany, between 1987 and 1992. Of 46 patients receiving a factor VQI 
preparation (Octavi, Octapharma, Düsseldorf) vdiich had undergone the same virus 
inactivation procedure as that implicated in the Italian outbreak, 13 contracted acute 
HAV infection during this period HAV RNA was amplified by nested PCR in 1 of the 
batches of factor VQI given to the patients (Normann et al, 1992). This prompted a 
retrospective study of HAV seroconversion amongst patients with haemophilia and von 
Willebrand’s disease at this centre (Brackmann et a l, 1994). The showed that of 29 
susceptible patients who had only received the solvent/detergent treated clotting factor, 
11 seroconverted, and of 27 patients receiving both solvent/detergent treated and ion 
exchange chromatography purified concentrates, 6 seroconverted In contrast, of 139 
susceptible patients receiving pasteurised clotting factors only 1 seroconverted and this 
was likely to have resulted from contact with an infected sibling.
A third outbreak of hepatitis A amongst haemophiliacs occurred at a centre in Leuven, 
Belgium, (Peerlink and Vermylen, 1993). All of the 250 patients with haemophilia A 
were transfused with solvent/detergent treated factor VQI manufactured by 
Biotransfusion (Lille, France) from 1991 until April, 1992 when the production site was 
changed to Octapharma (Vienna, Austria). Between May and November 1992, 5 of the 
patients presented with clinical hepatitis A and 1 further patient was found to have
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seroconverted in subsequent screening. Each of these patients were being treated for 
severe haemophilia A by transfusion of very large amounts of factor Vin.
The final outbreak of hepatitis A amongst European haemophiliacs that has occurred to 
date was located in the Republic of Ireland (Temperley et a l, 1993; Lawlor et a l, 1994). 
During the months of May to December, 30 patients with haemophilia A became 
infected with HAV. Solvent detergent treated factor VIE, Octavi™, fractionated by 
Octapharma, Vienna from Irish plasma donations, was used exclusively from 1990 
onwards. The 3 implicated batches were prepared from a single plasma pool. It was 
subsequently discovered that an outbreak of hepatitis A had occurred specifically in an 
area from \ ^ c h  a portion of this plasma had been collected.
More recently, in the United States transmission of HAV via clotting factors has also 
been documented (MMWR, 1996). In the latter half of 1995, 3 recipients of Alphanate^** 
factor Vin concentrate (Alpha Therapeutic Corporation, California) and one recipient of 
Alphaninc '^^ factor DC, produced by the same company, jM'csented with hepatitis A. 
Amplification and nucleic acid sequencing of the VPl region of the HAV genome 
revealed that 2 of the factor Vffi recipients were infected with HAV genotype lA which 
was also present in the implicated lot of Alphanate. The sequences found in each of the 
three PCR products were identical. Both of the clotting factor concentrates used by the 
patients were prepared using the solvent/detergent method of virus inactivation.
Concerns as to the safety of blood products with regard to HAV as well as other non­
enveloped viruses have arisen due to these outbreaks amongst patients with haemophilia. 
The routinely used virus inactivation procedures, particularly solvent/detergent treatment 
need td be re-evaluated and where necessary, alternative or additional steps should be 
taken to ensure the safety of these medicines. Vaccination has been adopted in several
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countries as an alternative approach to protect blood product recipients against HAV 
infection. However, this does not address the issue that not all viruses are inactivated by 
the solvent/detergent methods currently employed by certain manufacturers.
1.11.1 Steps taken to ensure safety of plasma products with regard to viruses
Several medicinal products are derived from human plasma including clotting factors 
(e.g. factor VIU, factor IX and fibrinogen), albumin, fibronectin and immunoglobulins. 
Since the 1940’s, a viral inactivation step has been used in the preparation of such 
products. The risk of parenteral transmission of the naturally blood borne viruses, 
hepatitis B, C and Delta viruses and HIV, is of major concern. A viraemic phase occurs 
during infection with most viruses, therefore, there is also a small risk of parenteral 
transmission of those viruses such as HAV which are not usually considered to be blood 
borne. Transmission of HAV and parvovirus B19 by plasma products has been 
documented. In order to the reduce the risk of transfusion of virally contaminated 
products, manufacturers use plasma which has been screened for HCV, HBV and HTV 
antigen or antibodies and perform viral elimination or inactivation procedures during the 
preparation of plasma products. However, plasma is not presently screened for HAV or 
parvovirus B19.
1.11.1.1 Donor selection
The source of plasma from which the above derivatives are made is volunteer or 
remunerated human donors collected either as whole blood or more frequently from 
remunerated donors by plasmapheresis. It has been noted that the risk of transmission of 
viruses in products manufactured from plasma of non-remunerated donors is lower than 
that of products from paid donors (Leikola, 1993). However, it is not possible in some
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countries such the United States, for the demand for plasma products to be met by 
unpaid donors alone.
When the transmission of HIV via blood became apparent, so did the need to prevent 
high risk individuals from donating blood. In the early 1980s, as well as raising the 
public awareness of AIDS, a donor selection process was set up. Prospective donors are 
now asked to complete a self assessed health check, directly questioned to determine 
wliether the donor is in an ‘high risk’ group and examined for signs of intravenous drug 
abuse. This process helps to identify those at risk of transmitting hepatitis B, C and Delta 
viruses as well as HIV.
1.11.1.2 Plasma screening
Donated blood or plasma is routinely tested for HIV and hepatitis B and C infection. The 
test for hepatitis B introduced in the early 1980s was a radioimmunoassay of hepatitis B 
surface antigen which is present at high levels in the plasma of infected individuals. 
Subsequently testing of all donations for antibodies to HIV in 1985 and HCV in 1990 
was introduced in the UK when commercial kits became available for routine testing for 
these viral markers. These assays are however limited by being unable to discriminate 
samples taken at the initial stages of infection. The time taken from infection with a virus 
until a marker of the infection such as antibodies, antigen or genome, can be detected is 
called the ‘window period’. Using the currently available antibody marker tests, the 
window period for HTV has be estimated to be 22 -32 days however, the introduction of a 
test for HIV p24 antigen may reduce this time to 10-12 days (Dodd, 1996). In the case of 
hepatitis B, the assay currently used in screening of blood donations detects HBV surface 
antigen. The window period associated with detection of this antigen is 37-87 days 
(Mimms et al., 1993). Based on retrospective study of transfusion transmitted cases of
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HCV, the window period for detection of antibodies to this virus has been estimated to 
be 54-192 days (Busche et al., 1995; Lelie et a/., 1992). While selection of donors and 
screening of blood and plasma reduces the risk of a plasma product being contaminated, 
the safety of the plasma cannot be guaranteed. The screened viruses, HBV, HCV and 
HTV, may escape detection during the window period and other viruses for vriiich there 
is no routine testing, for example. Parvovirus B19 and HAV, may be present in the 
starting material. The introduction of virus elimination or inactivation during 
manufacture is an additional step to ensure the virological safety of blood products.
1.11.1.3 Virus elimination procedures
An approach to ensuring the virological safety of blood products is to introduce a 
procedure for elimination of any contaminating virus during manufacturing. The 
methods currently employed are affinity chromatography (Schreiber, 1989), anion 
exchange chromatography (Bumouf, 1991) and membrane filtration (Bumouf- 
Radosevich, 1994). In affinity chromatography purification, the plasma cryoprecipitate 
flows through an affinity column allowing the desired blood product to bind to specific 
antibodies and the colunm is then extensively washed before the purified protein is 
eluted in an appropriate buffer. Anion exchange chromatography is based on electrostatic 
interactions between the desired product and an exchange resin such as 
diethylaminoethyl cellulose (DEAE) or sepharose. At a specific pH and salt 
concentration, the desired protein wiU be held within the exchange resin whereas 
contaminating molecules or virus particles with a different isoelectric point flow through., 
After extensive washing with the appropriate buffer, the target protein may be eluted 
from the resin by altering the pH. Affinity chromatography appears to be more effective 
in virus elimination than ion exchange chromatography, however validation experiments 
show that the efficiency of either of these techniques vary depending on the virus used
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The efficacy of membrane filtration in virus elimination depends on the pore size of 
filter. Microporous hollow fibre filters capable of removing viruses as small as 25-30 nm 
such as HAV and parvovirus B19 are available, however, they may only be used with 
products smaller than 10 kDa e.g. factors H, DC, X and XI. Filters of larger pore size are 
required for factor VQI (100 kDa) and IgG (160 kDa).
1.11.1.4 Virus inactivation procedures
Contaminating viruses are routinely inactivated physically, by heating either dry or wet 
(pasteurisation), or chemically, by solvent detergent treatment. Dry heat treatment has 
the advantage that the lyophilised blood product may be heated severely (e.g. 80°C / 72 
hours) and this inactivation step can be performed on the final product with no 
requirement for further processing. The efficiency of viral inactivation using terminal dry 
heat may however be reduced by increased stability of the lyophilised virus and 
incomplete drying of the samples. Solvent/detergent virus inactivation involves the 
addition of solvent (usually tri-(n-butyl) -phosphate) and detergent (usually Tween-20) 
during the manufacture of the blood product. The chemicals are subsequently removed 
by further processing in a virus fi’ee environment. This method of virus inactivation 
works by dissolving the lipid envelope of contaminating viruses, however, viruses such 
as HAV and parvovirus B19 are not affected as they do not posses an outer lipid 
envelope. In order to overcome this problem, the solvent/detergent method may be 
combined with heat treatment.
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1.12 QUANTITATION OF HAV
The slow, non-cytopathic growth of the majority of strains of HAV has made detection 
and quantitation of the virus difficult. Prior to adaptation to growth in tissue culture, 
HAV antigen and antibodies against HAV were quantitated by radioimmunoassay (RIA, 
Hollinger et o/., 1975; Purcell et al., 1976). Samples are incubated in wells of microtitre 
plates previously coated with convalescent serum from a patient with hepatitis A. 
Antibodies to HAV, radiolabelled with are then added to the wells and the washed 
wells are cut out and placed in a gamma spectrometer for quantitation of bound 
radioactivity. Samples with gamma counts above a calculated cut-off are deemed 
positive. This assay is limited in the fact that it does not distinguish between non- 
infectious HAV antigen and infectious virus particles.
The development of a tissue culture based assay by Lemon and co-workers in 1983 
significantly aided the study of HAV. This radioimmunofocus assay (RDFA) is a 
combination of the traditional cytopathic plaque assay and detection with radiolabelled 
antibodies. Cells grown in petri dishes are inoculated with the sample and incubated with 
an agarose overlay for up to 2 weeks. The overlay is then removed and the foci of 
infection detected by incubation with ^^^-labelled anti-HAV antibodies followed by 
autoradiography. The RIFA is useful in that it quantitates only cell culture infectious 
virus and has become a popular method in the study of HAV, however, the technique is 
extremely labour intensive and time consuming. Fluorescently labelled antibodies have 
subsequently been used to demonstrate foci of infection in a similar assay (Seigl et a l, 
1984). More recently, several assays have been reported in which cells in microtitre 
plates are incubated with serial dilutions of HAV and viral antigen detected using 
labelled antibodies to give a measure of virus titre in 50 % infectious doses (TCID50) / 
ml. These assays are also complex as they rely on either enzyme immunoassay (Yap and 
Lamb, 1994), fluorescent antibody detection and microscopic analysis (Nadala ^ d  Loh,
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1990) or adsorbing, washing and eluting radio-iodinatied antibodies from individual 
wells prior to scintillation analysis (Krah, 1991). Each of these infectivity assays involve 
the maintenance of cells for long periods followed by careful manipulation in order to 
retain the integrity of cell monolayers during immunodetection.
In 1985, a strain of HAV was reported to produce cytopathic effects in cell culture 
(Venuti et cd., 1985). This fast growing (FG) strain was isolated from an outbreak of 
hepatitis A in Southern Italy. During the third passage in Frp-3 cells (derived from FRhK- 
4 cells, a foetal rhesus monkey kidney cell line), after 7-9 days post infection, cytopathic 
effects were observed. Subsequently, several cytopathic variants of have been obtained 
by repeated passage of HAV strain HM175 (HM175A.2, Anderson, 1987; pHM175, 
Cromeans et al., 1987; 1989; Nasser and Metcalf, 1987).
These cytopathic strains of HAV made the development of cytopathic plaque assays 
possible and thereby greatly facilitated the study of frds virus in vitro, The use of these 
cytopathic plaque assays is however limited to the study of the small number of 
cytopathic strains available. Since the adaptation of HAV to growth in tissue culture is 
associated with attenuation of the virus (Provost et al., 1982; Karron et al., 1988), 
information gained regarding the replication of these highly adapted strains may not be 
applicable to that of wild type strains in vitro.
An alternative approach to detection and quantitative assay of HAV is the specific 
amplification of the genome. The polymerase chain reaction, as originally developed by 
Mullis (Saiki et a l, 1985; Mullis et a l, 1986; Mullis and Faloona 1987), allowed 
amplification of specific sequences of DNA using a bacterial DNA polymerase (Klenow
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enzyme) and oligonucleotide primers specific to the desired region of the genome to be 
amplified.
Extracted DNA was mixed with oligonucleotide primers in a buffer containing 
deoxyribonucleotides (dNTPs) and magnesium chloride at optimised concentrations. The 
mix was incubated at a high temperature, usually about 95 ®C, for several minutes in 
order to denature the double stranded DNA. The temperature was then reduced to 37 °C 
before adding the Klenow enzyme to the reaction mix. At this temperature, the 
oligonucleotide primers could bind to the sample DNA allowing polymerisation of a 
complementary strand to occur. The samples were once again heat denatured and cooled 
to 37®C before adding a fi'esh aliquot of polymerase. This process was repeated until the 
amount of amplified DNA was large enough to be visualise by agarose gel 
electrophoresis.
Whilst PCR became a useful tool in molecular biology the method was extremely labom* 
intensive and suffered with problems of specificity because the temperature of 
polymerisation was often lower than the optimal temperature for specific annealing of 
oligonucleotide primers. The technique was vastly improved by the introduction of 
thermostable DNA polymerase extracted firom thermophilic bacteria such as Thermits 
aquaticus (Taq polymerase). This enzyme can withstand the heat denaturing 
temperatures involved in PCR and therefore need only be added to the reaction mix at 
the beginning thereby simplifying the technique and reducing the risk of contamination. 
The optimal temperature for Taq polymerases is between 70-75 °C, therefore after heat 
denaturing the reaction mix may be held at an optimal temperature to allow annealing of 
primers to the correct region of the genome based on the melting temperature {Tm) of the 
sequence to be amplified. The temperature may then be raised to around 72 ®C, allowing
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the polymerase enzyme to synthesise the complementary DNA (Figure 1.3). The 
availability of automatic thermocycling machines has also greatly facilitated the use of 
PCR allowing more control over the temperature cycling parameters and overcoming the 
tedious task of manually placing the reaction mixes in different water baths.
In order to amplify RNA, a complementary strand of DNA (cDNA) must first be 
produced by reverse transcription (Veres et a l, 1987). Using primers and dNTPs in a 
buffered solution, virally encoded reverse transcriptase (from e.g. Moloney murine 
leukemia virus or Avian myoblastoma virus) catalyses the synthesis of DNA 
complementary to an extracted RNA template at 37-42 ®C . The primers used may be 
either a single specific primer to the desired sequence as shown in Figure 1.3, or a 
mixture of random hexanucleotide primers which allow reverse transcription of aU RNA 
present. The product of reverse transcription is heat denatured to destroy the activity of 
the reverse transcriptase prior to performing PCR. The methods of reverse transcription 
and PCR may be adapted to quantitate specific RNA sequences.
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Figure 1.3. The process of reverse transcription and PCR
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1.13 AIMS OF THE STUDY
The initial aim of this project was to study the effect of procedures used to eliminate or 
inactivate viral contamination of blood products such as factor Vm on HAV. This study 
required the development of techniques to be used in detection and quantitation of the 
virus. The increased use of gene amplification techniques in the field of blood virology 
has recently caused concern as little information is currently available in regard to the 
relationship between genome detection and infectivity. Therefore a further aim of this 
study was to investigate the use of RT-PCR in comparison with a tissue culture based 
infectivity assay. Since the infectivity assay relied on a highly cell culture adapted strain, 
the growth characteristics of this strain were studied both in tissue culture and a tamarin 
model and compared with that of the wild type virus and an alternative cell culture 
adapted strain. The use of tamarins in this study was necessary to demonstrate the 
changes in pathogenicity which occur upon adaptation to growth in tissue culture. 
Mutations which occurred during the selection of the strains used in the inactivation 
studies may affect the properties of the virus in vivo and also the stability of the virus 
during heat inactivation. Although not strictly within the remit of the title, the 
development of the PCR based quantitative assay made possible a study of the events 
which occur during infection of cultured cells with adapted strains of HAV and also a 
comprehensive comparison of the growth characteristics of the wild type and tissue 
culture adapted strains of the virus in a tamarin model.
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Chapter 2 
GENERAL METHODS
2.1 HAV GROWTH, ASSAY AND PURIFICATION
2.1.1 Virus
Wild type HAV strain HM175 was isolated during an outbreak of viral hepatitis in 
Australia (Daemer et cd., 1981) and found to cause persistent infection in a continuous 
African green monkey kidney cell line (BS-C-1 cells). Many variants have been 
described as this strain of HAV has become more adapted to growth in tissue culture. 
The viruses used in the present study are listed in Table 2.1
Table 2.1. Variants of HAV HM175 used in this study
HM175/wt Wild type Non-cytopathic
HM175/18f Tissue culture adapted Cytopathic in FRhK-4 cells
HM175A.2 Tissue culture adapted Cytopathic in BSC-1 cells
HAV HM175A.2 (kindly donated by Dr D. A. Anderson, Fairfield Hospital, Victoria, 
Australia) was one such variant derived from wild type HM175. BS-C-1 cells 
persistently infected with HAV HM175/wt were subcultured 30 times followed by 8 
passages of the virus at a multiplicity of infection (m.o.i.) of 0.01 radioimmunofocus 
forming units (RFU) / cell. A variant called HM175A was produced that was cytopathic 
in BS-C-1 cells. Plaque purification of this variant was carried out 3 times. A variant 
which produced large plaques was then selected and passaged a further 4 times as above. 
The resulting virus was designated HM175A.2 (Anderson, 1987).
HAV HM175/18f, (Lemon et a l, 1991) another variant of wild type HM175 
(HM175/wt), kindly provided by Prof. S. Lemon (University of North Carolina at Chapel 
Hill, NC., USA) was also studied. HM175/wt was derived after 3 passages of the original 
isolate in marmosets. A further 3 passages in marmosets were performed followed by 16
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serial passages in BS-C-1 cells. The resultant variant (HM175 p i6) was capable of 
persistently infecting BS-C-1 cells. A cytopathic variant pHM175 was recovered after 
21 to 23 subculture passages of BS-C-1 cells persistently infected with HM175 p l6 at 2 
to 4 week intervals. This virus was serially passaged 4 times at a low multiplicity of 
infection in foetal rhesus monkey kidney cells (FRhK-4) followed by 2 sequential plaque 
purifications in the same cells resulting in the variant HM175/18f which was used in this 
study.
2.1.2 Celb
Both of the cell culture adapted variants of HAV HM175, HM175A.2 and HM175/18f 
were propagated in BS-C-1 cells which were kindly donated by the University of 
Reading. Stocks of BS-C-1 cells were grown at 37 °C in Eagles Minimum Essential 
Medium containing 0.44 % sodium hydrogen carbonate, 15 mM HEPES pH 8.1 
(BMEM) supplemented with 10 % foetal calf serum (PCS), 200 units ml"^  penicillin G 
(sodium salt), 100 units ml'  ^ streptomycin sulphate (1 % from a combined 100 x stock of 
penicillin and streptomycin) and 2 g ml'  ^ Fungizone (1 % from a 100 x stock). Cells 
were split 1:2 weekly. Confluent monolayers of BS-C-1 cells (grown in 75 cm  ^ flasks. 
Falcon, ) were washed with 50 ml PBSA which was subsequently discarded. The cells 
were then incubated with 20 ml 1% trypsin (Difco, 1:250) in PBSA for 5 min followed 
by removal of the trypsin solution and further incubation at 37 °C until the cells had 
detached from the surface of the flask (usually 15 min). Clumps of cells were dispersed 
by vigorous pipetting. A 60 ml volume of BMEM containing 10 % FCS and antibiotics 
as above was then added to the flask and the cells spht equally between 2 fresh 75 cm  ^
flasks. Cells between passages 60-80 were used for growth and assay of HAV.
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2.1.3 Cytopathic microtitre plate assay of HAY HM17SA.2
This method was derived from the optimisation experiments described in section 3.1.2. 
Virus was serially diluted in 3 fold steps in BMEM containing 1 % penicillin and 
streptomycin and 1 % fungizone. A 100 pi volume of each dilution was placed in 
appropriate wells of 96 well microtitre plates (1 dilution in each of 8 wells in a column). 
As a negative control, 100 pi of the above diluent was placed in each row of the first 
column. BS-C-1 cells grown to confluence (4-5 days) were detached by trypsinization as 
described previously and resuspended in the above medium containing 4 % FCS at a 
concentration 10^  cells m l'\ An equal volume of the cell suspension (100 pi) was added 
to each well of the microtitre plates which were subsequently incubated at 35 °C, 5 % 
carbon dioxide. After 10 days incubation 50 pi of buffered MEM containing 2 % FCS 
and 250 mM sodium chloride was added to each well. Plates were incubated under the 
same conditions for a further 2 days prior to removal of medium, followed by staining 
with 0.1 % Naphthalene Black in 6 % acetic acid, 166 mM NaOAc (50 pi / well) for at 
least 30 min and washing with tap water. Stained wells were scored positive and clear 
wells negative.
A score of the number of positive wells out of the number of replicates for each dilution 
was determined and used to estimate the titre by limiting dilution analysis based on the 
Poisson distribution model, using the method of maximum likelihood for “dilution 
assays” (Collet, 1991). This model assumes the that the probability of a positive result at 
a given dilution follows a Poisson distribution, and that the only factor affecting the 
proportion of positive results is the diluting out of the sample in the dilution series. The 
calculations were carried out by fitting the appropriate statistical model to the observed 
dilution series of numbers positive out of numbers tested, using the statistical computer 
program GLIM 4 (copyright 1992 Royal Statistical Society, London). The estimated end-
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point is equivalent to the dilution at which there is an average of a single copy per 
sample tested, or the dilution at which 63% of samples tested are positive. The 
calculated endpoint is used to give an estimated “copies per ml” after correcting for the 
equivalent volume of the test sample. The values obtained were described as tissue 
culture infectious units (TCIU) m l'\
2.1.4 Preparation of virus stocks
Growth medium was removed from 75 cm  ^flasks of subconfluent BS-C-1 cells and the 
monolayers washed with 50 ml PBSA. After removing the PBSA, cells were infected 
with HAV HM175A.2 or HM175/18f at a concentration of approximately 10** tissue 
culture infectious units (TCIU) ml'^ or RFU ml"^  respectively in 0.5 ml BMEM (m.o.i. = 
-0.1 TCIU or RFU / cell). After 1 hr absorption at 35 °C, 30 ml serum free BMEM 
containing 1 % penicillin and streptomycin and 1 % fungizone was added to each flask. 
Flasks were then incubated at 35 °C, 5 % carbon dioxide for 9 days. Virus was released 
from the cells by 3 cycles of freeze thawing. Cell debris were pelleted by centrifugation 
at 2600 X g. The supernatant was extracted by mixing with an equal volume of 
chloroform in order to remove lipids which may be associated with the HAV capsids 
(Lemon and Binn, 1985), followed by centrifugation at 2600 x g. The aqueous phase 
containing virus was carefully removed and stored in 1 ml aliquots at -70 °C.
2 J.5 Purification of HAV HM175A.2
BS-C-1 cells (passage 76), split 1:2, were grown in 2 Winchester bottles (101) for 5 days 
prior to washing with PBSA and infecting with HAV HM175A.2 (m.o.i. = 0.01 TCIU / 
cell) as above. After 7 days incubation at 35 °C, when the majority of cells had become 
detached from the bottle, the contents of the Winchesters were centrifuged at 750 x g for 
10 min to pellet the cells.
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The supernatant was decanted, further clarified by centrifugation at 4800 x g for 30 min 
and mixed with polyethylene glycol and sodium chloride to final concentrations of 6.7 
% and 2.3 % respectively, for 4 hr at 4 °C. The resulting mixture was then centrifuged 
overnight at 750 x g, 4 °C. The supernatant was removed and the pellet resuspended in 
NT buffer (100 mM sodium chloride, 10 mM Tris HCl, pH 7.4) to give a total volume of 
6 ml.
The pelleted cells were washed in 50 ml PBSA, centrifuged at 1500 rpm for 10 min and 
after removing the supernatant, resuspended in 6 ml NT buffer. Nonidet P-40 (10 % vol / 
vol) was then added to a concentration of 1 % and cells were incubated on ice for 10 min 
prior to centrifugation at 1000 x g for 10 min to remove the nuclei. The resultant 
supernatant was further clarified by centrifugation at 13400 x g for 10 min in a 
microcentrifuge.
Discontinuous sucrose gradients were prepared as described by Bishop et al. (1994). 
Sequential layers of 0.5 ml 80 % (vol / vol) glycerol, 100 mM sodium chloride, 100 mM 
Tris HCl pH 7.4, 1.8 ml each of 30 % and 20 % (wt / vol) sucrose in 100 mM sodium 
chloride, 10 mM Tris HCl (pH 7.4), followed by 1.8 ml of 10 % sucrose in 100 mM 
sodium chloride, 10 mM Tris HCl (pH 7.4), 1 % SDS were carefully layered in Beckman 
SW41 tubes. Gradients were overlaid with 6 ml of the above virus suspensions (virus 
harvested from cell and supernatant fi-actions were loaded onto separate gradients) and 
centrifuged at 37000 rpm (170000 x g) for 6 hr at 18 °C. The bottom of the tubes were 
punctured and 1 ml aliquots collected into sterile 1.5 ml microtubes.
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2 .1.5 .1 Protein dot blot
The presence of HAV antigen in each fraction was determined by protein dot blot.
During each incubation and washing step, the filter was gently agitated in the appropriate
solution. From each fraction of gradient purified virus, 2 pi was spotted onto a
nitrocellulose filter and allowed to air dry. The nitrocellulose filter was then blocked by
gentle agitation with 5 % slammed milk (Marvel) in PBSA for 30 min. The primary
antibody, IgG afiinity purified human post HAV infection convalescent serum (kindly
donated by Dr Sellwood, Reading University) diluted 1:1000 in 1 % milk, PBSA, was
incubated with the filter for 1 hr at room temperature. The filter was then washed twice
for 10 min each wash in a total of 500 ml 1 % milk, PBSA. Goat anti-human IgG-
horseradish peroxidase conjugate (Sigma Chemical Co.) was diluted 1:5000 in 1 % milk,
PBSA and incubated with the filter at room temperature for 45 min. The filter was then
washed as above, followed by a further wash in PBSA only for 10 min at room
temperature. Substrate (0.64 mg ml'  ^ chloronaphthol in 25 mM Tris HCl pH 7.5, 0.03 %
hydrogen peroxide) was then added to the filter and incubated in a light proof box for 1
hr at room temperature. The filter was then washed in PBSA for 5 min followed by a
rinse in distilled water and air dried. The results of the protein dot blot showed that the
majority of antigen was present in the first firaction taken from the column (Figure 2.1)
as demonstrated by Bishop and co-workers (1994). This firaction was stored at -70 ®C
prior to use in the preparation of a working reagent for RT-PCR of HAV.
Figure 2.1 Protein dot blot of fraction from large scale purification of HAV 
HM175A.2
Samples
1-10 Fractions 1 to 10 from 
sucrose gradient 
L Material loaded onto the 
sucrose gradient 
P Positive control - HAV 
HM175A.2 stock.
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The large scale purification of HAV was performed in order to remove unencapsidated 
HAV RNA fi’om the preparation so that the RNA detected in the standards by RT-PCR 
would only be that extracted from virions. While the first fiaction may contain a small 
amount of debris, naked HAV RNA would not be present in this firaction.
2.2 DETECTION OF THE HAV GENOME BY RT-PCR
Care was taken to avoid contamination of samples during RNA extraction, reverse 
transcription and PCR following the suggestions of Kwok and Higuchi (1989). Three 
separate rooms were used. The first room was used for extraction of RNA, addition to 
the reverse transcription mixes and incubation, and addition of cDNA to the PCR mixes. 
The preparation of reverse transcription and PCR mixes was performed in a separate 
room and amplification followed by analysis by agarose gel electrophoresis in the third 
room. No equipment was transferred between the rooms. Laboratory coats were 
changed, gloves removed and hands washed before entering a different room At aU 
stages, tubes were briefly centrifuged before opening to avoid release of aerosols.
2.2.1 RNA Extraction
RNA was extracted fi'om cell culture supernatants, ceUs, human and tamarin sera and 
tamarin faeces by proteinase K / SDS extraction or using the QIAmp viral RNA 
extraction kit. Other established methods for total RNA extraction firom clinical 
specimens were also attempted. These include the use of the chaotropic agent, 
guanidiitium isothiocyanate, to release the RNA and also inactivate any ribonucleases 
present. The released RNA may then be purified by phenol chloroform extractions 
followed by ethanol or isopropanol precipitation (Chomczynski and Sacchi, 1987). 
Alternatively, after guanidinium isothiocyanate extraction, the purification of RNA may
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be achieved by chloroform extraction and adsorption onto silica particles (Boom et al., 
1990, Chungue et a l, 1993). Use of these methods however resulted in reduced 
sensitivity of RNA detection by RT-PCR.
2.2.1.1 Proteinase K / SDS extraction
From each sample, 250 pi was digested at 60 °C for 30 min with Img ml'  ^proteinase K 
and 2 % sodium dodecyl sulphate (SDS) in 50 mM Tris HCl pH 8.4, 10 mM EDTA, 200 
mM sodium chloride, 40 ng ml'  ^ glycogen in a total volume of 500 pi. The digested 
sample was allowed to cool to room temperature prior to two phenol / chloroform 
extractions followed by one chloroform extraction. Extracted RNA was precipitated by 
adding 2.5 volumes of absolute alcohol and incubating in a solid carbon dioxide/ ethanol 
bath for 1 hr or -20 °C overnight. The precipitated RNA was pelleted by centrifugation at 
13400 X g  for 20 min. The resulting RNA pellet was washed twice with 1 ml 70 % 
ethanol. The RNA pellet was vacuum dried and redissolved in 5 pi HPLC grade H2O.
2.2.1.2 QIAmp viral RNA Extraction Kit
The QIAmp viral RNA extraction kit (QIAGEN Ltd, Crawley, UK) was used according 
to the manufacturers instruction. A 140 pi sample was added to 560 pi buffer AVL 
containing carrier RNA (15 pg / extraction) and mixed thoroughly by vortexing. After 
incubation at room temperature for 10 min, 560 pi absolute alcohol was added and 
mixed by vortexing, Of this mixture, 630 pi was applied to a QIAmp spin column. The 
colunm was centrifuged at 6000 rpm for 1 minute in a microcentrifuge allowing the 
RNA extraction mix to pass through the column into a collection tube. This was repeated 
with the remainder of the mixture. The column was washed twice by the addition of 500 
pi buffer AW and centrifugation as above. After the final wash, the column was 
centrifuged for a further 2 min at 13400 x g. The column was then dried on a heating
block at 80 °C for 5 min before adding 50 pi HPLC grade water (preheated to 80 °C) and
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incubating a further 5 min at 80 °C. The RNA was then eluted in to a sterile 1.5 ml 
microtube bÿ centrifuging at 6000 rpm for 1 minute.
2.2.2 Reverse Transcription
RNA, purified by either proteinase K / SDS or Qiagen kit, was denatured by incubation 
at 75 ®C for 5 min followed by quenching on ice prior to reverse transcription. The 
denatured RNA (5 pi) extracted and purified by either the proteinase K / SDS method or 
QIAmp viral RNA kit was reverse transcribed using 16 U AMV reverse transcriptase 
(Life Sciences Inc., St Petersburg, FL, USA) / reaction in RT buffer (50 mM Tris HCl 
pH8.4 (42 °C), 45 mM potassium chloride, 10 mM magnesium chloride, 4 mM DTT), 
containing 0.4 mM each of dATP, dCTP, dGTP and dTTP and 0.5 pg ml"^  random 
hexanucleotide primers in a final volume of 20 pi. Samples were incubated at 42 °C for 
30 min followed by incubation at 80 °C for 5 min to inactivate the enzyme. The use of a 
ribonuclease inhibitor (RNAguard, Pharmacia Biotech) in the reverse tr^crip tion  mix 
was found to be unnecessary. The increase in glycerol concentration in the reaction mix 
due to the addition of the ribonuclease reduced the efficiency of reverse transcription. 
Therefore ribonuclease was omitted firom the reaction.
2.2.3 PCR
cDNA (5 pi) was amplified in a final volume of 50 pi containing 10 pmole of each 
appropriate primer, 1 x PCR buffer (20 mM ammonium sulphate, 75 mM Tris HCl, pH
9.0 (25 °C), 0.01 % (v / v) Tween), 1.5 mM magnesium chloride^ 0.4 mM each of 
dATP, dCTP, dGTP and dTTP and 0.6 U / reaction Red Hot DNA polymerase 
(Advanced Biotechnologies). The PCR reaction mix was overlaid with 30 pi mineral oil. 
After an initial dénaturation step of 94 °C for 3 min, samples were subjected to 40 cycles 
of 94 °C for 30 seconds, 50 °C for 20 seconds and 72 °C for 45 seconds followed by a
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single cycle of 94 °C for 30 seconds, 50 °C for 20 seconds and 72 °C for 3 min using a 
Omnigene thermocycler (Hybaid Ltd, Teddington, UK). PCR products were analysed by 
running 18 pi of each sample on a 2 % agarose gel containing ethidium bromide (10 pg 
ml-’).
Primers were designed with the aid of a computer program called Prime, part of GCG 
Wisconsin Sequence Analysis Package version 8 software (Genetics Computer Group, 
Madison, WI, USA). This programme checks primers for self-complementarity and pairs 
of primers for complementarity to each other. A further test is also used to determine 
complementarity between the primer and any non-specific binding sites on the template 
cDNA. By default, the programme requires G or C as the 3’-terminal base of all selected 
primers. Since G and C base pair via 3 hydrogen bonds, the presence of these bases at 
the 3’ end of the primer is less likely to result in mis-matching than A or T which pair 
with only 2 hydrogen bonds.
PCR primers - VPl/2a Junction (699 bases)
5’ 3’
Forward A7a GGTCTTGCCGTTGATACTCC
2694 2713
5’ 3’
Reverse A8a GAACCCCAGCATCCATTTC
3393 3375
The VPl/2a junction region of the HAV genome was chosen for amplification as this 
site contains a variable region which may be sequenced to determine the genotype of any 
unknown HAV isolate. Primers were selected to flank this variable region so that they 
would amplify all known genotypes. Initially, primers previously designed by Robertson 
and co-workers (1992) which recognise the VPl/2a junction were synthesised and used.
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However, the levels of sensitivity of PCR amplification using these primers was not 
acceptable for this study.
2.2.4 Preparation of working reagents for standardisation of RNA extraction and 
RT-PCR assays
HAV working reagents were prepared in plasma cryosupematant (CSlOl) and faecal 
material (FS232) so that the extraction of RNA from such samples and RT-PCR could 
standardised. The plasma cryosupematant was kindly donated by Dr Harrison (Bio 
Products Laboratories, Elstree, UK). For the faecal working reagent, a 10 % suspension 
of tamarin faeces was prepared in BMEM and clarified by centrifugation at 1300 x g for 
10 min. HAV strain HM175A.2 (7.7 logio TCIU ml'^), prepared from tissue culture by 
large scale purification, was diluted in 10 fold steps to a 1:10  ^ dilution in the 
cryosupematant and faecal material. The resulting working reagents were aliquoted in 
140 pi volumes and stored at -20 °C. The cryosupematant standard is always PCR 
positive when assayed at a 1:10 and positive 80 % of the time at a 1:100 dilution. The 
standard was included in each quantitative assay in duplicate at both a 1:10 and 1:100 
dilutiorL PCR results were only accepted if both of the 1:10 samples and 1 of the 1:100 
samples were positive. The 1:10 dilution is expected to contain 3.7 logio TCIU ml'^ and 
the 1:100 dilution, 2.7 logio TCIU ml \  Since only 3.5 pi of the diluted standard is 
present in each PCR mix the amount of RNA from infectious virus present in each 
reaction should be 20 TCIU and 2 TCIU respectively. The plasma cryosupematant 
standard, CSlOl, was included in each extraction run when assaying any blood product 
or tissue culture sample. The faecal standard, FS232, was used in the same way as the 
cryosupematant standard when tamarin stool samples were tested. The sensitivity of 
detection of the faecal standard was the same as that of the cryosupematant standard. 
The production of standards was done in a room not previously used for HAV growth, 
genome extraction or amplification using the precautions mentioned above.
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2.2.5 PCR quantitation by end point dilution
Extracted HAV RNA was quantitated by an end point dilution method Initially, a 
sample of extracted RNA was serially diluted in 3 fold steps in HPLC grade water and 
reverse transcribed as above. The lowest dilution of the resulting cDNA was also serially 
diluted in 3 fold steps. Five replicates of each dilution (made at both the RNA and cDNA 
stages) were amplified as described above. Analysis of the results (Figure 2.2) showed 
that titres estimated by dilution of cDNA (6.05 logio genomes ml'^) were comparable to 
those obtained by dilution of RNA (6.04 logic genomes ml'^).
In all subsequent quantitative PCR assays, serial dilutions of cDNA were made. In order 
to determine an approximate concentration of HAV RNA in samples prior to 
quantitation, serial 1:10 dilutions of the cDNA were first amplified. Five replicates of 3 
fold serial dilutions were then made from the concentration of the penultimate positive 
dilution. A score of the number of PCR positive samples out of the number of replicates 
for each dilution was determined and used in analysis with the log dilution to estimate 
the titre of HAV RNA using the computer program GLIM 4 as in the cytopathic 
microtitre plate assay. This value was adjusted to give a titre in logic genome equivalents 
(genomes) ml'  ^ as only 3.5 pi of original sample was present in the final PCR reaction 
mix.
As there was a decrease in band intensity in the higher PCR positive dilutions, it could 
not be assumed that the endpoint was digital. A gradual fading of band intensity at the 
higher dilutions until it was no longer possible to visualise bands by ethidium bromide 
staining may have occurred. However, nested PCR showed that no further bands could 
be detected and that single round PCR was adequate for digital enpoint detection (see 
appendix A)
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Figure 2.2 Comparison of RNA and cDNA PCR titration
Samples
M Molecular weight markers 1
1-5 Replicates of RNA diluted 1:10  ^^  and reverse transcribed
6 Negative control water
7-11 Replicates of RNA diluted 1:10  ^ and reverse transcribed 
12 Negative control water
13-17 Replicates of RNA diluted 1 ; 10^  ^and reverse transcribed 
18-22 Replicates of RNA diluted 1:10  ^ and reverse transcribed 
23 Negative control water
24-28 Replicates of cDNA diluted 1:10^
29 Negative control water
30-34 Replicates of cDNA diluted 1:10^^
35-39 Replicates of cDNA diluted 1:10  ^- 
40-41 Standard CSlOl 1:10
42-43 Standard CSlOl 1:100
M 1  2 3 4 5 6 7 8  9 10 11 121314  1516 17
M 18 19 2 0  21 22 23 24 25 26 27 28 29 30 31 32 33 34
M 35 36 37 38 39 40 41 42 43
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Chapter 3
OPTIMISATION AND VALIDATION OF METHODS
3.1 OPTIMISATION OF THE CYTOPATHIC MICROTITRE PLATE ASSAY
3.1.1 Introduction
Prior to adaptation of the virus to growth in tissue culture, HAV antigen and antibodies 
were quantitated by various radioimmunoassays (Hollinger et al, 1975, Purcell et al, 
1976). Subsequent methods developed to assay HAV in tissue culture include a 
radioimmunofocus assay (RIFA) (Lemon et a i ,  1983), in situ radioimmunoassay (RIA), 
and a fluorescent focus assay (Siegl et al., 1984). Each of these assays is complex and 
time consuming, involving the growth of HAV in tissue culture for at least a week 
followed by the use o f labelled antibodies to detect foci or relative quantity of the virus.
Various assays have been developed to measure virus titres in 50 % infectious doses m f‘ 
(TCID50). Again, these are complex as they rely on either enzyme immunoassay (Yap and 
Lam, 1994), fluorescent antibody detection and microscopic analysis (Nadala and Loh, 
1990) or adsorbing, washing and eluting radio-iodinated antibodies from individual wells 
prior to scintillation analysis (Krah, 1991).
Recently, cytopathic strains of the virus have been isolated and plaque purified for use in 
cytopathic plaque assay (Anderson, 1987, Cromeans et al., 1987). Initial attempts to use 
this assay for HAV were difficult to reproduce due to problems in maintaining the 
integrity of cell monolayers for the 2 week incubations described. Therefore a cytopathic 
microtitre plate assay which does not require the use of an agarose overlay was 
developed and routinely used.
3.1.2 Results
Infection of BS-C-1 cells with HAV HM175A.2 resulted in the appearance of 
cytopathology as shown in Figure 3.1. Little cytopathology was seen in these cells
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Figure 3.1 Cytopathology of HAV HM175A.2 and HM175/18f in BS-C-1 cells
Photographs o f unstained cells taken at 12 days post infection: a) Negative control mock infected 
BS-C-1 cells, b) HM175A.2 infected BS-C-1 cells showing rounding, clumping and detachmen 
o f ~ 95% o f cells and c) HM175/18f infected BS-C-1 cells showing only rounding o f occasional
cells. Magnification x30.
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when infected with HAV HM175/18f. BSC-1 cell monolayers were infected as described 
(2.1.4 Preparation of virus stocks) with 10  ^ TCIU HAV HM175A.2 or 10  ^ RFU HAV 
HM175/18f. Cytopathology, characterised by rounding, detachment and aggregation o f 
approximately 95% of cells was seen in HAV HM175A.2 infected cells by 10-14 days 
post infection. HAV HM175A.2 was subsequently used to develop a cytopathic 
microtitre plate assay.
The method described in Chapter 2 was chosen after careful optimisation of conditions. 
To determine the optimum concentration of cells, repeated assay of HM175A.2 
Preparation 13 was performed using cells at varying concentrations from 10  ^ cells / well 
to 10  ^cells / well. The optimum number of BS-C-1 cells was found to be 10"^  cells / well. 
If more than 10"^  ^cells were added to each well, the cells quickly over grew and began to 
die and with less than 10^^ cells / well, the staining of negative control wells was less 
distinct (Figure 3.2 and Table 3.1). Attempts to assay the virus by infecting monolayers 
of BS-C-1 cells previously seeded onto the microtitre plates were unsuccessful. Mixing 
of cells with virus at room temperature or 37 °C for 1 hr before addition to wells made no 
difference to the results and since this technique was more cumbersome, it was not 
adopted routinely. Although attachment of HAV occurs most efficiently with serum-free 
medium ( Zajac et al, 1991), the BS-C-1 cells grew poorly and the addition of 2 % FCS 
was found to be optimum (Figure 3.3, Table 3.2). The use of a synthetic serum substitute 
(Clex, Dextran Products Ltd) was also investigated. When 2 % Clex was added to the 
medium, the results obtained were no better than those observed with 2 % FCS. The 
addition of sodium or magnesium ions to the growth medium to enhance HAV 
cytopathology has been reported (Anderson, 1987, Cromeans et al., 1987). In this assay, 
the effect o f various concentrations of sodium chloride or magnesium chloride was 
investigated. No improvement of cytopathology was achieved by the addition of 26 mM
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magnesium chloride and the general appearance of uninfected cells was impaired. The 
addition of 100 mM sodium chloride after 10 days infection improved the clarity of the 
CPE without damaging the uninfected cells. Increasing the concentration o f sodium 
chloride to 200 mM led to general cell death (Figure 3.4 and Table 3.2).
A cell incubation temperature of 35 °C was chosen after comparison with incubation at 
37 °C and 34 °C. The range of incubation temperatures tested are those previously cited 
for growth and assay of cytopathic strains of HAV (Anderson, 1987, Cromeans et a i,  
1987, Nasser and Metcalf, 1987 and Lemon et a i ,  1991).
Table 3.1. Optimisation of cell concentration
No. of cells 
/well
Appearance of control cells 
after 1 week
Appearance of stained control 
cells
103.0 incomplete monolayers faint, patchy staining
103.5 good faint staining
104.0 good good dark staining
104-5 good patchy dark staining
1050 cells piled up and died dead cells detached
Table 3.2. Optimisation of assay conditions
Concentration of FCS Appearance of stained Appearance of stained
in wells uninfected wells infected wells
0% cells did not survive cells did not survive
1% faint, patchy staining very little stain
2% good dark staining very little stain
2.5% patchy dark staining patchy dark staining
Concentration of NaCl
in wells*
50mM good dark staining faint patchy staining
lOOmM good dark staining very little stain
150mM faint, patchy staining very little stain
200mM faint, patchy staining very little stain
Added after 10 days incubation
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Figure 3.2 Effect of cell concentration on the cytopathic microtitre plate assay of
HAV HM175A.2
HM175A.2 preparation 13 assayed in BS-C-1 cells. Column 1, uninfected cells; column 
2, HM175A.2 1:10^ dilution; columns 3-12, 0.5 log dilutions of HM175A.2 starting at 
1:10^. BS-C-1 cell concentrations a) 10^^ cells / well and b) 10"^  ^cells / well.
3 4 7 8 9 10 11 12
## #
m m m .
m# • w
m
#
6 7 8 d 10 11 12
###
( wm »m
m
m m
66
Figure 3.3 Effect of FCS concentration on the cytopathic microtitre plate assay of
HAV HM175A.2
HM175A.2 preparation 13 assayed in BS-C-1 cells. Column 1, uninfected cells; column 
2, HM175A.2 1:10^ dilution; columns 3-12, 0.5 log dilutions of HM175A.2 starting at 
1:10^. FCS concentrations a) 1 % and b) 2.5 %.
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Figure 3.4 Effect of sodium chloride concentration on the cytopathic microtitre
plate assay of HAV HM175A.2
HM175A.2 preparation 13 assayed in BS-C-1 cells. Column 1, uninfected cells; column 
2, HM175A.2 1:10^ dilution; columns 3-12, 0.5 log dilutions of HM175A.2 starting at 
1:10^. Concentration of sodium chloride added at 10 days post infection a) 50 mM and 
b) 150 mM
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Using the optimised conditions, a good CPE was obtained in infected cells. The titre of 
the tissue culture adapted strain o f HAV, HM175A.2, was easily determined using this 
assay. A representative assay plate is shown in Figure 3.5 and the scoring in Table 3.3. 
The log TCIU was determined by GLIM analysis to be 4.71. As only 100 pi of diluted 
virus was placed in each well, this figure was adjusted by a factor of 10 to give a titre of 
5.71 log TCIU ml '.
Assay plates were evaluated twice independently by blind microscopic analysis prior to 
staining. There was no person to person variation in microscopic evaluation. Scores 
obtained by microscopy and viewing stained plates by eye were exactly the same.
#
##
7 8 9 10 11 12
Figure 3.5 Cytopathic microtitre plate assay of HM175A.2 preparation 13
Wells in column 1 contain negative control uninfected BS-C-1 cells. Column 2, HM 175A.2 1:10^ dilution; 
columns 3-12, 0.5 log dilutions ofH M 175A .2 starting at 1:10^
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Table 3.3. Example of endpoint titration
logio
dilution
wells
infected
wells
uninfected
infected / replicates
Ratio %
-10 8 0 8/8 100
-3.0 8 0 8/8 100
-3.5 8 0 8/8 100
-4.0 8 0 8/8 100
-4.5 5 3 5/8 615
-5.0 1 7 1/8 115
-5.5 1 7 1/8 12.5
-6.0 0 8 0/8 0
-6.5 0 8 0/8 0
-7.0 0 8 0/8 0
-7.5 0 8 0/8 0
This cytopathic microtitre plate assay was also attempted using the HAV strain
HM175/18F. CPE was noted at 12 days post infection when plates were evaluated by
microscopic analysis, but the extent of cytopathology was not sufficient to determine the 
titre of the virus after staining (Figure 3.6). The reduced cytopathology of HM175/18f in 
BS-C-1 cells may be due to the fact that this variant had been clonally selected in FRhK- 
4 cells. The mutations required for cytopathic growth of HAV in this cell line may differ 
from those producing cytopathology in BS-C-1 cells.
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Figure 3.6 Cytopathic microtitre plate assay of HAV HM175/18f
Tissue culture extracted HM175/18f assayed in BS-C-1 cells. Column 1, uninfected cells; column 
2, HM175/18f 1:10  ^dilution; columns 3-12, 0.5 log dilutions o f HM175/18f starting at 1:10^
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3.1.1.2 Analysis of Assay Repeatability
The virus stock HM175A.2-13 was assayed by the optimised conditions a further ten 
times (Table 3.4) so that the statistical reproducibility of this cytopathic assay could be 
determined. Variability of the assay when repeated on the same day was calculated and 
expressed as a percentage coefficient of variation (% CV). The % CV is the standard 
deviation represented as a percentage of the mean. Similarly, analysis was also 
performed to determine the day to day variability (Table 3.5). The overall coefficient of 
variation between assays was found to be 4.0 %.
Table 3.4. Repeat assays of HAV HM175A.2 preparation 13
Assay
number
Assay
day
logio 
TCIU ml ^
1 28/3 5^6
2 13/4 5 68
3 13/4 5.78
4 13/4 5.81
5 20/7 5.71
6 20/7 5.71
7 20/7 5^2
8 29/7 5.75
9 4/8 5.19
10 4/8 5^8
Table 3.5. Variation between assays
Variation coefficient of
variation
Within-day 1.4%
Day to day 4J94
Overall 3.97%
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3.1.3 Antibody neutralisation assay
In order to demonstrate that the cytopathology obtained in the microtitre plate assay was 
due to infection of BS-C-1 cells with HAV, several antibody preparations were assayed 
against a low titre o f HAV HM175A.2, showing the ability of antisera to HAV to 
neutralise the virus.
Antibody preparations or immune sera were serially diluted in 10 fold steps in serum-free 
BMEM. Cytopathic HAV strain HM175A.2 was diluted to 10^^ TCIU ml'^ in serum-free 
buffered MEM. This concentration of virus was found to be the minimum titre required 
to give CPE in all wells. Equal volumes of the various antibody dilutions and virus were 
continuously mixed on a shaker for 2 hr at room temperature. O f each antibody dilution / 
virus mix, 20 pi were placed in appropriate wells of 96 well microtitre plates (I dilution 
in each of 8 wells in a column). . In wells of the first column 20 pi of diluent only was 
placed as cell control and in the second column, 20 pi of an equal mix o f medium and 
diluted virus as a virus control. BS-C-1 cells cultured as for cytopathic assay were 
resuspended at a concentration o f 10"^  ^ml'^ in buffered MEM containing 2 % FCS. The 
cell suspension (200pl) was added to each well of the microtitre plates which were 
subsequently incubated at 35 °C, 5 % carbon dioxide and treated exactly as in the above 
cytopathic assay. The titre of virus used was sufficient to cause cell destruction in all of 
the virus control wells. However, if  specific antibody was present, the CPE was inhibited 
by neutralisation of the virus. Therefore, if the cell monolayer remained intact, the well 
was scored positive for antibody. The results were analysed using the GLIM 4 statistical 
computer program to give titres of cytopathology neutralising units m V\
The WHO international anti-HAV human immunoglobulin standard (Gerety, 1983) was 
capable of neutralising the CPE of the virus in this assay system. Figure 3.7 shows the
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results of one neutralisation assay using the WHO standard. The titre determined by 
GLIM analysis o f this assay of the WHO standard was 1 ; 182000. Pooled immune human 
sera preparations and mouse sera from vaccine potency tests were also able to neutralise 
the virus (Figure 3.8). Non -immune human serum and pre-inoculation mouse sera did 
not appear have any neutralising affect on the virus.
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Figure 3.7 Assay of WHO immune serum globulin standard for HAV neutralising 
antibodies
The wells in column 1 contain uninfected BS-C-1 cells. The cells in the second column were 
infected with 10^  ^ TCIU / well HAV HM175A.2. Subsequent columns (3-12) were inoculated 
with virus neutralised by serial 10 fold dilutions o f the WHO standard starting from a 1:10  ^
dilution (HU/ml).
Neutralising antibody titres could be quantified by incubation of a known challenge dose 
of HAV HM175A.2 with serial dilutions o f immune sera or other antibody preparations. 
The residual infectious virus was detected by standard cytopathic assay. The end point 
titre of the WHO standard anti-HAV determined by this neutralisation assay was 
consistently 100 fold higher than those obtained by commercial HAV antibody detection
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kits. The lower limit of detection of anti-HAV in the described antibody neutralisation 
assay is approximately 1 mlU m l'\
An adaptation o f RITA called the radioimmunofocus inhibition test (RIFIT) is commonly 
used to detect neutralising antibodies. In this assay, a known quantity of tissue culture 
adapted virus is incubated with the test serum prior to performing the RIFA. The RIFIT
m
m
Figure 3.8 Neutralisation of HAV HM175A.2 cytopathology by pooled human sera 
and mouse sera from vaccine potency tests
a) Pooled human post convalescent sera (supplied by Reading University). Column 1, uninfected 
BS-C-1 cells; column 2, virus control (10*^ TCIU / well); columns 3-12, Pooled sera diluted 1:10 
in BMEM followed by serial 3 fold dilutions.
b) Assay o f mouse sera from vaccine potency test (lOpl at a 1:10 dilution in BMEM / well). 
Column 1, uninfected BS-C-1 cells; column 2 mock inoculated mouse serum; Columns 3-6, sera 
from mice inoculated with dilutions o f ’HAVRIX’ (SmithKline Beecham) - Column 3, 1:24; 
Colunm 4, 1:48; Column 5, 1/96; Column 6, 1/192
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has the same disadvantages as are encountered with the RIFA. A similar phenomenon 
was observed when the WHO international immune serum globulin standard was assayed 
by the RIFIT. Using this method titres between 1:150000 and 1:800000 were obtained in 
various different laboratories (Stapleton et al, 1985, Wood, unpublished data). This HAV 
cytopathic inhibition assay is less labour intensive and simpler to perform than the RIFIT.
3.2 OPTIMISATION OF HAV RT-PCR
3.2.1 Comparison of proteinase K / SDS and QIAmp kit methods in HAV RNA 
extraction
The proteinase K / SDS method was successfully used to extract HAV RNA from tissue 
culture, serum and blood product samples. However, the results of spiking experiments 
showed that this method was not suitable for routine detection of HAV RNA in stool 
samples. A reduction in sensitivity of the RT-PCR method when testing the HAV spiked 
stool samples was probably due to inefficient removal of contaminants which inhibited 
the reverse transcription and PCR. Using the QIAmp viral RNA extraction kit (Qiagen 
Inc.), the sample is incubated with a chaotropic agent, ethanol precipitated and 
centrifuged through a silica membrane. The membrane bound RNA may then be washed 
several times before elution in water. RT-PCR of HAV RNA extracted from tamarin 
stool samples using the QIAmp extraction kit was successful. The two methods were 
subsequently compared for water, normal tamarin serum and stool samples spiked with 
tissue culture extracted HM175A.2 at concentrations of 10  ^ TCIU mf^ (~ 14000 TCIU / 
extraction) and 10  ^ TCIU m f’ (-140 TCIU / extraction). A 10 % suspension of the 
tamarin stool sample in BMEM was prepared and clarified by centrifugation as 
previously described, prior to the addition of the virus. Using both
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Figure 3.9 Comparison of Proteinase K / SDS RNA extraction with the QIAmp 
viral RNA kit
1 2 3 4 5 6 7 8 9 10 11 12 13 M
i I
Samples
1 HAV spiked faecal suspension 10  ^TCIU ml*^  (Proteinase K/SDS)
2 HAV spiked faecal suspension 10  ^TCIU ml'* (Proteinase K/SDS)
3 HAV spiked faecal suspension 10  ^TCIU ml'* (QIAmp kit)
4 HAV spiked faecal suspension 10  ^TCIU ml'* (QIAmp kit)
5 HAV spiked tamarin serum 10  ^TCIU ml * (Proteinase K/SDS)
6 HAV spiked tamarin serum 10  ^TCIU ml * (Proteinase K/SDS)
7 HAV spiked tamarin serum 10  ^TCIU ml * (QIAmp kit)
8 HAV spiked tamarin serum 10  ^TCIU ml * (QIAmp kit)
9 HAV spiked water 10  ^TCIU ml * (Proteinase K/SDS)
10 HAV spiked water 10  ^TCIU ml * (Proteinase K/SDS)
11 HAV spiked water 10  ^TCIU ml * (QIAmp kit)
12 HAV spiked water 10  ^TCIU ml * (QIAmp kit)
13 Negative control water
M Molecular weight markers 2
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methods, 140 pi volumes of were extracted and the purified RNA resuspended or eluted 
in 50 pi water. O f the extracted RNA, 5 pi was reverse transcribed in 20 pi reaction 
mixes as described previously and 5 pi of the resulting cDNA was amplified by PCR, 
using primers HA IF and HAIR (See appendix B).
The proteinase K / SDS extraction method allowed amplification of HAV HM175A.2 in 
water and serum at both the high and low concentrations (Figure 3.9). However no HAV 
RNA was detected in the proteinase K/SDS extracted tamarin stool samples. HAV RNA 
was detected by RT-PCR in all spiked samples which had been extracted by the QIAmp 
kit. This method was subsequently used in all RNA extractions prior to RT-PCR
3.2.2 Optimisation of PCR conditions
3.2.2.1 Magnesium chloride titration
In order to determine the optimal magnesium chloride concentration required for PCR 
using primers A7a and A8a, cDNA reverse transcribed from tissue culture extracted 
HAV RNA was amplified in reaction mixes containing differing concentrations of the 
salt. Each reaction mix contained 1 x PCR buffer, 0.2 mM each of dATP, dCTP, dGTP 
and dTTP and 0.4 pM primers A7a and A8a. Magnesium chloride was added to 
individual reactions at concentrations of 1 mM, 1.5 mM, 2 mM, 2.5 mM and 3 mM. The 
cDNA was diluted 1:10 in reverse transcription buffer and 5 pi added to each PCR 
reaction mix. The tubes were subjected to 30 amplification cycles indicated above and 
15 pi of the amplification products were analysed on a 1 % ethidium bromide-agarose 
gel. The optimal conditions were those which gave the greatest product band intensity as 
determined by eye. Figure 3.10 shows that the optimal magnesium chloride concentration 
for PCR using primers A7a and A8a is 1.5 mM.
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Figure 3.10 Optimisation of RT-PCR for HAV RNA
a) Magnésium chloride titration 
M 1 2 3 4 5
b) PCR primer titration 
M 6 7 8 9 10
Samples
M
1
2
3
4
5
M
6
7
8
9
10
molecular weight markers 1
1 mM magnesium chloride
1.5 mM magnesium chloride
2 mM magnesium chloride
2.5 mM magnesium chloride
3 mM magnesium chloride
molecular weight markers 1 
0.1 pM primers 
0.2 pM primers 
0.4 pM primers 
0.8 pM primers 
1 pM primers
c) Red hot polymerase titration 
M 11 12 13 14 15
M molecular weight markers 1
11 0.2 U Red hot polymerase
12 0.4 U Red hot polymerase
13 0.6 U Red hot polymerase
14 0.8 U Red hot polymerase
15 1 U Red hot polymerase
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3.2.2.2 Primer titration
The above cDNA preparation was also used in the titration o f primers A7a and A8a. 
Each reaction mix contained 1 x PCR buffer, 1.5 mM magnesium chloride and 0.2 mM 
each of dATP, dCTP, dGTP and dTTP. Primers were added to individual reactions at 
concentrations o f 0.1 pM, 0.2 pM, 0.4 pM, 0.8 pM and 1 pM. The cDNA was added and 
tubes were treated exactly as above. The optimum concentration of primers was found to 
be 0.2 pM. While higher concentrations of primer also gave comparable results, the 
above concentration was chosen in order to conserve resources.
3.2.2.3 Red Hot polymerase titration
The amount of Red Hot polymerase required for optimal amplification of HAV RNA 
with primers A7a and A8a was determined. Red Hot polymerase was added at 0.2 - 1 unit 
/ reaction in 0.2 unit increments to 50 pi reaction mixes containing Ix PCR buffer, 1.5 
mM magnesium chloride, 0.2 mM each of dATP, dCTP, dGTP and dTTP, primers A7a 
and A8a (0.2 pM), and 5 pi o f the above control cDNA. Tubes were subjected to 30 
amplification cycles and analysed as above. The PCR product bands became more 
intense with increasing Red hot polymerase concentration until 0.6 units / reaction. As no 
further improvement was seen, this concentration of enzyme was used in all subsequent 
reactions.
3.2.3 Estimation of efficiency of HAV RT-PCR
In order to determine the efficiency of the reverse transcription and PCR, a known 
concentration of RNA encoding the VP 1:2A junction was titrated using the optimised 
method. To accurately quantitate RNA by UV spectroscopy, a concentration greater than 
20 pg ml * is required. Initially, extraction of RNA from high titre preparations of tissue 
cultures infected with HAV HM175A.2 was attempted. RNA was extracted by the
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proteinase K / SDS method. However, insufficient yields were obtained for accurate 
quantitation. Therefore, in order to produce the large titre o f RNA for quantitation by 
UV spectroscopy, a PCR derived 1.5 Kb area of the HAV genome including the VP 1:2A 
junction was cloned into a pGEM vector (Promega, Figure 6.11) and transcribed using 
SP6 RNA polymerase.
Figure 3.11 pGem-T vector map
Xmn I 1994 
Sea I 1875
pGEM®-T
Vector
T7 >1, 1
Apa I 14
A a tl l 20
Sph I 26
B stZ I 31
Nco I 37
Sac I I 46
Spe I 55
Not I 62
62
Pst I 73
W / 75
82
Sac I 94
Mlu I 99
103
Nsi I 112
126
3.2.3.1 Purification of PCR products
RNA from a tissue culture extract o f HAV HM175A.2 was extracted, reverse transcribed 
and amplified using primers A5 (forward, nucleotides 1918-1937 5' -AGC AAG CAA 
CTA CTG CTC C-3') and ASa (reverse, as described) exactly as previously described. 
The resulting 1.5 kb product covers the VPl / 2A junction of the HAV genome. After 
electrophoresis on ethidium bromide stained, 1 % agarose gel amplification products
80
were purified using a freeze-squeeze method optimised by Tautz and Renz (1983). The 
appropriate band of DNA was cut from the gel under UV illumination, and placed in a
1.5 ml microtube. The tube was then filled with 0.3 M sodium acetate (pH 7.0), ImM 
EDTA and gently agitated in the dark for 45 min. The gel slice was then placed on a 
spin-X column (Costar, Cambridge , MA) and immersed in a solid carbon dioxide / 
ethanol bath until the gel was completely frozen (~30 min). The column was then 
immediately centrifuged at 13000 xg for 10 min. The recovered DNA was precipitated 
by the addition o f 2.5 volumes of ethanol and incubation in a solid carbon dioxide / 
ethanol bath for 30 min. Precipitated DNA was pelleted by centrifugation at 13000 x g 
for 20 min and washed twice in 1 ml 70 % ethanol. The DNA pellet was vacuum dried, 
resuspended in TE buffer and analysis by agarose gel electrophoresis (Figure 3.12).
Figure 3.12 Purification of amplification products
M1 2 M 3 Samples
M molecular weight markers 1
1+2 A5/A8a PCR product
3 Purified PCR product
3.2.3.2 Ligation
The freeze squeeze purified PCR product was cloned into the pGEM-T vector (Promega) 
according to manufacturers instructions. Vector pGEM-T is Promega's pGEM-5Zf(+) 
vector, EcoR V cut with 3’ terminal dTTP added to each end. Since several thermostable
DNA polymerases generate 5’ dATP overhangs, products o f amplification can ligated
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into this vector directly after purification. Freeze squeeze purified DNA (30 ng) was 
ligated to 50 ng of vector in a 10 pi reaction mix containing 1 x ligase buffer (30 mM 
Tris HCl pH 7.8, 10 mM magnesium chloride, 10 mM DTT, 1 mM ATP) and 3 Weiss 
units T4 DNA ligase (supplied with the vector). The ligation mix was incubated at 4 °C 
overnight prior to transformation o f E.co// DH5a cells.
3.2.3.3 Production of Competent cells
E. coll DH5a cells were made competent for transformation by the method of Hanahan 
(1983) using aseptic techniques throughout. A 5 ml overnight culture of E. coli DH5a 
cells in SOB was grown at 37 °C, shaking at 275 rpm. A sterile 1 1 flask was rinsed with 
100 ml SOB. A further 100 ml SOB was subsequently added to the flask and inoculated 
with 0.2 ml o f the overnight culture. The flask was incubated as above until the 
absorbance o f the cell suspension at 550 nm was approximately 0.5 ( -  3 hr incubation). 
All subsequent stages were done at 0-4 °C. The cell suspension was then equally divided 
between 2 pre-chilled 50 ml polypropylene centrifuge tubes and centrifuged at 2.5 krpm, 
4 °C for 15 min. The supernatant was removed and ice cold FSB was added to 1 / 3 of 
the original volume. The cells were resuspended gently by carefully pipetting up and 
down a sterile Pasteur pipette. Cells were pooled, centrifuged at 2.5 krpm, 4 °C for 15 
min and the pellet resuspended in 1 / 12.5 the original volume FSB. Dimethylsulphoxide 
(DMSO) was added to 3.3 %, the cells swirled gently and incubated on ice for 10 min. A 
further equal volume of DMSO was added and after swirling, the cells were incubated as 
above for 15 min. Cells were aliquoted in 200 pi volumes frozen in a solid carbon 
dioxide / ethanol bath and stored at -70 °C.
The efficiency of the competent cells was tested using purified plasmid pUC19 DNA 
(Beohringer Manheim). Transformation with 2 pg of the plasmid produced 226 blue 
colonies giving a transformation efficiency of 1.13 x 10  ^colonies per pg of plasmid.
82
3.2.3.4 Transformation of competent E.coli DH5a cells
For each transformation, a 200 pi aliquot of competent DH5a cells in a 2 ml microtube 
was taken from -70 °C , thawed on ice. All of the ligation mix was added whilst gently 
swirling the cells and the mixture incubated on ice for 30 min. Cells were then heat 
shocked by incubation at 42 °C for 1.5 min and returning to ice. SOC was then added to 
give a final volume of 1ml and after swirling, tubes were incubated at 37 °C for 1 hr. 
Cells were dispersed by shaking every 15 min during this incubation. All o f the cells 
were then spread onto AIX plates which were allowed to absorb the fluid for 30 min 
prior to inversion and incubation overnight at 37 °C.
3.2.3.5 Small scale purification of plasmid from transformed E.co/z DH5a cells 
Plasmid was purified using a QIAprep Spin Miniprep Kit (QIAGEN Ltd, Crawley, UK) 
according to manufacturers instructions. Five ml of Luria Bertani broth containing 100 
pg mf^ ampicillin were inoculated with single bacterial colonies from transformed 
E.coli DH5a cells and grown overnight at 37 °C. The cultures were pelleted by 
centrifugation at 2600 x g, 4 °C for 10 min. The supernatant was removed, the cells 
resuspended in 250 pi buffer PI and transferred to a 1.5 ml microtube. An equal volume 
of buffer P2 was then added and mixed by gentle inversion. Chilled N3 buffer (350 pi) 
was added and the tube again mixed by inversion. The mixture was incubated on ice for 
10 min prior to centrifugation at 13400 x g  for 10 min. The supernatant was applied to a 
QIAprep column which was placed in a 2 ml collection tube. The column was 
centrifuged at 13400 x g for 1 minute and the flow through discarded. The column was 
washed with 750 pi PE buffer and centrifuged as before. Again the collection tube was 
drained and the column centrifuged a further minute at 13400 x g. Fifty pi 10 mM Tris 
HCl pH 8.0 was applied to the column which was incubated for 1 minute at ambient
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temperature before placing in a clean 1.5 ml microtube and centrifuging as above. The 
eluted plasmid was stored at -20 °C.
Each o f the plasmid preparations were analysed by restriction digestion in order to 
determine whether the HAV PCR product had been inserted. In 10 pi reaction mixes, 1 
pi of the eluted plasmid was incubated with 5 units of enzyme Bam HI at 37 °C for 1 hr. 
Half o f each restriction digestion mix was then run on an ethidium bromide stained, 1 % 
agarose gel. The pGEM plasmid does not contain a restriction site for Bam HI whereas 
the HAV PCR product does, therefore, only plasmids with the insert will be restricted. 
Of 6 colonies picked, only 1 contained the pGEM plasmid with desired insert (Figure 
3.13, lane 5). The size of this plasmid, designated pGEM-HAV5, was found to be 
approximately 4.5 kbp by comparison with the molecular weight markers as expected 
(Vector - 3 kbp, insert - 1.5 kbp). Uncut plasmids appear to run with a lower molecular 
weight due to the super coiled nature of these nucleic acids. By comparison of the 
intensity o f the ethidium bromide stained band with those of the markers after 
electrophoresis, the concentration of pGEM-HAV5 was determined to be 40 pg m \'\
Figure 3.13 Restriction enzyme digestion products from small scale plasmid 
preparations
All small scale plasmid preparations were digested with restriction enzyme Bam HI.
M 1 2 3 4 5 6 Samples
M Molecular weight markers 1
1 pGEM-HAV clone 1
2 pGEM-HAV clone 2
3 pGEM-HAV clone 3
4 pGEM-HAV clone 4
5 pGEM-HAV clone 5
6 pGEM-HAV clone 6
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3.2.3.6 Large scale preparation of pGEM-HAV5
A large scale preparation o f pGEM-HAV5 was purified using a QIAfilter Plasmid Midi 
Kit (QIAGEN Ltd, Crawley, UK) according to manufacturers instructions. E. coli DH5a 
cells, transformed with plasmid pGEM-HAV5 were harvested from a 30 ml overnight 
culture by centrifugation at 4 °C for 15 min at 6000 x g. The drained cell pellet was 
resuspended in 4 ml of buffer (PI) containing RNase A, mixed with 4 ml of lysis buffer 
(P2) containing sodium hydroxide and SDS and incubated at room temperature for 5 
min. The lysate was neutralised by the addition of ice cold 4 ml buffer P3, containing 
acidic potassium acetate which causes precipitation of proteins, chromosomal DNA, 
cellular debris, and SDS and incubation on ice for 15 min. The precipitate was pelleted 
by centrifugation at 4 for 30 min at 30000 x g. The clear supernatant was applied to a 
pre equilibrated QIAGEN-tip 100 column which was allowed to empty by gravity flow. 
After washing the column 3 times with 10 ml of buffer QC, the plasmid DNA was eluted 
by the addition of 5 ml of buffer QF. The eluted DNA was precipitated by the addition of 
0.7 volumes of isopropanol and centrifuged immediately at 4 °C for 30 min at 15000 x g. 
The pellet was washed with 5 ml ice cold 70 % ethanol, air dried for 5 min and 
resuspended in 100pi TE buffer.
3.2.3.7 Restriction digestion analysis
In order to determine the orientation of the cloned HAV DNA insert in pGEM-HAV5, 
two restriction digestions were performed. In the first reaction mix, the plasmid was cut 
with enzymes Bam HI, Hind III and Sac I and in the second mix with Bam HI, Hind III 
and Sph 1. In each reaction 20 pi mix, 2 pi o f the eluted plasmid was digested by 
incubation for 1 hr at 37 °C in 1 x 'One-phor-all' restriction enzyme buffer (Pharmacia ), 
containing 2 units of each of the appropriate restriction enzymes. Five pi from each
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reaction mix was then electrophoresed on a ethidium bromide stained 1 % agarose gel 
(Figures 3.14 and 3.15).
Figure 3.14 Restriction enzyme digestion of products from large scale preparation 
of plasmid pGEM-HAV5
m  L 2 M Samples
m molecular weight markers 2
1 Sac I, Hind 111 and Bam HI cut 
pGEM-HAV5
2 Sph I, Hind III and Bam HI cut 
pGEM-HAV5
M Molecular weight markers 1
Figure 3.15. Estimation of the size of restriction digest products
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Table 3.6. Restriction analysis ofpGEMHAV-5
Reaction Mix Band Distance Band Expected
travelled (mm) size (b) SP6 T7
A: Sac I, Hind III and 1 26 290 190 300
Bam H I 2 22 425 300 430
3 18 610 620 620
B: Sph I, Hind HI and 1 31 180 300 170
Bam H I 2 26 290 1200 300
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The results of restriction digestion analysis revealed that the HAV insert in pGEM-HAV5 
was positioned such that transcription by T7 RNA polymerase resulted in the formation 
of positive sense transcripts.
3.2.3.8 In vitro transcription
Plasmid pGEM-HAV5 contains a T7 RNA polymerase promotor region adjacent to the 
multiple cloning site, therefore the HAV insert could be transcribed to RNA using T7 
RNA polymerase. The plasmid also contains a SP6 RNA polymerase promotor, however, 
the cDNA was orientated in such a way as to produce negative strand RNA when 
transcribed by SP6 RNA polymerase and positive strand RNA when T7 RNA polymerase 
is used, making the latter polymerase the enzyme of choice.
In order to create RNA transcripts similar in size to that of the insert, 50 pg of the 
plasmid was first digested with 10 units of restriction enzyme Mlu-I in a 50 pi reaction 
mix containing 50 mM Tris HCl, 10 mM magnesium chloride, 100 mM sodium chloride 
and 1 mM DTT, pH 7.5. After incubation at 37 °C for 1 hr , 2 pi of the reaction mix was 
analysed by electrophoresis on an ethidium bromide stained 1% agarose gel to check for 
complete digestion of the plasmid. The volume of the reaction mix was increased to 200 
pi with TE buffer and the restriction enzyme removed by extraction with an equal 
volume of phenol / chloroform followed by a chloroform extraction. The linearised 
plasmid was precipitated by incubation with 0.1 vol 3 M sodium acetate and 2.5 volumes 
ethanol on ice for 30 min and pelleted by centrifugation at 15000 x g for 20 min. The 
pellet was washed with 5 ml ice cold 70 % ethanol, air dried for 5 min and resuspended 
in 20 pi water.
The cut plasmid was transcribed in vitro using a RiboMAX transcription kit (Promega). 
In a total volume of 20 pi containing 80 mM HEPES buffer pH 7.5, 32 mM magnesium
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chloride, 40 mM DTT, 2 mM spermine and 7.5 mM of each of ATP, CTP, GTP and 
UTP, 10 pi of the linearised plasmid was transcribed using 30 units of T7 RNA 
polymerase. Ribonuclease activity was inhibited by the addition of 100 U RNAsin . The 
transcription reaction mix was incubated at 37 °C for 2 hr after which the DNA template 
was destroyed by incubation with 2 U RQI RNase free DNase (Promega) for a further 30 
min. The volume of the reaction mix was increased to 500 pi by the addition o f DEPC 
treated water and the enzymes removed by extraction with an equal volume of phenol / 
chloroform followed by chloroform extraction. Unincorporated nucleotides and degraded 
DNA template were removed by ethanol precipitation. A 0.5 volume of 7.5 M 
ammonium acetate and 2 volumes of ethanol were added to the RNA sample. The sample 
was mixed, placed at -20 °C for 30 min and centrifuged at 13400 x g  for 5 min in a 
microcentrifuge. The pellet was washed twice with 1 ml 70 % ethanol and resuspended 
in 100 pi o f DEPC treated water. A 1:10 dilution o f the RNA was heat denatured in a 
boiling water bath for 5 min immediately prior to analysis on an ethidium bromide 
stained 1 % agarose gel (Figure 3.16). The RNA obtained was the expected size and the 
DNA template was not visible.
Figure 3.16 In vitro transcribed HAV RNA 
M 1
Samples
M RNA molecular weight markers 
1 In vitro transcribed RNA
A 1:25 dilution of the transcribed RNA was made in nuclease free water and the 
absorbance at 260 nm and 280 nm measured using a spectrophotometer (Kodak) in order 
to determine its concentration and purity.
O.D .260 o f transcribed RNA (1:25) = 0.784 
1 A260 unit = 40 pg m f'
.'.Concentration o f transcribed RNA = 0.784 x 40 x 25 (dilution factor)
= 784 ug ml'^ (0.784 pg / pi)
The ratio o f absorbance at 260 nm and 280 nm gives an estimation of the purity of 
nucleic acid with regard to protein or phenol contamination. An A260 / A280 ratio of 
approximately 2.0 indicates that the sample is not contaminated with any protein or 
phenol.
O.D .280 o f transcribed RNA = 0.437
A260 /  A280 ~  1-8
3.2.3.9 Calculation of molecular concentration o f RNA
In order to determine the concentration o f transcribed RNA in terms of molecules / pi, 
the molecular weight of the molecules was estimated. The composition of the RNA was 
determined by analysis of the published sequences of wild type HAV HM175 and the 
pGEM vector and used in the following equation.
Mw = (An X 347.2) + ( x 324.2) + (Cn x 307.2) + (On x 363.2) + 60"
 ^ The addition of 60 at the end of the molecular weight calculation corresponds to the 
phosphate group at the 5’ end o f the RNA molecule.
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Table 3.7 Composition of transcribed RNA
Nucleotide HAV Insert
Transcribed region of 
pGEM vector Total
A 433 17 450
G 263 33 296
G 329 34 363
U 451 15 466
Mw of transcribed RNA = 5.3 x 10^
5.3 X 10  ^g RNA = 6.023 x 10^  ^molecules (Avagadro's constant)
Concentration of transcribed RNA = 0.784 pg / p.1
= 8.9 X 10^ * molecules / ui
3.2.3.10 RT- PGR quantitation
Ten fold dilutions o f the RNA were prepared in nuclease free water containing 2 pg ml'* 
carrier RNA . O f each dilution from 1:10^ to 1:10*^, 5 pi was reverse transcribed and 
amplified by PGR as described in chapter 2. Analysis by agarose gel electrophoresis 
showed that the RNA could be detected by RT-PGR up to the 1:10*° dilution. From 
cDNA prepared using the 1:10*° dilution, 0.5 log dilutions were prepared in the above 
diluent and five replicates of dilutions from 1:10*°^ to 1:10*^^ were amplified as 
previously described and the results are shown in Table 3.8.
Table 3.8. Assay of transcribed RNA
Dilution Number of replicates positive / 5
1 2 3
l:10io.5 5 5 5
1:10" 2 2 3
1:10"* 1 2 1
1:10" 0 0 0
1:10"* 0 1 0
Estimated titre 10.89 11.13 10.96
Mean RT-PCR titre = 9.77 x 10^ ° genomes /sample
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Figure 3.17 RT-PCR of ten fold dilutions of in vitro transcribed RNA
Samples
m 1 2 3 4 5 6 7 8 9  1011 12 M molecular weight markers 1
Reverse transcribed RNA 
1 1: 10^
2 1:10°
3 1:10
4 1:10
5 1:10
6 Negative control water
RNA (not reverse transcribed)
7 1:10*
8 1:10’
9 1:10*
10 1:10’
11 Positive control CS101 
(1:10 dilution)
12 Negative control water
Ten fold dilutions o f RNA which had not been reverse transcribed were also amplified 
by PGR to determine whether sufficient template DNA had been removed such that it 
did not interfere with the results o f RNA quantitation. DNA was detected in dilutions to 
1:10^ so that levels were almost 1000 fold lower than that o f the RNA and therefore 
negligible in the calculation of the RNA titre.
3.2.3.11 Calculation of RT-PGR efficiency
Reverse transcription was done using 5 pi of sample in a 20 pi reaction mix of which 5 
pi was added to the PGR mix. Therefore only 1.25 pi o f the original sample was 
amplified.
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Figure 3.18 Example PCR titration of in vitro transcribed RNA
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 151617  18
M 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Samples
M molecular weight markers 1
1 negative control water
2-6 cDNA diluted
7 negative control water
8-12 cDNA diluted 1:10"
13 negative control water
14-18 cDNA diluted 1:10 '11.5
19 Negative control water 
20-24 cDNA diluted 1:10"
25 Negative control water 
26-30 cDNA diluted 1:10"* 
31 Negative control water 
32+33 Standard CS 101 1:10 
34+35 Standard CS 101 1:100 
36 Negative control water
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In 1.25 pi there were 1.11 x 10*^  molecules (=1.25 x 8.9x 10**)
% RT-PCR efficiency =  100 x mean RT-PCR RNA titre
Actual RNA titre
100 X 9.77x10*°
1 .11  X 10*^
8.8 %
3.3 DISCUSSION
The cytopathic TCIU assay described is simple to perform, using traditional virus culture 
techniques and does not rely on an intricate detection system. Results achieved using this 
assay are comparable with those gained by plaque assay. The virus strain used 
(HM175A.2) has been well characterised and shown to have single hit kinetics in the 
cytopathic plaque assay (Anderson, 1987). The repeatability o f the assay was confirmed 
by statistical analysis.
In the development o f HAY vaccines, an adequate antibody response needs to be 
established. According to studies using human immune serum globulin, which is used in 
the prophylactic prevention of HAV, the level of serum anti HAV required for protection 
for several weeks may be below 20 mlU ml * (Stapleton, 1995). The ability to detect 
neutralising antibodies using a microtitre plate cytopathic inhibition assay opens up new 
possibilities for large scale seroepidemiological studies and thereby aids the 
rationalisation of vaccination schedules.
The use of RT-PCR quantitation has become widespread in the estimation of viral load, 
particularly when studying viruses which cannot easily be quantitated by infectivity 
based assays, such as HIV or HCV. An advantage of amplification based RNA
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quantitation is the high sensitivity of RT-PCR compared with alternative techniques such 
as Northern blotting, RNA dot blot and RNase protection assay which require between 
10  ^ and 10  ^ copies of the target molecule (Sambrook et al., 1989; Farrell, 1993). Using 
an RT-PCR based method, Becker-Andre and Hahlbrock (1989) were able to 
reproducibly quantitate as little as 100 copies of target RNA.
Several different approaches to quantitative PCR have been reported and are either based 
on limiting dilution analysis or comparison of the quantity of amplicons produced 
compared to a standard curve of DNA or RNA which has also been quantitated by an 
alternative technique. For the latter approach, there is also a variety o f techniques used in 
the measurement of amplification products including the use of radiolabelled or 
fluorescently labelled primers combined with analysis of electrophoresed products 
(Ferré, 1992; 1994; Cottrez et a i, 1994), chemiluminescent analysis, involving the use of 
biotinylated primers to allow capture of the amplicons in a streptavidin coated microtitre 
plate and hybridisation of specific, alkaline phosphatase labelled oligonucleotide probes 
(Suzuki et a i ,  1992; Whitby and Garson, 1995). Since the equipment required for 
accurate quantitation of amplicons was not available, the limiting dilution approach to 
RT-PCR was adopted.
Concerns have been raised as to the accuracy of quantitative amplification of RNA due 
to variability in the efficiency from 5 -90 % of the reverse transcription step (Noonan et 
ai, 1990; Flenrard et a i ,  1992; Simmonds et a i ,  1990). In order to overcome this 
problem, a HAV standard was produced which was included in every RNA extraction, 
reverse transcription and PCR reaction so that the performance of each assay could be 
monitored. The performance o f this standard over 20 assays suggests that there is little 
between assay variation in RT-PCR efficiency. The efficiency of the RT-PCR method
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was also determined using in vitro transcribed HAV RNA which had been quantitated by 
UV spectroscopy. The results of 3 separate quantitative RT-PCR assays o f the RNA 
showed that the efficiency of this method varied from 7-10 % with a mean of 8.8 %. The 
mean value of the efficiency of RT-PCR was taken in to account in subsequent 
estimations o f HAV RNA copy numbers.
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Chapter 4
INACTIVATION AND ELIMINATION OF HAV IN
FACTOR VIII
4.1 INTRODUCTION
The transmission of HAV by blood transfusion is rare and until recently there was no 
evidence of transmission of the virus via plasma products (Gerety, 1982). However, 
outbreaks of hepatitis A since 1989 amongst haemophiliacs receiving solvent detergent 
treated clotting factor concentrates have caused concern to manufacturers of blood 
products and control agencies. Possible transmission of HAV by clotting factor 
concentrates was first reported in Italy by Mannucci (1992). Subsequently the use of 
solvent/detergent treated clotting factors was implicated in clusters of hepatitis A 
occurring in haemophiliac populations of Germany (Gerritzen at a l ,  1992), Belgium 
(Peerlink and Vermylen, 1993), Ireland (Temperely et a i,  1993) and the United States 
(MMWR,1996). Solvent/detergent treatments are used to destroy contaminating viruses 
during the manufacturing process by destroying the lipid viral envelope. Since HAV does 
not possess a lipid envelope, it is resistant to solvent detergent inactivation as is 
Parvovirus B19, another non-enveloped virus of concern in blood virology. Alternative or 
additional virus inactivation or elimination approaches are now being assessed.
Wild type strains o f HAV grow poorly in tissue culture and therefore infectivity titres 
cannot be measured. Tissue culture adapted strains are available which can be used in 
viral inactivation or elimination experiments, however, the widely used assays take up to 
2 weeks to complete and often are complex involving the used o f labelled antibody 
detection systems. The polymerase chain reaction (PCR) offers a more rapid viral 
detection method for such investigations and can be used to detect wild type HAV, 
however, the results are difficult to interpret in ternis of potential infectivity.
The European Medicine Evaluation Agency (EMEA) have recently adopted a plan for the 
implementation of plasma pool testing for hepatitis C RNA by gene amplification
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technology prior to use in the manufacture of blood products. Testing for other viruses 
such as HIV, HBV and parvovirus B19 by nucleic acid amplification methods has also 
been proposed by the EMEA and is likely to be adopted in the future. The recent 
outbreaks of HAV amongst recipients of blood products has also brought about plans to 
test plasma pools for HAV RNA by RT-PCR as wild type HAV cannot be easily 
measured by infectivity assay.
The terminal dry heat inactivation of HAV has been assessed in spiked factor VIII by RT- 
PCR. The results of nucleic acid quantitation have also been compared to infectivity data 
in order to determine the value of gene amplification technology to the area of validation 
of viral inactivation procedures and screening of plasma pools. The fate of HAV in spiked 
factor VIII during the affinity purification technique used in the production of Replanate 
(BPL, EIstree,UK) was also studied by HAV RT-PCR of material at each stage of the 
process.
Picornaviruses are typically highly susceptible to heat inactivation (Wallis and Melnick, 
1962). The nature o f the effect of heat on poliovirus and rhinovirus in suspension has 
been demonstrated by electron microscopy (McGregor and Mayor, 1970). At 45 °C, the 
poliovirus capsid becomes unstable with holes appearing in the structure after only 30-60 
seconds. Heating to 50 °C for 10 minutes resulted in the appearance of empty capsids and 
naked RNA. Rhinovirus 14 was found to be a little more stable than polioviruses. The 
majority of rhinovirus particles remained intact after heating to 45 °C for 1 minute. 
However, at 50 °C, release of RNA from the rhinovirus capsids occurred quickly. Siegl 
and co-workers (1984) showed that HAV has a higher thermostability than poliovirus. 
The temperature at which 50 % of poliovirus particles were inactivated after a 10 minute 
incubation was 43 °C whereas that o f HAV was 61 °C. The addition of 1 M MgCl^
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elevated the temperature required for 50 % inactivation in 10 min to 61 °C for poliovirus 
and 81 °C for HAV.
The themostability of viruses may also be increased by lyophilisation. FMDV in blood 
droplets was found to be susceptible to thermal inactivation at 80 °C for 30 seconds. 
However, heating to 86 °C for 8 min was required for complete inactivation of the virus 
in lyophilised blood powder (Forbes and Cottral, 1969). Since HAV is more stable to 
high temperatures than other picornaviruses, in this study, temperatures between 80 °C 
and 100 °C were selected for dry heat inactivation studies.
4.2 TERMINAL DRY HEAT INACTIVATION STUDY 1
In this study, the dry heat inactivation of HAV in spiked factor VIII, as detected by a 
radioimmunofocus assay (RIFA), was compared with the loss of HAV RNA as 
determined by quantitative PCR assay. As this study was initiated prior to the 
development o f the cytopathic microtitre plate assay previously described, the strain of 
HAV used was suitable for RIF A and could not subsequently be used in the cytopathic 
assay. Samples used in this experiment were taken from a previous investigation of the 
effect of dry heat treatment on HAV spiked factor VIII (Hart et al., 1994a). The 
temperatures and time points chosen were those most likely to ensure the inactivation of 
HAV whilst maintaining the activity of the factor VIII.
High purity solvent detergent treated Factor VIII prepared by the Scottish National Blood 
Transfusion Service (SNBTS, Edinburgh, UK) from serum cryoprecipitate (Burnouf et 
a i,  1991, Hart et a i ,  1994a) was spiked with tissue culture adapted HAV strain HM175 
SLI8F (Kindly provided by S. Lemon). After freeze drying in 1 ml aliquots, samples were 
heated at either 80 °C or 90 °C. Samples were taken at different time intervals (80 °C - 24 
hr, 48 hr, 72 hr; 90 °C - 2 hr, 6 hr, 10 hr) and stored at 4 °C. The spiking and heat
inactivation steps were performed by Dr H. Hart at the Protein Fractionation Centre 
SNBTS. Prior to analysis, samples were reconstituted in sterile distilled H2O and 
subsequently stored at -70 °C. RIF A was performed by Ms A. John (NIBSC) the results of 
which have previously been published (Hart et al., 1994b). Samples were diluted at a 
minimum of 1:10 and 100 pi of inoculum was used in each dish therefore the minimum 
detectable titre was 10  ^ RFU ml *. A 250 pi volume of each sample extracted by the 
proteinase K/SDS method as detailed in Chapter 2. All o f the extracted RNA was reverse 
transcribed and a 5 pi the cDNA was used in PCR reactions as previously described, 
using primers HA IF and HAIR (appendix B). The limit o f detection of the assay based on 
the quantity of material used and the efficiency of the assay is 2.3 log genomes ml*.
The results o f this study are summarised in Table 4.1. Titres o f virus in the stock 
HM175A.2 preparation and spiked factor VIII quantified by PCR titrations were similar 
to those obtained by RIF A. HAV infectivity in spiked factor VIII samples was reduced by 
100 fold upon freeze drying. The titre of viral RNA in freeze dried factor VIII decreased 
more slowly than the drop in infectivity. However, after 24 hr at room temperature post 
freeze drying the RNA and infectivity titres were more comparable. Heating freeze dried 
samples to 80 °C for 24 hr or 90 °C for only 2 hr was sufficient to completely eliminate 
FIAV tissue culture infectivity as defined by RIFA. Although levels of viral RNA were 
reduced by 1 log after 48 hr at 80 °C (4.1 log genomes ml'*) and by 1.5 log after 6 hr at 90 
°C (3.6 log genomes ml'*) the HAV genome was still detected in the samples after each 
of the heat treatments (Figure 4.1). A 3.6 logio genomes decrease in HAV RNA titre was 
achieved by combined freeze drying and heating samples to 80 °C for 72 hr whereas 
when lyophilised samples were heated to 90 °C for only 10 hr the titre was reduced by 4.1 
logio genomes. Figure 4.2 shows an example quantitative RT-PCR assay of HAV RNA in 
spiked factor VIII.
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Figure 4.1 Terminal dry heat inactivation of HAV in spiked factor VIII (SNBTS)
M 1 2 3 4 5 6 7 8 9  10111213
Samples
M molecular weight markers 2 Thermal inactivation o f factor VIII
1 HAV spiked factor VIII 5 80 °C - 24 hr
2 Post freeze drying 6 80 °C - 48 hr
3 24 hr post freeze drying 7 80 °C - 72 hr
8 90 °C - 2 hr
4 Negative control water 9 90 °C - 6 hr
10 90 °C - 10 hr
11 Negative control water
Table 4.1. Term ina! dry beat treatm ent of HAV spiked factor VIII
Sample Infectious HAV 
logio RFU ml"
HAV RNA 
logio genomes ml"
Stock HAVHM175A.2 63-1.2 7.5
HAV spiked factor VIII 6.7 7.3
Post freeze drying 4.4 7.2
24hr post freeze drying 4.3 5.1
80 °C 24hr <2.0 5.1
48hr <2.0 4.1
72hr <2.0 3.7
90 °C 2hr <Z0 6.1
6hr <2.0 3.6
lOhr <2.0 3.2
100
Figure 4.2 Example quantitative PCR titration of HAV spiked factor VIII
M1  2 3 4 5 6 7 8  9101112131415161718 M
M 19202122 23 2425 26272930313233343536 M
Samples (dilutions of spiked factor VIII)
M molecular weight markers
1-5 cDNA diluted 1:10^^ 19-23 cDNA diluted 1:10^
6 negative control water 24 Negative control water
7-11 cDNA diluted 1:10^ 25-29 cDNA diluted 1 ; 10^^
12 negative control water 30+32 Negative control water
13-17 cDNA diluted LIO'^^ 33+34 Standard CSl 01 1:10
18 negative control water 35+36 Standard CS 101 1:100
Calculation of HAV RNA titre
Result o f GLIM analysis = 10  ^genomes / sample
log RNA titre ml ' = log (10* x (100/8.8)“ x (1000/62.5)’’)
= 7.3 log genomes ml"
 ^ Replication efficiency factor 
 ^Volume factor (Proteinase K / SDS extraction)
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4.3 TERMINAL DRY HEAT INACTIVATION STUDY 2
A second study of terminal dry heat inactivation was performed using factor VIII samples 
prepared at Bio Products Laboratories (BPL, Elstree, London). The factor VIII 
(Replenate) was prepared from cryosupematant and purified by monoclonal antibody 
affinity purification and has been shown to be more stable at high temperatures than the 
factor VIII prepared at SNBTS (Roberts, 1995). On heating the Replanate factor VIII to 
72 °C for up to 72 hr, less than 10% of the clotting activity was lost compared to a 33.8 % 
loss seen with the SNBTS preparation (Hart et a i ,  1994b). This study was performed in 
order to exammine whether determinants which increased the thermal stability of the 
factor VII also conferred greater viral stability. The inactivation of HAV at 80 °C at 24 hr, 
48 hr and 72 hr were performed for direct comparison with the previous study. Earlier 
time points of 2 hr and 8 hr were also included to determine whether the length of 
incubation time at this temperature could be reduced whilst still inactivating HAV with 
regard to tissue culture infectivity. As the factor VIII sample used in this study was of 
greater stability than that of the previous study, the effect o f heating spiked samples to 
100 °C could be compared with the other inactivation temperatures used.
The factor VIII was spiked with tissue culture extracted HAV cytopathic strain 
HM175A.2 by making a 1:10 dilution in the sample of virus stock (10^ TCIU ml") to give 
a concentration of 10° TCIU ml". The spiked factor VIII was then placed in 5 ml aliquots 
and freeze dried prior to heat treatment. Two vials of lyophilised factor VIII were heated 
at 80 °C for 2 hr, 8 hr, 24 hr, 48 hr or 72 hr at 100 °C for 2 hr, 4 hr, 8 hr, 16 hr or 24 hr. 
Samples were stored at 4 °C. Prior to use, samples were reconstituted in 5 ml sterile 
distilled H2O and subsequently stored at -70 °C. All samples were analysed by cytopathic 
microtitre plate assay and quantitative RT-PCR as described in chapter 2. For the 
cytopathic microtitre plate assay, samples were diluted at a minimum of 1:100 as more
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concentrated preparations resulted in lysis of BS-C-1 cells. Since 100 pi of sample was 
added to each well, the minimum detectable titre was 10  ^ TCIU ml". RT- PCR 
quantitation was performed on samples extracted by the QIAmp Viral RNA extraction kit 
as detailed in Chapter 2. RNA was extracted from 140 pi o f each sample. A tenth of 
extracted RNA (5 pi out of 50 pi) was reverse transcribed and a quarter of the cDNA was 
PCR amplified. The detection limit of the RT-PCR protocol based on the efficiency of 
the system and the volume of sample used is therefore 3.5 log genomes ml".
When HAV spiked Replenate factor VIII was dry heat treated at 80 °C for 2 hr or longer, 
the tissue culture infectivity was decreased from 5.3 log TCIU ml" to a level that was not 
detectable by the cytopathic microtitre plate assay (Table 4.2, Figure 4.3). Similarly 
heating lyophilised samples to 100 °C for 2 hr also abolished the infectivity. HAV RNA 
was however detected in all samples which had been treated at 80 °C. After 72 hr at 80 
°C, a 2.9 logio reduction in RNA titre was seen. Heating the spiked factor VIII to 100 °C 
for 8 hr was sufficient to reduce the titre of the HAV genome to a level below the limit of 
RT-PCR detection.
Table 4.2 Terminal dry heat inactivation of HAV in spiked Replenate factor VIII
Sample
Infectious HAV 
login TCIU ml"
HAV RNA 
login genomes ml"
HAV spiked factor VIII 6.2 6.5
Post freeze drying 5.3 6.1
80 °C 2 hr < 3 ^ 5.2
8 hr < 10 5.0
24hr < 3 ^ 4.2
48hr <3.0 3.7
72hr < 1 0 3.6
100 °C 2 hr < 1 0 4.6
4 hr < 1 0 3.8
8 hr < 3 ^ <3.5
16 hr < 1 0 <15
24 hr < 3 ^ <15
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Figure 4.3 Terminal dry heat inactivation of HAV in spiked factor VIII (BPL)
1 2 3 4 5 6 7 8 9 10 1112 13 14 15
Samples
M molecular weight markers 1 Thermal inactivation of factor VIII
1 HAV spiked factor VIII
2 Post freeze drying
3 80 °C - 2hr 8 100 ^C - 2 hr
4 80 °C - 4hr 9 100 ° C - 4 h r
5 80 °C - 24 hr 10 100 ° C -8 h r
6 80 °C - 48 hr 11 100 °C - 16hr
7 80 ° C - 72 hr 12 100 °C -2 4  hr
13 Control CSlOl (1:10)
14 Control CSlOl (1:100)
15 Negative control water
4.4 ANALYSIS OF THE INTEGRITY OF THE HAV RNA AFTER HEAT 
INACTIVATION
The RT-PCR method used in the inactivation studies quantitates only the region 
amplified by the set of primers used, i.e. nucleotides 2694 - 3393, spanning the VP 1:2A 
junction of the HAV genome. No information is given as to the integrity o f the complete 
HAV genome and it’s ability to cause infection using this method. Therefore the 
following approach was used in order to clarify this point.
In reverse transcription, the genome is copied from the 3 prime end of the sequence to be 
transcribed by extension o f the 5 prime end of the primer. If a specific primer is used.
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only areas upstream of the primer should be transcribed and therefore available for 
amplification. Any break along the RNA molecule would result in the production of a 
truncated cDNA strand and the inability to amplify areas upstream of the break by PCR
Reverse transcription and PCR primers (Table 4.3) were designed to amplify regions 
toward the 3 prime and 5 prime ends of the genome as shown in Figure 4.4. The RNA 
extracted from tissue culture harvested HAV HM175A.2 was reverse transcribed using 
either primer 2, to produce cDNA corresponding to the first 2241 bases of the HAV 
genome, or primer 5, transcribing almost all of the genome. The reverse transcription 
mixes were prepared as in Chapter 2, however, instead o f random primers, 10 pmole of 
the appropriate specific primer was added to each reaction mix. As a reverse transcription 
control, a reaction was also set up containing extracted HAV RNA and reverse 
transcriptase but no primer included in the mix. The resulting cDNA was amplified using 
primer sets land 2 or 3 and 4
Figure 4.4. Reverse transcription and PCR primers
1..1 1..1 3 '
Primer ' ' cDNA
PCR Product
Table 4.3. Reverse transcription and PCR primer sequences
Primer_____________________________ Sequence
1 1918 1936
5' -AGC-AAG-CAA-CTA-CTG-CTC-C-3'
2 2241 2221
5'-ACT-GTT-GTT-GAA-AAA-CCT-CC-3'
3 6723 6743
5-GAA-CGA-GGT-AGA-ATC-ATG-AG-3'
4 6869 6850
5'-TGT-ACA-AGG-AGA-CCC-AGA-G-3'
5 7345 7319
5'-TCT-ATC-ATC-TCT-TTC-TCC-AAA-CAG-GAC-3'
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The initial control experiments using tissue culture extracted RNA gave surprising results 
as shown in Figure 4.5. Positive PCR results were obtained using RNA that had been 
incubated with the reverse transcription mix in the absence of reverse primers 2 or 5. 
Sequences were also amplified from the RNA transcribed with primer 2 at the 
downstream position using PCR primers 3 and 4. These results may be the result o f the 
ability of the HAV genome to “self-prime” or the presence o f small complimentary 
nucleic acid sequences in the extracted RNA sample (Freeh and Peterhans, 1994).
Figure 4.5 Non specific priming of HAV RNA during reverse transcription
Samples (HM175A.2)
M molecular weight markers 1
PCR primers 1 + 2
1 Random primed cDNA
2 RT primer 2
3 RT primer 5
4 No RT primers
PCR primers 3 + 4
5 Random primed cDNA
6 RT primer 2
7 RT primer 5
8 No RT primers
9 negative control water
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In order to overcome the problem of non-specific priming, several different approaches 
were tried (Table 4.4). Initially, the approach used by Freeh and Peterhans (1994) was 
attempted. Ethanol precipitated RNA extracted from tissue culture harvested HAV strain 
HM175A.2 by the proteinase K / SDS method described in chapter 2 was resuspended in 
20 pi 6 X SSC containing 7.4 % formaldehyde and incubated at 75 °C for 5 min to 
denature the RNA and quenched on ice prior to spotting 1 pi of the RNA onto 8 
nitrocellulose filters (0.5 cm^, pore size 0.45 pm, Schleicher and Schuel, Dassel,
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Gennany). The RNA was fixed to the filters by oven drying for 3 hr at 80 °C. The 
immobilised RNA was reverse transcribed by the addition of the filters to 20 pi of reverse 
transcription mix as described in chapter 2 containing either 0.5 pg ml" random primers, 
40 pmoles / reaction specific reverse primers 2 or 5, or no primers. Following reverse 
transcription at 42 °C for 30 min, the mixes were denatured at 80 °C for 5 min and 
quenched on ice prior to PCR amplification using 10 pmole / reaction of either primer set 
1 and 2 or set 3 and 4.
Alternative or additional extraction methods were also examined. The QIAmp extraction 
method was performed as described in chapter 2. Proteinase K / SDS extracted RNA was 
also further purified using Microspin S400HR columns to remove small nucleic acid 
molecules according to the manufacturers instructions. The column resin was 
resuspended by vortexing, the cap loosened one fourth of a turn and the bottom closure 
removed. The column was placed in a 1.5 ml microtube and spun in a microcentrifuge at 
735 x g  for 1 min. The column was then transferred to a clean tube and the RNA sample, 
which had been resuspended in 50 pi nuclease free water, was carefully added to the top 
of the resin and spun as above. The purified RNA was collected in the bottom of the 
support tube and heat denatured as previously described prior to reverse transcription.
A commercial kit designed to extract poly adenylated RNA were also used to extract the 
viral RNA from other nucleic acid molecules after proteinase K / SDS extraction. The 
PolyATract mRNA isolation kit (Promega) was used according to manufacturers 
instructions. The ethanol precipitated RNA pellet was resuspended in 24 pi of 
ribonuclease free water and incubated at 65 °C for 10 min immediately prior to the 
addition of 1 pi of biotinylated oligo dTTP probe and 6 pi of SSC. The mixture was 
allowed to cool to room temperature for 30 min. A 50 pi volume of streptavidin coated
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paramagnetic beads was washed in 150 pi 0.5 x SSC. A magnet was used to draw the 
beads to the bottom of the tube so that the wash buffer could be removed. After 3 washes 
beads were resuspended in 50 pi 0.5 x SSC and the annealing reaction mix added to the 
beads. The mixture was incubated at room temperature for 10 min. A magnet was then 
used to capture the particles at the bottom of the tube so that supernatant could be 
removed and the particles were washed 3 times in 0.1 x SSC (150 pi / wash). After the 
final wash, the particles were resuspended in 100 pi of nuclease free water and then 
magnetically captured. The supernatant was transferred to a clean 0.5 ml microtube and 
centrifuged at 13400 x g  for 10 min to pellet any remaining particles. The resulting RNA 
was reverse transcribed and amplified as previously described.
Table 4.4. Prevention of non-specific priming during reverse transcription of HAV 
RNA
RT PRIMERS 
PCR PRIMERS
Random 5 (3* end) 2 (5* end) None
1+2 3+4 1+2 3+4 1+2 3+4 1+2 3+4
Expected Result + + + + + - - -
RNA Extraction
Proteinase K, SDS digestion and Phenol 
chloroform extraction
+ + + + + + + +
QIAamp viral RNA extraction kit 
(Qiagen)
+ + + + + + + +
Further RNA purification
RNA immobilised on nitrocellulose filter + + - - - - - -
Microspin columns 
(Pharmacia)
+ + + + + + + +
Poly-A-tract mRNA isolation kit 
(Promega)
+ + + + + + + -
Table 4.4 shows that nitrocellulose membrane immobilisation was the only method to 
completely remove the priming of reverse transcription when no primers were added to 
the RT mix. However, using this method, the yield of PCR product using random primed 
cDNA was much lower than expected and the specific reverse primers both failed to 
produce sufficient cDNA to be detected by PCR. All o f the other methods resulted in 
PCR products , even when no primers were added to the reverse transcription step.
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However, no amplification was detected when RNA purified by the PolyAtract kit was 
transcribed without primers and amplified with primers 3 and 4.
An alternative approach was the use of an oligonucleotide poly dTTP probe to capture 
poly adenylated RNA only. HAV RNA is poly adenylated at the 3 prime end, therefore 
any HAV genomes with an intact 3 prime end could be captured and purified from other 
RNA fragments. Reverse transcription and PCR of the HAV RNA at the 5 prime end 
would show the presence of full length genomes.
Total RNA from SNBTS factor VIII samples post freeze drying and after heating to 80 °C 
for 24 hr (Table 4.1) using the QIAmp HCV RNA extraction kit as previously described. 
The poly adenylated RNA was purified using an Oligotex mRNA kit (QIAGEN Ltd) 
according to the manufacturers instructions. The volume of RNA was increased to 250 pi 
by the addition of HPLC grade water and 250 pi of 2 x binding buffer was added 
followed by 15 pi o f Oligotex beads (poly dTTP oligonucleotides bound to polystyrene 
latex particles). The mixture was incubated at 65 °C for 3 minutes to denature the RNA 
and then cooled to room temperature for 10 minutes allowing the hybridisation of poly 
adenylated RNA to the oligo dTTP. The RNA was then centrifuged for 2 min at 13400 x 
g and the supernatant carefully removed. The pelleted beads were resuspended in 400 pi 
of wash buffer and transferred to a spin column which was placed in a 1.5 ml 
microcentrifuge tube and centrifuged at 13400 x g for 30 seconds. Two further washes 
were performed by adding 400 pi of wash buffer to the spin column and centrifuging as 
above. The spin column was placed in a clean tube and 50 pi of HPLC grade water 
containing carrier RNA (0.3 pg m l") which had been heated to 70 °C was added, the spin 
column was centrifuged at 13400 x g  for 30 seconds to elute the poly adenylated RNA.
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The poly adenylated RNA was reverse transcribed using random primers as previously 
described. Serial ten fold dilutions of each of the cDNA preparations were made to 1 : 
1000 and the neat and diluted cDNA was amplified using primers HA IF and HAIR at 10 
pmole per reaction in the PCR mix previously described.
PCR primers (5 prime non-coding region)
HAIF
HAIR
57 77
5' -GAC-TTG-ATA-CCT-CAC-CGC-CGT- 3'
312 292
5’ -AGA-CTC-CTA-CAG-CTC-CAT-GCT- 3’
Figure 4.6 Analysis of the integrity of heat treated HAV in spiked factor VIH
M 1  2 3 4 5  6 7 8 9  10 11 12
Samples
M Molecular weight markers
Spiked SNBTS factor VIII 
a) 24 hr post freeze drying b) Heated to 80 °C for 24 hr
1 neat 5 neat
2 1:10 6 1:10
3 1:100 7 1:100
4 1:1000 8 1:1000
9 negative control water
10 CSlOl 1:10
11 CSlOl 1:100
no
The results show (Figure 4.6) that the 5 prime non-coding region of HAV RNA could be 
detected to the same dilution prior to and after heating of the spiked factor VIII sample. 
Both samples were positive to the 1:100 dilution which, when adjusted for sample 
volume and efficiency of the reverse transcription, gives an approximate titre of 10  ^
genomes ml".
4.5 ELIMINATION OF HAV BY MONOCLONAL ANTIBODY AFFINITY 
CHROMATOGRAPHY OF FACTOR VIII
In the production of Replenate, a high purity preparation of factor VIII produced by BPL 
(Elstree, UK), monoclonal antibody affinity chromatography is performed on the 
supernatant taken after cold precipitation o f cryoprecipitated plasma. In this study, the 
elimination of virus from HAV spiked supernatant during this process of factor VIII 
purification was examined by RT-PCR.
The cold precipitation supernatant was spiked with HAV strain HAV HM175/18f (stock 
concentration ~ 10° RFU m l") at a 1:200 dilution. Samples of the spiked factor VIII were 
taken before loading onto the affinity purification column and 1 day after being loaded 
onto the column. The column flow through, wash and eluted product were also collected 
for analysis.
Figure 4.7 shows the results of RT-PCR analysis of each step in the process of 
monoclonal antibody affinity chromatography purification o f factor VIII used in the 
manufacture of Replenate. HAV RNA was clearly detected in the load material 1 day 
after loading onto the column demonstrating the stability of the virus in the factor VIII 
preparation. A faint band of HAV RNA was detected in the material that flowed through
the column as the factor VIII was loaded, however, more of the virus appeared to be 
eluted in the wash buffer. Initial results of RT-PCR of the eluted factor VIII suggested 
that the affinity purification process had removed the virus from the preparation. When a 
50 times concentrated sample of eluate (25 ml concentrated to 0.5 ml) in PBS was tested, 
a strong signal was obtained. After collection of eluate, sanitisation and regeneration of 
the column is performed so that it can be reused to purify further batches o f factor VIII. 
The flow through of the 2 washes used in these steps were also tested for HAV RNA by 
PCR and found to be negative.
Figure 4.7 Elimination of HAV by monoclonal antibody affinity purification 
M 1 2  3 4  5 6 7 8  9 10 11 12
Samples
M molecular weight markers 2
1 Stock HAVHM 175/I8f 7 50 X concentrate of eluted factor VIII
2 Spiked load material 8 Sanitisation step (NaCI)
3 Spiked load material - 9 Regeneration step (Ac)
24 hr after loading 10 Positive control CSIOI (diluted 1:10)
4 Column flow through 11 negative control water
5 Column wash
6 Eluted factor VIII
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4.6 DISCUSSION
Several different methods which may be combined or used independently, are capable of 
eliminating or inactivating contaminating viruses in blood products. Events during the 
manufacture processes may also inadvertently lead to a reduction in virus titre such as the 
presence of virus specific antibodies in a proportion of the donations in a pool causing 
neutralisation of the contaminating virus or freeze drying of the product. Freeze drying of 
HAV spiked factor VIII prior to heat inactivation studies resulted in a reduction in 
infectious titre of 2.3 log RFU ml" and 0.9 log TCIU ml". The transmission of HAV to 
haemophiliacs in recent years shows that the lyophilisation o f blood products and 
presence of anti-HAV in the starting material is not sufficient to remove the risk of 
infection with this virus.
Additional steps may be added to the production o f clotting factor concentrates which are 
designed to physically remove contaminating viruses such as affinity chromatography, ion 
exchange chromatography and membrane filtration. In the production of Replanate (BPL, 
Elstree, UK) the factor VIII is purified by affinity chromatography. The fate of HAV in 
spiked material was studied during this process by RT-PCR. The purification of factor 
VIII from the supernatant o f cold precipitation of plasma cryoprecipitate reduced the 
level the spiked HAV. The majority o f virus appeared to be eluted from the column 
during the washing steps. Analysis o f concentrated factor VIII eluate revealed however, 
that not all of the FIAV was removed during the purification process. Additional virus 
elimination or inactivation steps are therefore necessary to ensure the safety o f factor VIII 
produced by monoclonal antibody affinity purification.
Inactivation of viruses in spiked blood products may be achieved by solvent detergent 
treatment (non-enveloped viruses only) and heating whilst solubilised or lyophilised.
n.3
While pasteurisation o f factor VIII in solution (63°C for 10 hours) results in inactivation 
of HAY (Schwinn et al., 1994), the addition of sugars, amino acids or salts is required to 
prevent inactivation of the blood product. These stabilisers must be subsequently 
removed from the preparation resulting in an increase in the number of manipulations 
required in the production of the factor VIII and a potential risk of contamination after 
the inactivation step. Severe heating lyophilised factor VIII in the absence of stabilisers 
does not result in an excessive loss of product activity (Hart et a l, 1994b). No further 
processing of the factor VIII is required after dry heat inactivation. Tenninal dry heat 
treatment of HAV spiked, freeze dried factor VIII was assessed in two studies by 
infectivity assays and quantitative RT-PCR. Comparison of the results obtained by 
detection of infectious virus and genome were used to determine the usefulness of PGR 
detection in blood virology.
The similarity in HAV titre detennined by infectivity and PGR in untreated samples 
shows that the titre of HAV genome equivalents as determined by the PGR titration assay 
used correlates well with tissue culture infectivity. In the initial study of thermal 
inactivation, the delay seen in reduction o f HAV RNA levels after freeze drying 
compared with that of infectivity may be due to slow release and subsequent ribonuclease 
digestion during the 24hr following disruption of virus particles upon freeze drying.
Dry heat treatment o f HAV spiked SNBTS factor VIII at 80 °G for 24 hr or 90 °G for 2 hr 
was adequate for elimination of tissue culture infectivity as defined by RIFA. Since tissue 
culture infectious virus was not detected in any o f the heat treated samples, it was not 
possible to determine the half lives of infectivity at the various temperatures used. Further 
inactivation studies in which samples are taken at earlier time points are required to 
determine the kinetics of thermal inactivation of HAV with regard to infectivity.
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Figure 4.8 Half life of RNA integrity during dry heat inactivation
a) Study 1, 80°C b) Study 1, 90°C
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The heat treatments used in this study were not sufficient to eliminate HAV RNA as 
detected by RT-PCR. Figure 4.8 shows the reduction in HAV nucleic acid detection upon 
terminal dry heat treatment of spiked factor VIII. The calculated half lives of nucleic acid 
integrity are based on single experiments and therefore require confirmation in repeat 
studies. The kinetics of inactivation of HAV in the factor VIII from SNBTS appear to 
differ from those in the BPL produced factor VIII. In the initial study, there was a delay 
before any RNA degradation as detected by RT-PCR occurred, whereas, in the spiked 
factor VIII from BPL, a reduction in HAV RNA titre is seen in the first heat treated 
samples (2 hr at 80 °C and 100 °C). The first half life at 80 °C of the HAV genome in 
factor VIII from BPL is therefore much lower than that in corresponding samples from 
SNBTS. Since the first half lives o f genome degradation observed in study 2 occurred 
before the initial heat treated sample was taken, in further studies, earlier time points 
should be sampled to more accurately determine these figures. This study does however, 
highlight the contribution of composition o f the factor VIII preparation to kinetics of heat 
inactivation.
The increased thermostability o f the Replenate factor VIII compared with the SNBTS 
product does not appear to increase the stability o f spiked HAV at 80 °C. Heating the 
factor VIII to 100 °C for 2 hr was sufficient to eliminate tissue culture infectivity and 
after a further 6 hr at this temperature, viral RNA was also no longer detected. Heating at 
100 °C for at least 8 hr is therefore necessary if factor VIII is required to be negative by 
PCR rather than infectivity. Inactivation at 80 °C for 2 hr would be sufficient based on 
infectivity results however, viral RNA was still detected after 72 hr at 80 °C. The loss of 
product activity during heat treatment may prohibit the use of temperatures as high as 100 
°C in the inactivation steps o f some blood products such as the SNBTS factor VIII,
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therefore the importance of PCR negativity in determining the safety of blood products 
with regard to viral contamination must be carefully considered if blood products are to 
be tested at the end of manufacture.
The use of nucleic acid amplification screen for viruses in plasma pools before 
manufacture of blood products is favourable at this stage for several reasons. The 
presence of viral genome is more likely to correlate with infectivity in the starting 
material than after the steps involved in the manufacture of the blood product. If 
contaminating plasma pools are detected and removed prior to manufacture, there is less 
financial loss than would occur if the final product was to be destroyed. Strategies for 
testing of mini-pools rather than the large pools used in the manufacture of blood 
products would also reduce the loss of starting material and facilitate the tracing of 
infected donors (McOmish et a i ,  1993).
Dry heating may cause alteration in viral capsid protein structure which prevents 
infection of cells. Further heat treatment being required for the RNA to be released and 
degraded. However, since only 699 bases of the HAV genome were amplified in the 
initial studies, it was unclear whether the whole RNA molecule is intact after heat 
treatment or only small fragments are resulting in amplification.
The initial approach used in an attempt to determine the integrity o f heat treated RNA 
was to use specific primer to at the 3 prime non-coding region to prepare cDNA and then 
amplify a region towards the 5 prime end of the HAV genome. Control experiments 
showed that non-specific priming occurred during reverse transcription resulting in 
amplification of products after the reverse transcription reaction had been performed in 
the absence of primers. Several strategies were tried in order to remove the nucleic acids
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which acted as primers for reverse transcription. The only method that completely 
abolished non specific priming was immobilisation o f the RNA on a nitrocellulose filter. 
However, using this method, PCR amplification only succeeded when random primers 
were used in the reverse transcription. Immobilisation of the RNA on the filter may have 
restricted binding of the specific primers.
In an alternative approach to assess the integrity of heat treated HAV RNA, the Oligotex 
mRNA kit was used to capture the RNA at the 3 prime end followed by reverse 
transcription and PCR amplification in the 5 prime non-coding region, allowing the 
detection of full length RNA only. The results showed that full length RNA was present 
to approximately the same level in the heated factor VIII sample which no longer 
contained tissue culture infectious virus as in the post freeze drying sample in which RNA 
levels were comparable to that of infectious virus.
This study highlights the disparity between the use of infectivity assay and RT-PCR in the 
detection of viruses after inactivation procedures. A question which must now be 
addressed is whether the presence of full length HAV RNA in the blood products poses a 
risk to the recipients. It may be supposed that the full length RNA found in inactivated 
samples is encapsidated otherwise it would be quickly destroyed by ribonucleases present 
in the factor VIII preparation. While the heat treated virus is unable to penetrate and 
cause infection cells in culture, it may be possible for the intact RNA to infect cells in 
vivo. The use of nucleic acid based detection of wild type RNA in blood products may be 
implemented routinely in the future following the outbreaks o f HAV amongst recipients 
of blood products. While nucleic acid amplification technology is highly sensitive, 
interpretation of the results from such techniques is difficult with regard to defining the 
risk of transmission of HAV in material which is tested positive for the viral genome. The
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high demand for products derived from voluntarily donated plasma necessitates the 
careful management of this limited resource. Therefore the potential of in vivo infectivity 
o f blood products containing the HAV genome must be assessed before destroying such 
material.
The choice of primers used in PCR amplification of viral RNA genomes after heat 
inactivation may also affect the relationship between PCR positivity and infectivity. 
Areas o f the genome with a high degree of secondary structure will be more resistant to 
heating and ribonuclease digestion and should therefore be avoided. Amplification of 
small targets may result in positivity when very little of the genome is intact. In this study, 
it was shown that the whole genome remained intact by capturing the RNA at the 3 prime 
end and amplifying the 5 prime end.
These results also have implications for the use of nucleic acid amplification technology 
in the detection of other viruses which cannot be assayed in tissue culture, such as HCV 
and parvovirus B19, in virally inactivated blood products. It must be remembered that 
presence o f PCR positivity does not necessarily indicate that the product contains 
infectious virus or even full length viral genomes.
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Chapter 5
TIME COURSE OF HAV REPLICATION IN BS-C-1 CELLS
5.1 INTRODUCTION
The study of replication in picomaviruses has been facilitated by the rapid growth, high yields 
and cytopathogenicity, typical of members of this family. Poliovirus, the first of the 
picomaviruses to be propagated in cultured cells, replicates to produce yields of up to 10  ^PFU 
/ cell in less than 10 hours of infection (Baltimore et a i, 1966). The typical single step growth 
curve of poliovirus consists of a lag phase, in which the vims attaches to the cell via a specific 
receptor, is internalised and uncoated, followed by a period of logarithmic replication until 
maximum vims titres are reached. During the lag phase, an eclipse of infectivity occurs as the 
viral RNA is released from the vims particles. The duration of this phase is usually 2-3 hr in 
poliovims (Lwoff and Lwoflf, 1961) and foot and mouth disease virus (Bachrach er al., 1957). 
Rhinovims 2 and 14 have a longer replication cycle, with a lag phase of 4-7 hr and maximal 
titres obtained at 10-18 hr post infection (Fiala and Kenny, 1967; Stott and Heath, 1970). The 
behaviour of HAV in cell culture markedly differs from that of other picomaviruses in that 
after 4-8 days of replication, persistent infection is generally established (De Chastoney and 
Siegl, 1987).
While the replication kinetics of the majority of picomavimses may be comparable, the 
optimal conditions for maximum virus replication differs. The temperature at which infected 
cells are incubated particularly affects the yield of these vimses. Rhinovimses 2 and 14, 
replicate optimally at 33-35 °C (Stott and Heath, 1970), whereas foot and mouth disease virus 
requires temperatures of 35-39.5 °C (Sharpe, 1958). Poliovims replication is most efficient at 
37 °C and is partially blocked at 39 °C (Lwoff and Lwoff, 1961).
Studies by Anderson et a l (1988) have suggested that the poor growth of HAV in tissue 
culture may be dependent on the efficiency of packaging of the HAV genome. These studies 
were based on a dot blot hybridisation method for RNA detection in which a single dilution 
series of the RNA was assayed be hybridisation with a radiolabelled probe. The amount of
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RNA was quantitated by comparing the intensity of signal with known amounts of DNA from 
a plasmid containing the HAV sequence, detected by the hybridisation probe. While the dot 
blot method is quantitative, it does not take into account Poisson distribution as only a single 
sample at each dilution was hybridised. In addition, it also assumes that the sensitivity of 
detection of DNA by hybridisation is the same as that of RNA. Therefore the HAV genome 
copy number could not be directly correlated with the formation of infectious particles.
In the present study, the replication of HAV cytopathic strain HM175A.2 in BS-C-1 cells was 
assessed by comparing production and release of infectious virus particles with synthesis of 
HAV RNA using sensitive tissue culture and quantitative RT-PCR assays along with in situ 
hybridisation of viral RNA and immunofluorescent detection of antigen. The growth curve of 
strain HM175/18f which is less cytopathic in BS-C-1 cells was also determined by RNA 
quantitation and compared with that of HM175A.2. This study was initially designed to 
correlate RNA quantitation by RT-PCR with infectivity assay of HAV in order to investigate 
the value of nucleic acid based detection in determining the risk of transmission HAV via 
blood products. The quantitation of the HAV genome in this time course experiment is also 
useful in demonstrating the growth characteristics of HAV HM175A.2 and HM175/18f in BS- 
C-1 cells, although this does not strictly relate to the title of this thesis.
5.2 METHODS
5.2.1 Infection of BS-C-1 cells
Confluent flasks of BS-C-1 cells (passage 68) were split 1:2 into 12 culture flasks (25 cm^) 
After 3 days incubation at 37 °C in buffered MEM containing 10 % PCS, cells from one flask 
were detached by treatment with 1 % trypsin as previously described and counted in a 
haemocytometer. Cells in 10 of the flasks were then inoculated with HAV HM175A.2 at a 
m.o.i. of 1 TCIU per cell. The culture medium was removed from 10 of the flasks and cells 
were washed with phosphate buffered saline. Cells were incubated with 0.5 ml virus at a
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concentration of 1 x 10^  TCIU mf^ in buffered MEM 2 hr at 35 °C, 5 % carbon dioxide. A 9.5 
ml volume of buffered MEM containing 2 % FCS was then added to the flasks. The remaining 
flask was mock infected with buffered MEM in exactly the same way. The time at which the 
virus was placed on the cells was designated 0 hr.
5.2.2 Harvesting cells and virus
At each time point (1-170 hr), a flask of infected cells was taken, 2 ml of medium was taken 
and stored at -70 °C . The cells were washed in PBS and detached by incubation with 4.8 % 
trypsin in PBS. The resuspended cells were washed twice in a total o f 40 ml PBS and 
resuspended in 10 ml PBS. A 2 ml aliquot of the resuspended cells was subjected to 3 cycles of 
freezing at -20 °C and thawing at room temperature followed by centrifugation at 2600 x g  to 
remove cellular debris. The supernatant was mixed with an equal volume of chloroform and 
centrifuged at 2600 x g. The resulting aqueous phase was stored at -70 °C. The remainder of 
the cell suspension was diluted to 2 x 10  ^ cells / ml and cytospun onto ethanol washed 
microscope slides at 500 rpm for 5 min (250 pi /“cell spot”). After centrifugation, slides were 
air dried and fixed in 1 x Histochoice (Ameresco) for 30 min at room temperature. Fixed slides 
were washed in PBS and dehydrated through a series of 30 %, 50 %, 70 %, 90 % and 100 % 
ethanol, air dried and stored at -70 °C.
5.2.3 Immunofluorescence (IF)
Slides were taken from -70 °C to room temperature, allowed to equilibrate for 30 min and 
rehydrated through a series of 100 %, 90 %, 70 %, 50 % and 30 % ethanol. Affinity purified 
human post-convalescent serum diluted 1:250 in PBS was applied to each “cell spot” and 
incubated 4 hr at room temperature in a humidified chamber. Slides were then washed 3 times 
in PBS for 5 min. The secondary antibody, anti-human IgG, FITC conjugate (Sigma Chemical 
Co.) was diluted 1:20 in PBS, 0.005 % Evans blue and applied to the slides. After 30 min
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incubation slides were washed as above and mounted in 10 % glycerol in PBS containing 0.25 
% DABCO (Sigma Chemical Co.).
5.2.4 In situ hybridisation (ISH)
ISH was performed by Dr M. Taylor (St Mary's Hospital Medical School) on histochoice fixed 
cytospins of infected BS-C-1 cells using 30 base oligonucleotide probes as previously reported 
(Taylor et a l, 1992). Both antisense and sense polarity probes were used as shown in Table 5.1 
The latter were used to examine the cells for the presence of replicative intermediates of the 
antigenomic HAV RNA. The probes were prepared on a Cyclone DNA oligonucleotide 
synthesizer (Biosearch Inc., New Brunswick Scientific Co., Inc., Edison, NJ) and 3' end- 
labelled to a specific activity of approximately 1x10^ cpm / pmol with dATP ^^ S (Amersham, 
code SJ1334) using a commercial kit (NEP-100; NEN Du Pont, UK Ltd., Stevenage, UK) 
which uses a terminal deoxynucleotidyl transferase to add a polymeric tail of the radioligand 
to the 3' end of the probes. Throughout the in situ hybridisation procedure, only sterile diethyl 
pyrocarbonate-treated water or PBS and molecular biology grade chemicals (Sigma Chemical 
Co.) were used. Prior to hybridisation, slides were rehydrated by 2 min incubations in each of 
100 %, 90 %, 70 %, 50 % and 30 % ethanol and washed for 5 min in PBS with gentle stirring. 
The slides were then blocked by incubation in 0.1 % acetic anhydride in 0.1 M 
triethanolamine, pH 8.0, for 10 min at room temperature with stirring followed by rinsing in 
water and dehydrating. Each cell spot was overlaid with 100 pi of hybridisation buffer 
consisting of 50 % deionized formamide (Fluka Chemie AG, Glossop, UK), 1 x Denhardfs 
solution (BSA, Ficoll and polyvinylpyrolidone, each at a final concentration of 0.02 %) 1 mM 
EDTA, 250 pg m f’ denatured salmon sperm DNA, 10 % Dextran sulphate, 250 pg mf^ yeast 
transfer RNA,, 250 pg m f' polyadenylic acid and 4 x sodium chloride / sodium citrate (0.6 M 
/ 0.06 M). Before use, the hybridisation buffer was heated in a boiling water bath for 3 min and 
quenched on ice. DTT was added to yield a final concentration of 10 mM. Sections were 
overlaid with hybridisation fluid and incubated in a moist chamber for 3 hr at room
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temperature. The oligonucleotide probes were diluted to give between 2.0 x 10  ^and 3.0 x 10  ^
cpm / 100 pi of hybridisation fluid (1:5 dilution) and 50pl added to each prehybridised and 
drained 'cell spot'. Slides were incubated overnight in an air tight moist chamber. After 
hybridisation the slides were washed in 2 changes of 1 x SSC (150 mM sodium chloride, 15 
mM Sodium citrate) at room temperature and 4 changes of 1 x SSC at 54-56 °C for 15 min 
each followed by a dip in water and air drying. Slides were then coated in 0.1 % chromalum, 
0.01% gelatin, air dried and dipped in K5 nuclear track emulsion (Ilford Ltd, Mobberley, 
Cheshire, UK), diluted 1:1 in deionized H2O containing 0.025% glycerol, and exposed in a 
light proof box for 19 days. Development was with Phenisol (Ilford Ltd.) followed by transfer 
to a acid stop bath (1 % acetic acid , 1 % glycerol), fixation in sodium thiosulphate and 
extensive washing in deionized water under dark room conditions. Slides were counter stained 
in Mayer's haemalum and mounted in DePex mounting medium (both from Merck Ltd., 
Lutterworth, Leicester, UK.). Slides were examined by conventional light microscopy and 
scored subjectively for intensity of hybridisation signal.
Table 5.1 Oligonucleotide Probes
Probe_______________________________ Sequence_________________________________ %GC_____
Antisense
1049 1380
HAV-1 5'-CAG-TGA-AGT-ATA-AGC-TGA-AGT-TCC-TGT-CCC-3' 4 7
3082 3053
HAV-2a 5-CTA-GGA-TCA-TCC-ACT-GAT-GAC-TCC-AGG-TCT-3' 4 7
2371 2342
HAV-3 5'-ATT-GTT-GTG-ATA-GCT-CCC-ACA-GGT-GCT-TGT-3' 4 7
Sense
3053 3082
HAV-2S 5'AGA-CTT-GGA-GTC-ATC-AGT-GGA-TGA-TCC-TAG-3' 4 7
Controls
HAV-2 reverse antisense
HAV-2ra 5'-TCT-GAA-CCT-CAG-TAG-TCA-CCT-ACT-AGG-ATC-3' 4 7
Irrelevant 30-mer
Cl 5’-AGC-TAC-AAG-CAC-AAT-GGA-ACA-GAA-CTC-ACC-3' 4 7
5.2.5 HAV infectivity assay
Tissue culture fluid and lysed cells were assayed for infectious HAV by the cytopathic 
microtitre plate assay previously described. Briefly, 100 pi of 3 fold dilutions of each sample
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in buffered MEM containing 2 % FCS were placed in wells of a microtitre plate (5 replicates 
per dilution). To each well was added 100 pi BS-C-1 cells (10^ cells / ml) and plates were 
incubated at 35°C, 5 % CO]. After 10 days incubation, 50 pi of buffered MEM containing 2 % 
FCS and 250 mM NaCl was added to each well and plates incubated a further 2 days prior to 
staining with Naphthalene black.
5.2.6 HAV RNA quantitation
RNA was extracted from tissue culture supernatant and lysed cells using a QIAmp viral RNA 
extraction kit (Qiagen Ltd.), reverse transcribed and amplified using primers A7a and A8a in 
the quantitative PCR method previously described (Chapter 2).
Infection of BS-C-1 cells with HAV FIM175A.2 and subsequent harvesting and quantitative 
analysis was performed a total of 3 times on different days. All PCR and cytopathic microtitre 
plate assay results are shown as means. Flasks of BS-C-1 cells were also infected in exactly the 
same way with HAV HM175/18f (m.o.i. = 1 RFU m f') and cells and media harvested as 
above for quantitative RT-PCR analysis.
5.3 RESULTS
5.3.1 Expression of HAV antigen in BS-C-1 cells
Infection of BS-C-1 cells was confirmed by immunofluorescent staining. Figure 5.1 is 
representative of the immunofluorescent staining seen throughout the time course of infection. 
Very little background was seen in the uninfected BS-C-1 cell control (Figure 5.1a) and a 
second negative control of infected cells incubated with diluted normal human serum instead 
of the primary antibody. HAV antigens were not detected until 40 hr post infection (p i.) when 
approximately 10 % of cells were positive (Figure 5.1b). By 72 hr p i., the majority of cells 
were expressing antigen at low levels.
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Figure 5.1 Immunofluorescent staining of HAV HM175A.2 infected BS-C-1 cells
a) Mock infected BS-C-1 cells b-d)HAV HMl 75A.2 infected BS-C-1 cells
_____________________________________ b)40 hr p.i.
c) 120 hr p.i. d )146 hr
I f  ■ ^
V  « f .J  .
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Staining was most intense at 120 hr p.i. however, by 146 hr p.i., fewer cells expressed antigen 
(Figures 5.1c and 5. Id). Very few cells expressed antigen at 170 hr p.i..
5.3.2 Detection of HAV RNA by in situ hybridisation
5.3.2.1 Using antisense probes
The presence of HAV RNA was only detected in cells from the 40 hr time point onwards. At 
this time, silver grains (20-50 grains / cell) were seen to be overlying approximately 3-4 cells 
per high power field. The distribution of this focal signal was predominantly cytoplasmic, 
although grains were also seen overlaying the nuclei. At 48 hr, the number of positive cells per 
high power field had risen to about 20. By 72 hr nearly all cells per field were positive (Figure 
5.2a). No great change could be discerned on the 90 hr sample. By 120 hr all the cells 
remained positive and occasional cells showed more intense clusters o f silver grains (80-120 
grains / cell). Maximum hybridisation signal was seen on the 146 hr sample where 9 / 1 0  cells 
exhibited similar intense labelling with the antisense probes (Figure 5.2b). The pattern of 
signal described was representative of 3 separate timecourse experiments. Appreciable cell 
loss was frequently associated with the last time point at 170 hr. These cells were lost during 
the high stringency washes at 56 °C in 1 x SSC. No significant cell loss was noticed from 
slides at the other time points. Cells which remained on the 170 hr slides showed only sporadic 
silver grains. In contrast, very few background grains were seen in uninfected cells (Figure 
5.2c)
5.3.2.2 Using sense probes
No specific hybridisation signal was found at any of the time-points when sense polarity 
probes were used.
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Figure 5.2 In situ hybridisation of HAV HM175A.2 infected BS-C-1 cells
a) HAV HM175A.2 infected BS-C-1 cells - 72 hr p.i., b) 146 hr p.i., c) Mock infected BS-C-1 cells
L-’
»
• - “v.
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I
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5.3.2.3 Control experiments
The ISH method has previously been fully validated on both cryostat and paraffin embedded 
tissue sections (Taylor et al.,\992, Taylor et ai, 1994). In the present study using cytospins, 
specificity was again confirmed by prior digestion with RNases A and TI. This treatment 
abolished hybridisation.
5.3.3 Cell and culture medium associated infectious HAV particles
Variations in levels of released and cell associated infectious virus throughout the timecourse 
are shown in Table 5.2 and Figure 5.3 and total infectious virus titres in Figure 5.4. All data 
were adjusted to give titres per 10  ^ cells for ease o f comparison. Cells were infected at a 
multiplicity of infection of 1 TCIU per cell (6 logio TCIU / 10  ^ cells). After 1 hr virus 
adsorption, the titre of infectious virus in the cell culture medium was 4.88 logio TCIU / 10  ^
cells. Thus approximately 90 % of virus was taken up by the cells during the first hour (Figure
5.3 -#-). At 16 hr p.i., only 2 % of the initial inoculum was recovered in the culture medium. 
The titre of infectious HAV virions released into the cell culture medium increased 
logarithmically from 4.27 logio TCIU ! \&  cells at 16 hr to 6.93 logio TCIU /10^ cells at 48 hr 
p.i. (Figure 5.3 -#-). The rate of viral replication then began to decrease. By 72 hr, a stationary 
phase was entered (7.24 logic TCIU / 10  ^cells. The mean titre obtained in the stationary phase 
was 7.31 logic TCIU released / 10  ^cells (~20 TCIU released / cell). In this ‘stationary phase’ 
no further increase in total HAV titre was detected, however, cells remained viable and CPE 
was not seen. The growth curve for cell associated virus followed the same pattern as that of 
released virus with a mean titre of 7.28 logic TCIU /10^ cells (~20 cell associated TCIU / cell) 
during the stationary phase (Figure 5.3 -□-). The total amount of HAV produced per cell 
during the timecourse was approximately 40 TCIU / cell.
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Table 5.2. Levels of cell and culture medium associated HAV HM175A.2 tissue culture 
infectious particles following infection of BS-C-1 cells
Time
(Hr)
Cell associated infectious Hv 
HM175A.2 (TCIU / lO^ c^el
W
s)
Medium associated infectious 
HM175A.2 (TCIU /10^ cel
HAV
Is)
Total1 j 2 3 1 Mean S. E. 1 2 3 Mean S. E.
1 4.35 1 4.66 4.43 4.48 0 . 1 0 5.15 4.67 4.83 4.88 0.15 5.02
16 4.30 4.66 i 4.16 ; 4.Ï5 0.09 4.52 i Ï9 5  1 4.35 [ 4.27 0.17 4.52
24 ^63 1 i5 3  [ 5.77 [ 5.64 0.07 5.94 I 6.10 [ 6.08 1 6.04 0.05 6.19
40 6.23 I 6.30 [ 6.13 [ 6.22 0.05 6.56 1 6.61 [ 6.46 1 6.54 0.05 6.71
48 7.23 1 6.75 I 7.17 ; 7.05 0.15 6.88 1 6.87 1 7.03 i 6.93 0.05 7.30
72 7.39 [ 7.16 [ 7.06 [ 1 2 \ 0 . 1 0 7.29 ! 7.30 [ 7.12 [ 7.24 0.06 7.52
90 129  1 ÏA5 7.20 1 1 2 \ 0.04 T89 111  1 7.28 7.48 0 . 2 1 7.67
120 7.38 I 7.49 i 7.27 [ %38 0.06 7.36 ; 7.30 I 7.12 i 7.26 0.07 7.63
148 7.57 [ 7.22 [ 7.14 [ I M 0.13 7.3 i [ 7.13 1 7.32 1 7.25 0.06 7.58
170 7.20 i 7.16 1 7.45 1 7.27 0.09 7.54 1 T Ï 8  i 7.26 ; 7.33 0 . 1 1 7.60
5.3.4 Cell and culture medium associated HAV RNA
The release of HAV RNA from BS-C-1 cells during the timecourse was similar to that of 
infectious particles (Table 5.3, Figure 5.3). The levels of RNA in the culture fluid increased 
logarithmically from 4.54 logio genomes /10^ cells at 16 hr to 7.16 logio genomes /10^ cells at 
48 hr. As seen with the levels of infectious virus, at 72 hr, a stationary phase was entered. The 
mean titre of HAV RNA detected in the cell culture medium was 7.61 logio genomes / 10^  
cells (-41 genomes released / cell. Figure 5.3 - A - ) .
The titres of cell associated HAV RNA were higher than the corresponding titres of cell 
associated infectious virus particles, although the patterns of the time courses were similar 
(Figure 5.3). A logarithmic increase in cell associated RNA was seen from 5.59 logio genomes 
/10^ cells at 16 hr to 8.44 logio genomes / 10  ^cells at 48 hr. The mean titre of cell associated 
HAV RNA during the stationary phase (72 - 170 hr) was 8.59 logio genomes / 10  ^cells (-355 
genomes / cell. Figure 5.3 -A-). At the stationary phase, combined titres o f cell associated and 
released HAV give a total of -396 genomes / cell. Figure 5.4 shows the production of total 
HAV infectious virus and total HAV RNA.
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Figure 5.5 Example quantitative RT-PCR assay of ceil associated HAV HM175A.2 
M 1 2 3 4 5  6 7 8  9 10 11 12 13 14151617I8M
M19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 M
Samples (dilutions of cell associated HAV RNA 1 hr post infection)
M molecular weight markers 1
1-5 cDNA diluted 1:3 19-23 cDNA diluted 1:10^
6 negative control water 24 Negative control water
7-11 cDNA diluted 1:10 25-29 cDNA diluted 1:10^^
12 negative control water 30-32 Negative control water
13-17 cDNA diluted 1:10'“ 33+34 Standard CSlOl 1:10
18 negative control water 35+36 Standard CSlOl 1:100
Calculation of HAV RNA titre
Result of GLIM analysis 
log RNA titre /10^ cells
“ Replication efficiency factor 
Volume factor (1ml)
Cell concentration = 3 x lOV ml
= 50 genomes / sample 
= log (50 X (100/8.8)“ X (1000/3.5)^ x 3.33“) 
= 5.73 log genomes ml''
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Although the curves are similar, a t-test of the mean data taken at the stationary phased showed 
that levels of total RNA are significantly higher (P<0.01) than those of infectious virus. Levels 
of total RNA were 10 fold higher than infectious virus during this phase.
Table 5.3. Levels of cell associated and released HAV HM175A.2 RNA following 
infection of BS-C-1 cells
Time
(Hr)
Cell associated HAV HM175A.2 RNA 
(genomes /10^ cells)
Medium associated HAV HM175A.2 RNA 
(genomes /lO  ^cells)
Total1 1 2 ! 3 1 Mean S. E. 1 ! 2 ! 3 ! Mean S. E.
1 5.73 5.80 5.62 5.72 0.05 4.75 5.05 5.13 4.98 0.12 5.97
16 5.62 5.49 5.66 5.59 0.05 4.49 4.75 4.39 4.54 0.11 5.62
24 6.2 i 6.48 6. i s  6.’39 0.10 5.88 6.40 6.23 6.17 0.16 6.54
40 7.24 7.46 7.62 7.44 0.11 6.95 6.79 6.74 &83 0.06 7.54
48 7.68 8.16 8.Î9 8.01 0.17 7.25 7.24 7.00 7.16 0.08 8.07
72 8.26 8.56 8.50 8.44 0.09 7.35 7.63 7.62 7.53 0.09 8.49
90 8.25 8.37 8.6Î 8.41 0.10 7.48 7.74 7.53 7.58 0.08 8.47
120 8.88 ! 8.48 8.65 8.67 0.12 7.38 7.68 7.59 7.55 0.09 8.70
148 8.46 8.54 8.83 8.61 0.12 7.92 7.56 7.78 7.75 0.10 8.67
170 8.80 ; 8.46 : 8.60 | 8.62 0.10 7.49 1 7.75 1 7.64 | 7.63 0.08 8.66
5.3.5 Assay of HAV HM175/18f RNA
The accumulation of HAV HMl 75/18f RNA in BS-C-1 cell can be seen in Figure 5.6. Each 
data point represents the mean of 3 experiments. During the first 16 hr post infection, levels of 
HAV RNA in the medium decreased from 6.2 logio genomes / 10  ^cells to 5.14 logic as virus 
was taken up into the cell while conversely, an increase in the cell associated RNA to 5.5 logic 
genomes /10^ cells was seen. By 24 hr, a small increase in the level of viral RNA was seen in 
the culture medium and HAV continued to be released until at 170 hours post infection the 
titre reached 7.63 logic genomes / 10  ^cells (~ 42 genome equivalents / cell). The titre of cell 
associated RNA also continued to rise at a logarithmic rate until 72 hr post infection (7.97 
logic genomes /10^ cells). The rate of viral RNA accumulation in the cells then decreased and 
a stationary phase was entered. Levels of RNA associated with the cells were generally higher 
than that in the medium, reaching a maximum of 8.30 logic genomes /10^ cells at 170 hr post 
infection (-200 genome equivalents / cell)
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5.4 DISCUSSION
Several studies into the kinetics o f HAV replication have been carried out using various 
cytopathic strains (Anderson et a l, 1987; Anderson et al, 1988; Cromeans et al, 1989) 
However, where levels of RNA have been measured, the results given have not been in terms 
of genome copies and therefore could not be directly compared with yields of infectious virus. 
In this study, sensitive RT-PCR assay for HAV RNA gave results in a form which could be 
directly related to that of the cytopathic microtitre plate assay for infectivity as they are both 
based on limiting dilution analysis. As H M l75/18f did not give a good CPE in BS-C-1 cells, it 
was not possible to obtain reliable data in the time course of infectious virus for this variant.
In order to obtain results that could be directly compared with those of Anderson and co­
workers (1987; 1988), cells were infected at a multiplicity of infection of 1. However, at this 
concentration, it cannot be guaranteed that all cells will become infected simultaneously due to 
Poisson distribution. While it is possible that infection at a higher multiplicity of infection may 
have resulted in earlier production of virus, in a similar study, Harmon et a l (1989), showed 
that infection of cells at a multiplicity of infection of both 10 and 1 RFU/cell resulted in similar 
growth curves. Inoculation at 0.1 RFU/cell resulted a 2-3 day lag in the appearance of virus.
The first event in HAV infection of BS-C-1 cells is the uptake and uncoating of the virus. In 
the present study, during the absorption phase, the total amount o f infectious virions present in 
the medium decreased by 90 % (from 6 to 4.88 logio TCIU /10^ cells) and after 16 hr, only 2 
% (4.27 logic TCIU / 10  ^cells) o f the initial inoculum was detected by cytopathic assay. The 
eclipse phase of HAV in BS-C-1 cells is therefore comparable that o f poliovirus in which 90 % 
of virus is eclipsed by 2 hr p.i. (Anderson et al, 1988). However with poliovirus, the production 
o f progeny virus can be seen 2-4 hr p.i. whereas progeny virus was not detected in BS-C-1 
cells with HAV HM175A.2 until 24 hr p.i. (Figure 5.3). The low levels of infectious virus
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associated with the ceil at 1 and 16 hr p.i. compared with levels of RNA tends to suggest that 
the majority of virus was quickly uncoated upon cell entry. It has been suggested extended lag 
phase of HAV compared with poliovirus may be due to asynchrony in the uncoating of HAV 
infection (Wheeler et a l, 1986; Cromeans et a l, 1989; Cho and Ehrenfeld, 1991). However, 
Anderson et al. (1987) showed that penetration and uncoating of variant HMl 75A occurred at 
a similar rate to that of poliovirus. These data along with the results of this study suggest that 
the replication of HAV is not restricted by slow or asynchronous uncoating but rather at a later 
stage in infection The rate at which cytopathic variant HM175A.2 is rendered non-infectious 
by uncoating in BS-C-1 cells appears to a little higher than previously reported for HAV 
(Anderson et al., 1987) in which 25 % of the closely related strain H M l75A was still 
recovered up to 9 hr p.i.. HAV strain HM175A.2 is a large plaque forming variant of 
HMl 75 A which was clonally selected and acutely passaged 4 times. The ability of this variant 
to form large plaques may be related to the faster uptake of the virus by BS-C-1 cells.
Since no samples were taken between 1 and 16 hours or 16 and 24 hours, information 
regarding the initial stages of HAV infection may have been lost. For example, the titre of the 
virus in the supernatant may have been further reduced by cell entry than has been recorded 
either before or after the 16 hour time point. A more detailed study of early events occurring in 
the infection of cells with HAV would require the assay of more samples between the first and 
twenty fourth hours o f infection. The fact that only 10 % of the cells expressed levels of viral 
antigen or RNA that could be detected by in situ methods also suggests that this is not a single 
step growth curve.
Following the lag phase, HAV accumulated logrithmically until 48 hr p.i. and by 72 hr p.i., 
reached total mean titre of 40 infectious particles / cell. The yield of this virus is higher than the 
value of 20 RFU/cell observed by Anderson et a l (1987) although the kinetics of replication 
appear to correlate well. The increase in viral yield may be a result o f the more efficient virus
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uncoating seen with this variant. More efficient uncoating of HAV and subsequently higher 
viral yield may be responsible for improved development o f cytopathic effects.
Throughout the timecourse, levels of HAV RNA released into the culture fluid closely 
resembled those o f infectious virus. However, statistical analysis of the mean titres obtained 
during the stationary phase showed significant difference between released infectious virus and 
viral RNA at the 95 % confidence level. Approximately 50 % of HAV genomes released 
during this stationary period were capable of infecting BS-C-1 cells (20 released TCIU / cell, 
42 released genomes / cell). It is expected that all viral RN A detected would be encapsidated as 
any naked RNA would be quickly degraded once released into the tissue culture fluid. 
Therefore, a proportion o f HAV RNA appears to be released as non-infectious particles which 
may correspond to the RNA containing provirions detected by Ruchti et a/. (1991) or correctly 
encapsidated, defective RNA genomes. The ratio of PCR detected RNA molecules to TCIU 
released into the tissue culture medium during the stationary phase was found to be 
approximately 2:1. Based on cDNA-RNA hybridisation studies, Jansen et al. (1988) found a 
tissue culture extracted preparation of HAV strain HMI75pI6, which had been adapted to 
rapid, non-cytopathic growth in BS-C-1 cells, to contain approximately 58 genomes per RFU 
whereas a preparation of the wild type HM175 contained 2.4 x 10  ^genomes per RFU.
The ratio of RNA to infectious virus (58:1) reported by Jansen and co-workers for the tissue 
culture adapted strain of HAV, p i 6  HM175 (non-cytopathic), was determined after CsCl 
density gradient purification of virus from the lysate obtained after fi'eezing and thawing 
infected cells. This figure should therefore be compared with the ratio of cell associated HAV 
genome to cell associated infectious virus. The mean level of cell culture infectious HAV 
HM175A.2 in the stationary phase was 7.28 log TCIU /10^ cells while that of the viral genome 
was 8.55 log genomes /lO * cells. Therefore the ratio of Cell associated HAV genome to 
infectious virus was 19:1. Jansen and co-workers showed that after 16 passages in cell culture,
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the genome to infectivity ratio of HAV HM175 was reduced from 2.4 xlO^ genome copies per 
RFU to 58 genome copies per RFU. The cytopathic strain, HAV HM175A.2 is derived from 
the wild type virus after 30 passages of persistently infected cells, and 8  passages of the 
resulting virus followed by 3 rounds of plaque purification and 4 further passages (Anderson 
1987). The high level of adaptation to tissue culture achieved may also have resulted in a 
further reduction in the genome to infectivity ratio.
Levels of HAV remaining associated with BS-C-1 cells during the stationary phase were 
similar to those of released virus. Therefore, approximately 50 % of all infectious virions were 
released. This percentage of released virus is higher than previously noted with non-cytopathic 
strains of HAV (Siegl et al, 1984; Nasser and Metcalf, 1987) but correlates well with data 
obtained with an alternative HM175 derived cytopathic variant (Cromeans et a/., 1989). The 
release of infectious virus may be either a result of cytopathology or a factor involved in the 
ability of cytopathic strains to cause cell death.
The amount of HAV RNA remaining associated with the cells throughout the timecourse was 
generally 10 fold higher than that of cell bound infectious virus. During the stage of virus 
adsorption and uncoating, the majority of HAV RNA was taken up into the cells and only a 
small percentage was degraded by 16 hr p.i.. However, the logarithmic rate o f infectious HAV 
replication between 16-24 hr was double that of viral RNA replication (Figure 5.4). By 24 hr 
p.i., approximately 44 % o f viral RNA was detected as infectious virus particles. Since the ratio 
of packaged RNA to infectivity was estimated at 2:1, the actual percentage of RNA which is 
packaged at this stage may be as high as 90 %. This supports the theory o f Anderson et a l
(1988) that during the early stages of HAV infection in cell culture, the levels o f RNA are low 
due to highly efficient encapsidation. The subsequent increase in the pool of non-encapsidated 
RNA may be due to an alteration in processing of the HAV polyprotein caused by the high 
excess of pentamers during the earlier stages of replication. Borovec and Anderson (1993)
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suggested that cleavage of the polyprotein tends to occur in tram  when pentamer levels are 
high, resulting in the formation of 5 S monomers which cannot assemble into virions.
Both immunofluorescent staining of HAV antigen and ISH demonstrated the asynchronous 
nature of HAV replication previously reported. The percentage o f cells expressing HAV RNA 
and antigen increased over time. At 40 hr only 10 % of cells were expressing viral antigen or 
RNA apparently at differing levels, however, by 72 hr, viral transcription and translation was 
demonstrated in the majority of cells. These results are similar to those seen by Harmon et al
(1989) who used the same in situ techniques to study the replication of a non-cytopathic stock 
of HAV HM175 (passage 30). This non-cytopathic virus replicated veiy slowly reaching 
maximum yields of RNA at 8  days p.i. and only showing antigen expression in all cells after 14 
days. Although asynchrony may be partly responsible for the protracted replication of HAV, it 
appears that the final yield and cytopathic effect are not influenced. It is possible that the low 
titre the HAV inoculum may have been responsible for the apparent asynchronous replication, 
however, Harmon and co-workers showed comparable results after infection of B-SC-1 cells 
with HAV at titres of both 1 and 10 RFU / cell.
Levels of antigen expressed in infected BS-C-1 cells appear to decline by 146 hr when both 
HAV RNA and infectious virus titres are still at a maximum. This may be due to the loss of 
fragile infected cells from the slides during washing leaving only cells expressing small 
amounts of antigen.
The sensitivity of the ISH method used was determined from the RNA titre determined by 
quantitative PCR and the staining seen in cells at 40 hr. The number of genomes required for 
ISH detection was estimated at approximately 28 copies per cell. Negative strand HAV RNA 
could not be detected using sense polarity probes in ISH. Assuming that the sense polarity 
probes were of the same sensitivity as the anti-sense probes, it may be concluded that levels of 
the replicative intermediate did not reach 28 RNA copies per cell throughout the timecourse.
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When the replication of poliovirus was studied in HeLa cells, it was estimated that 5-10 % viral 
RNA was in the negative strand form (Baltimore and Girard, 1966). Since levels of positive 
strand HAV RNA were only estimated to be 355 genomes / cell it is not surprising that the 
replicative intermediate was not detectable by ISH.
RNA replication determined by the quantitative PCR method showed good correlation with the 
infectivity growth curve. Therefore the method was also used to compare the growth of the 
variant HM175A.2 with the less cytopathic variant HM175/18f. During the initial stages of 
infection, levels of HM 175/18f RNA in the medium decreased as expected. However, the 
degree to which this variant was removed from the culture medium by cell entry was less than 
that of HM175A.2. After the initial hour post infection, 25 % of the initial RNA titre was still 
detected in the culture medium and only 90% of the virus appeared to have entered the cells at 
16 hr, after which released progeny virus was detected by RT-PCR (Figure 5.6).
After 24 hr, HM175/18f RNA accumulated in BS-C-1 cells at in a similar manner to that of 
the more cytopathic variant, with a logarithmic growth phase from 24 - 72 hr followed by a 
stationary phase (Figure 5.7). However, the rate of RNA replication is slower and maximum 
levels of viral RNA in the cells is lower than that of HM175A.2. Between 24 and 48 hr p.i., the 
rate of release of viral RNA paralleled that of increase in cellular levels whereas later in 
infection, the rate of increase is slower. In the early stages of HAV replication efficient 
packaging of RNA may result in the release of virus particles at the same rate as RNA 
accumulation. The polyprotein processing mentioned above may subsequently restrict viral 
packaging and therefore result in an accumulation of non-packaged RNA which is not released. 
The lower rate of release of HM175/18f continues while viral RNA replication appears to be in 
the stationary phase. Levels o f released HMl 75/18f RNA released into the medium eventually 
rise to a similar level to that o f released HM175A.2. RNA.
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Chapter 6
REPLICATION OF WILD TYPE AND CELL CULTURE 
ADAPTED STRAINS OF HAV IN A TAMARIN MODEL
6.1 INTRODUCTION
Passage o f HAV in cell culture has led to attenuation of virulence in marmosets and 
chimpanzees (Provost et a l,  1982, Bradley et al., 1984; Karron et a l ,  1988 and Taylor et 
al., 1993). In this study, the virulence of two cell culture adapted variants of HAV HMl 75 
were compared with the wild type virus in a tamarin model. The variant H M l75/18f is 
cytopathic in FRhK-4 cells but shows limited cytopathology in BS-C-1 cells whereas 
HM175A.2 has been adapted to cytopathic growth in BS-C-1 cells. The quantitative RT- 
PCR assay was used in order to directly compare faecal shedding and viraemia between 
the animals inoculated with the various HAV preparations. Replication o f the virus in the 
liver was also demonstrated by immunohistochemistry. The extent o f liver damage was 
determined by histological analysis and measurement o f serum alanine amino transferase 
(ALT) levels which become elevated upon disruption of the liver. An enzyme linked 
immunosorbant assay was used to show seroconversion. Faecal and serum samples from 
animals inoculated with strain HM175A.2 were also analysed by the cytopathic microtitre 
plate assay for HAV.
6.2 METHODS
6.2.1 Inoculation of animals
The progression of infection of 3 variants of HAV strain HAV H M l75 was studied in red 
bellied tamarins (Sanguinus labiatus). Three groups of 3 tamarins were intravenously 
inoculated with 0.1 ml of HAV H M l75 wild type (obtained from Dr Purcell, National 
Institute of Health, Bethesda, Maryland, USA) or the tissue culture adapted variants 
HM175/18f and HM175A.2 (Table 6.1) by staff in the Biological Services Section at 
NIBSC. Each of the virus preparations were diluted to approximately 10  ^ genomes m f’ in 
6  salt PBS containing 10 % FCS. The 3 groups of tamarins were selected to give the same 
distribution of males and females in each group and similar mean group weights.
143
Table 6.1 Tamarin inoculation groups
Group Tamarin Sex Weight (g)
1:
HAV HM175 wt
C9 M 540
C16 F 615
C20 M 500
2:
HAV HM l 75/18f
C13 M 612
C17 F 615
C19 M 425
3:
HAV HM175A.2
C12 M 530
C15 F 540
D3 M 555
6.2.2 Collection of samples
Prior to inoculation and until day 70 post inoculation, blood, faeces and needle liver 
biopsies were taken for analysis as shown in Table 6.2.
Table 6.2. Collection of samples from tamarins
Day Bleed Faecal
collection
Liver
biopsy
-28 / y X
-13 / y y
0 / y X
4 / y X
9 / y X
14 y y X
17 y y X
2 1 y y y
28 y y X
35 y y X
42 y y X
49 y y X
56 y y X
63 y y X
70 y y y
On the day of collection, 1 g of faeces was weighed and placed in a universal tube and 10 
ml MEM + 5 % bicarbonate was added. A faecal suspension was made by adding 2 ml 
sterile glass beads (BDH) and vortex mixing. The suspension was then centrifuged at 1300 
X g  for 10 min at 4 °C. The supernatant was transferred to a sterile polypropylene tube. A
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1 ml volume of supernatant was placed in a 2  ml screw capped microtube and extracted 
with an equal volume of chloroform. After mixing the sample with chloroform, it was 
centrifuged at 13400 x g  for 5 min. The aqueous layer was transferred to a new microtube 
and stored at -70 °C. The remainder of whole faeces and non-extracted supernatant were 
stored at -20 °C.
Tamarin blood samples (0.5-1 ml) were taken and stored in 2 ml microtubes at 4 °C for 12- 
16 hr allowing clotting to occur. Samples were then centrifuged at 13400 x g for 20 min at 
4 °C. The supernatant was transferred to a clean microtube and centrifuged a further 20 
min as above. The supernatant was stored in 2 ml microtubes at -70 °C.
6.2.3 HAV RNA quantitation
RNA was extracted from all faecal suspensions and serum samples using QlAmp viral 
RNA extraction kit (Qiagen Inc.), reverse transcribed and amplified using primers A7a and 
A8 a in the quantitative PCR method.
6.2.4 Infectivity assay for HAV HM175A.2
Faecal and serum samples from tamarins infected with HAV HM175A.2 were diluted 1:10 
followed by 0.5 log dilutions and analysed by the cytopathic microtitre plate assay.
6.2.5 Detection of antibodies to HAV in tamarin sera
As time did not permit the use o f the antibody neutralisation assay described in chapter 3, 
serum samples were assayed for an immune response to HAV using the commercial kit 
Murex HAV VK38 (Murex Biotech Ltd, Dartford, UK) which detects total antibodies to 
HAV by enzyme immunoassay. In this assay, the test sample is incubated with peroxidase 
conjugated anti-HAV in a HAV coated well. Any antibodies to HAV in the sample
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compete with the peroxidase conjugate in binding to the antigen in the plate. After 
washing, the peroxidase activity is measured by the addition of a chromogen which 
develops a blue colour which can be measured by spectrophotometry at 450 nm in 
proportion to the amount of peroxidase conjugate present. If the test sample contains 
antibodies to HAV, the O.D .450 will be reduced. The assay was performed according to the 
manufacturers instructions. A 96 well microtitre plate which had been coated with 
formalin inactivated, heat treated human HAV (supplied in the kit) was taken from 4 °C to 
room temperature. Leaving the first well (A l) blank as a substrate control, 10 pi o f a 
negative control was dispensed into each of 3 wells and 10 pi of the positive control into a 
further 2 wells. The remainder of the wells were used to assay 10 pi o f each of the tamarin 
serum samples. A 200 pi volume of conjugate was then placed in each well except AI and 
the edge of the plate tapped to mix the conjugate with the samples. The plate was sealed 
with an adhesive cover and incubated at 37 °C for 3 hr. The contents of each well was then 
removed by aspiration and wells were washed four times in the supplied wash buffer. The 
plate was blotted onto absorbent tissue and 2 0 0  pi o f chromogen / substrate was added to 
each well. After a 30 min incubation at room temperature, 50 pi o f stop solution was 
added in the same sequence and time intervals as for the chromogen/substrate. The plate 
was read on a spectrophotometer at 450 nm using well Al as a blank. In order to determine 
the validity of the test, the mean O.D .450 o f the 2  positive control wells was subtracted 
from that of the negative control wells. For the assay run to be valid, this value must be 
greater than 0.3. A cut-off value for determining positive samples was obtained by dividing 
the sum of the mean positive and negative absorbencies by 2. All samples with readings 
lower than or equal to the cut off were positive for anti-HAV and those with a higher 
reading were considered negative.
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6.2.6 Assay of serum alanine amino transferase levels
Each serum sample was measured for ALT levels using the commercial kit ALT 10 (Sigma 
Diagnostics, St Louis, MO, USA). In this assay, the sample is incubated with L-alanine, 2- 
oxoglutarate, nicotinamide adenine dinucleotide (NADH) and lactate dehydrogenase (LD). 
Any ALT present in a sample catalyses the conversion of L-alanine and 2-oxoglutarate to 
pyruvate and L-glutamate as shown in Figure 6.1. The lactate dehydrogenase then causes 
the reduction of pyruvate to lactate and simultaneous oxidation of NADH to NAD. NADH 
absorbs light at 340 nm and conversion to NAD causes a decrease in the absorbance at this 
wavelength. The rate of decrease in absorbence at 340 nm in this assay is directly 
proportional to the ALT activity of the sample.
Figure 6.1 Enzymatic reactions involved in the measurement of ALT levels
L -  Alanine + 2 -  oxoglutarate— —- >Pyruvate + L -  Glutamate
Pyruvate + NADH  — > Lactate + NAD
The ALT assay was performed according to the manufacturers instructions. The ALT 
reagent was reconstituted in deionized water to contain L-alanine (400 pM), 2- 
oxoglutarate (12 pM), microbial LD (2000 U / L) and NADH (0.25 pM) at pH 7.4. For 
each sample, a 1 ml volume of the ALT reagent was placed in a cuvette and brought to 30 
°C in a water bath. The test sample (100 pi) was then added and mixed with the ALT 
reagent by inversion. After 90 seconds at 30 °C, the absorbance of the mixture was read at 
340 nm (Initial A). Continuing to incubate at 30 °C, the absorbance was read at after a 
further 30 seconds and 60 seconds (Final A). The rate of change in O.D .340 per min is 
calculated by subtracting Final A from Initial A. The ALT activity can be calculated using 
the millimolar absorbance of NADH at 340 nm which is 6.22 in the following equation.
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ALT (U/L) = AA per min x TV x 1000 
6.22 X LP X SV
where; AA per min = Change in absorbance per minute at 340 nm 
TV = Total volume (1.1 ml)
SV = Sample volume (0.1 ml)
LP = Light path ( 1 cm)
1000 = Conversion of U / ml to U / L
6.2.7 Histological processing of liver biopsies.
After 24 hr formalin fixation, liver biopsies were carefully arranged in unicassettes 
(Raymond A Lamb, London, UK). Biopsies from individual tamarins were placed together 
in one cassette. The cassette lids were securely fitted and cassettes loaded into an 
automatic processor (Jung TP 1050, Leica UK Ltd, Milton Keynes, UK). The tissues were 
dehydrated by incubation for 4 hr in each of 70 %, 80 %, 90 %, 95 % and 100 % industrial 
methylated spirit (IMS) followed by a second 4 hr incubation in 100 % IMS. A 4 hr 
incubation in IMS / chloroform followed by 2 washes in chloroform (4 hr each) were 
performed in order to clear the tissues which were then impregnated with paraffin wax. 
The tissues were immersed in 3 changes of molten paraffin wax at 60 °C. The first 
incubation was for 4 hr followed by 2 further incubations for 2 hr each. The cassettes were 
then removed from the processor wax bath and transferred to a paraffin wax bath at 65 °C. 
Cassettes were individually removed from the paraffin wax bath and, working on a 
blockmaster stage heated to 60 ^C, the biopsies were placed in a disposable mould filled 
with molten paraffin wax. The base of the cassette was placed onto the top o f the mould 
which was then transferred to the cold plate of the blockmaster to cool at a temperature of 
-2 °C until the wax had set firmly. The blocks were then removed from the moulds.
148
The blocks were prepared for microtome cutting by trimming excess paraffin wax from the 
cassette. The cassette was then mounted onto the microtome and aligned parallel to the 
cutting edge of the knife. Sections were cut at a thickness of 10 pm and floated onto the 
surface of a water bath at 45 °C until fully stretched. The sections were then transferred to 
aminoproyltriethoxysilane (Sigma Chemical Co., St Louis, MO, USA) coated slides by 
submerging behind the sections and drawing the slides up so that the sections became 
attached. Two sections were placed on each slide. The slides were placed in an incubator 
at 45 °C until dry.
Prior to use, sections were dewaxed by submersion in 2 changes o f xylene for 5 min each 
followed by 2 washes in absolute alcohol for 5 min each. The section were then air dried 
before rehydration in 70 % alcohol for 4 min and 2 changes of distilled water for 4 min 
each.
6.2.7.1 Haematoxylin and eosin staining
Rehydrated sections were submerged in Harris' haematoxylin stain (BDH) for 10 seconds 
and washed in a running tap water bath for 5 min. Differentiation was achieved by 
incubating the sections in 1 % HCl, 70 % alcohol for 5 seconds and again washing in tap 
water as above. Sections were then stained in 1% eosin (yellowish) for 10 min. After a 5 
minute wash in running tap water, sections were dehydrated by 2  minute incubations in 
each of 50 %, 70%, 90 %, 95 % and 100 % alcohol followed by clearing in xylol for 2 min 
and mounting in DPX. Stained sections were viewed by light microscopy and post 
inoculation biopsies were compared with those taken prior to inoculation.
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6.2.7.2 Immunohistological detection of HAV
Dewaxed sections were placed in 0.05 % hydrogen peroxide in methanol for 10 min to 
inactivate endogenous phosphatase activity followed by a 5 min PBS wash . Slides were 
then placed in a 1 1 beaker containing 250 ml sodium citrate buffer which was covered and 
microwaved at 850 W (Panasonic) for 40 min in order to increase the permeability of the 
cells. After a 5 min wash in PBSA, sections were overlaid with 50 pi of IgG affinity 
purified human post-convalescent serum diluted 1:250 and PBSA and incubated in a moist 
chamber at room temperature for 4 hr. Sections were then washed in 3 changes of PBSA 
for 15 min each before incubation with anti-human IgG - alkaline phosphatase conjugate 
(Sigma Chemical Co.) diluted 1:500 in PBSA for 1 hr. After washing in PBSA as 
previously, bound antibody wash visualised by incubation of sections with 
bromochloroindolylphosphate / nitro blue tetrazolamine (BCIP / NBT stable preparation. 
Life Technologies Inc.) until sufficient colour was visible by light microscopy, usually 
approximately 1 hr. Slides were rinsed in tap water and counter stained with Harris' 
haematoxylin stain (BDH) for 10 seconds. Stained sections were rinsed, dehydrated and 
mounted in DPX as above. All incubations were performed at room temperature.
As a negative control, a section from each liver biopsy was treated as above except for 
being incubated with human serum which had previously been found to be negative for 
anti-HAV rather than primary affinity purified IgG from human post-convalescent serum. 
No immunostaining was seen in these sections.
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6.3 RESULTS
6.3.1 Detection of HAV RNA in faecal samples
Prior to inoculation with HAV, all faecal samples were tested by RT-PCR and found to be 
negative for HAV RNA. In 2 out o f the 3 Group 1 tamarins, inoculated with the wild type 
HAV H M l75, viral RNA was detected as early as 4 days p. i. (Table 6.3, Figures 6.2 and 
6.3). Faecal shedding of HAV commenced between days 4 and 9 in the third Group 1 
tamarin. Maximum titres of up to 11 logio genomes g’’ o f faeces (tamarin C9, 14 days p.i.) 
were detected in this group between days 14 and 21 p. i.. The duration of excretion of the 
wild type virus as detected by reverse transcription and PCR varied from 31 to 54 days.
In each of the tamarins infected with HAV H M l75/18f (Group 2), faecal shedding 
occurred 4 days after inoculation (Table 6.3, Figure 6.4). Excretion of viral RNA reached a 
peak at 9 days p.i.. However, maximum titre detected in this group was only 7.5 logio 
genomes g’* of faeces (Tamarin C l3, 9 days p.i.) and the duration o f faecal shedding was 
between 10 and 17 days. No HAV RNA was detected in Group 3 tamarins infected with 
the cytopathic FLAV HM175A.2
6.3.2 HAV Viraemia
FLAV RNA was only detected by quantitative RT-PCR in Group 1 tamarins which were 
inoculated with the wild type H M l75 (Table 6.4). In tamarins C16 and C20, only one 
serum sample was viraemic at 14 and 21 days respectively whereas in tamarin C9, 
viraemia was detected from day 9 to day 17 p.i.. The maximum titre of HAV RNA 
detected in the serum samples was 4.3 logio genomes m f' (tamarin C9, 17 days p.i.).
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Figure 6.3 Example quantitative RT-PCR assay of HAV RNA in tamarin faeces
M 1 2 3 4 5 6 7 8  9101112131415161718 M
M l92021 22232425262728 293031 32 33 3435 36 M
Samples (Faecal sample from tamarin C9, 9 days post inoculation)
M molecular weight markers 1
cDNA diluted 1:10’^1-5 cDNA diluted 1;10^ 19-23
6 negative control water 24 Negative control water
7-11 cDNA diluted 1:10^^ 25-29 cDNA diluted 1:10"^
1 2 negative control water 30-32 Negative control water
13-17 cDNA diluted 1:10^ 33+34 Standard CSl 01 1:10
18 negative control water 35+36 Standard C S101 1:100
Calculation of HAV RNA titre
Result of GLIM analysis =883 genomes / sample
log titre = log ( 8 8  X (100/8.8)" X (1000/3.5)^ x 10")
= 7.5 log genomes g"
“ Replication efficiency factor 
 ^Volume factor (1ml)
Faecal suspension = 0.1 g /  ml
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Table 6.4 HAV viraemia in Group 1 tamarins (HM175/wt)
Day
Virus titre genomes ml'^ 
C9 1 C16 r  C20
0 0
1
1 0 1 0
4 0 1 0 1 0
9 4.1 1 0 r1 0
14 3.3 1 3.2 T ~1 0
17 4.3 1 0 1 0
2 1 0 1 0 1 3.8
28 0 1 0 11 0
35 0 1 0 “ T1 0
42 0 1 0 1 0
49 0 1 0 1 0
56 0 1 0 1 0
63 0 1 0 1 0
70 0 1 0 1 0
6.3.3 Cytopathic microtitre plate assay of HAV HM175A.2
Faecal and serum samples from Group 3 animals inoculated with HAV HM175A.2, the 
cytopathic variant, were analysed by cytopathic microtitre plate assay. No virus was 
detected in any of these samples.
6.3.4 Immunological response
The production of antibodies was monitored by enzyme immunoassay of serum samples. 
Two kits were used to test the samples and the performance o f the positive and negative 
controls and calculated cut off values are shown in Table 6 .5 . Test validity values of above 
0.3 indicate that both of the assays were successful. The calculated cut off values were 
0.428 and 0.419. Readings lower than these values indicate that the sample is positive. The 
results o f enzyme immunoassay of the tamarin sera are shown in Table 6 .6 . Antibodies to 
HAV were detected in all tamarins regardless o f the HAV variant inoculated. 
Seroconversion occurred between days 14 and 28 p.i.. All tamarin serum samples then 
remained positive for total anti-HAV to the end of the time course.
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Table 6.5. Performance of Murex HAV VK38 assays
Assay 1 Assay 2
Negative control 1 0.732 0.765
2 0.849 0.794
3 0.792 0.776
Mean negative control (N) 0.791 0.778
Positive control 1 0.066 0.060
2 0.065 0.059
Mean positive control (?) 0.066 0.06
Test validity value (N-P) 0.725 0.719
Cut off value (N+P)/2 0.428 0.419
6.3.5 C irculating ALT levels
All tamarin serum samples were tested for changes in ALT levels. A cut-off value for 
normal ALT levels was calculated as the mean of 30 serum samples taken before 
inoculation on days -13 and 0 (Table 6.7), plus 3 times the standard deviation. The 30 
normal serum samples included 1 2  pre-inoculation samples taken from groups of tamarins 
not otherwise used in this study. The mean was 5 U L*’ with a standard deviation of 3 , 
therefore the normal cut-off was calculated to be 14 U L '\ Serum levels o f ALT in the 
Group 1 tamarins are shown in Figure 6.5. In 2 of the tamarins (C16 and C20) the ALT 
levels rose above the cut-off level by day 9 p.i. and tamarin C9 showed abnormal ALT 
levels by day 14 p.i.. A peak of 69 ALT U L'  ^ was seen on day 14 in tamarin C20 however, 
the other Group 1 tamarin serum levels were not at a maximum until 21 days p.i.. The 
highest titre of serum ALT found in Group 1 animals was 90 ALT U L‘‘ ( 6  x the cut-off 
value). Serum ALT levels in Group 1 animals returned to normal between 35 and 42 days 
p.i..
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Only 2 of the tamarins (C l7 and C l9) inoculated with HAV HM175/18f had markedly 
elevated ALT levels (Figure 6 .6 ). Peak ALT titres were detected in these animals at 21 
days p i. and the highest titre found in Group 2 was 46 U L'  ^ (3 x the cut-off value). In 
tamarin C l3, the serum ALT levels at 9 to 14 days p i. were at the cut-off value. The ALT 
levels returned to normal in tamarins C l7 and C19 at days 56 and 49 p i. respectively. 
Serum ALT levels in all o f the Group 3 animals inoculated with HAV HM175A.2 
remained normal throughout the timecourse (Figure 6.7).
6.3.6 Liver histopathology
Liver biopsies were taken from each animal 13 days prior to inoculation, 21 days and 70 
days p.i.. Light microscopy of haematoxylin and eosin stained sections of all biopsies taken 
prior to inoculation showed normal liver histology (Figure 6 .8 , Table 6 .8 ). At 21 days p.i., 
all biopsies taken from the tamarins in Group 1, infected with the wild type virus, showed 
signs of liver damage characteristic of viral infection. Lymphocytic and macrophage 
infiltration was mainly seen around the portal tracts and the lobular periphery. Due to the 
small size of the biopsies, it was difficult to determine whether infiltrating cells connected 
neighbouring portal tracts. To a lesser extent, cellular infiltration was also seen around 
central hepatic veins. In the parenchyma, focal areas o f infiltration and necrosis were 
demonstrated. Pathological changes were visible in sections of the 70 day biopsies, 
however, at this stage, the infiltration had receded and was generally only seen around the 
portal tracts.
Only one o f the biopsies taken from the tamarins infected with HAV FlM175/18f at 21 
days showed signs of liver damage characterised by infiltration and enlargement o f portal 
tracts. Occasional areas of infiltration and necrosis was also seen in the parenchyma to a 
lesser extent than in the biopsies of group 1 tamarins. Two large areas of periportal
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Figure 6.8 Histological analysis of tamarin liver biopsies 
Group 1 (HAV HM175/wt)
a) Pre-inoculation biopsy 
h- hepatocytes 
k- Kupffer cells
b) 2 1  day post inoculation biopsy 
i- cellular infiltration 
p- hepatic portal vein
c) 70 day post inoculation biopsy
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(Figure 6.8 continued)
Group 2 (HAV HM175/18f)
d) Pre-inoculation biopsy 
V-  central vein
e) 2 1  day post inoculation biopsy 
i- cellular infiltration
f) 70 day post inoculation biopsy
a- hepatic artery
b- bile duct ^  portal tract
p- hepatic portal vein }
166
m* < >
m m
*
%
Û
167
(Figure 6.8 continued)
Group 3 (HAV HM175A.2)
g) Pre-inoculation biopsy
h) 21 day post inoculation biopsy
i) 70 day post inoculation biopsy
168
i169
c
z93
S
I
î
X
s
I
.2
ao
0 
.2
33
1 
Sî
.2
00
vo
z
H
O
fS
<
V-4
Sa
o;3
2
O
If)
U
fS
U
©
u
g
T—4
i?)r~
a
ri
as
2
O
r-
V
a
d
forH
U
ori
V
a
If)
a
\o
U
a3
2
O
o\
U
a
I
.2
6Q
H3■3
m
I
C3
Io
Z
z
d
z
d
z
cc
0)
tiCl- il
| 1 1 |
0 
■| t1Ifl
1 1 1V3
'o- 'a.
3 3xs ■O
Ori
d
O
Z
3
gO
Z
3
gO
Z
(4-,O .
ü
I
z
Bcf)
(4M0
1
00
tl
g 'S
(+-Io I
hd  Æ  — O-
l i
00
§
d
tec
I7n
infiltration were seen in the 70 day liver biopsy from the same tamarin and no damage was 
visible in biopsies from the other group 2 tamarins.
None of the liver biopsies from the Group 3 tamarins, inoculated with HM175A.2, showed 
any signs of liver pathology.
6.3.7 Immunohistological staining of HAV in liver biopsy sections
Immunohistology was performed on sections from each of the tamarin biopsies using 
human post-convalescent serum and alkaline phosphatase conjugated anti-human IgG. 
Very little background staining was seen in sections taken from biopsies of 13 days prior to 
inoculation (Figure 6.9, Table 6.9). The pale pink patches in the centre of each 
photomicrograph is an artefact of photography. FIAV antigen was demonstrated in 2 of the 
Group 1 tamarins at 21 days p.i. however, no positive signal was detected in the 
corresponding biopsy of tamarin C20. In the positive sections, staining was seen in the 
cytoplasm of hepatocytes and Kuppfer cells. The distribution of FIAV antigen appeared to 
be confined to individual cells and in portal tracts and parenchyma with a random 
distribution. At 70 days post infection, none of the Group 1 tamarin biopsies were positive 
for HAV antigen.
Very low levels of viral antigen were demonstrated as dense staining in the cytoplasm of 
occasional hepatocytes in only one of the tamarins (Cl 7) inoculated with HAV HM175/18f 
at 21 days p.i.. Light, granular HAV antigen staining was detected in the cytoplasm of cells 
around a single large area of infiltration seen in the 70 day p.i. biopsy of tamarin Cl 7. All 
biopsies from the remaining 2 tamarins in Group 2 and each o f the Group 3 animals were 
negative for HAV antigen.
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Figure 6.9 Immunohistochemical staining of HAV antigen in tamarin liver biopsies
— ► Immunohistochemically stained HAV antigen 
Group 1 (HAV HM175/wt)
a) Pre-inoculation biopsy
b) 21 day post inoculation biopsy
c) 70 day post inoculation biopsy
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(Figure 6.9 continued)
Group 2 (HAV HM175/18f)
d) Pre-inoculation biopsy
e) 21 day post inoculation biopsy
f) 70 day post inoculation biopsy
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(Figure 6.9 continued)
Group 3 (HAV HM175A.2)
g) Pre-inoculation biopsy
h) 21 day post inoculation biopsy
i) 70 day post inoculation biopsy
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6.4 DISCUSSION
The virulence o f two tissue culture adapted strains of HAV, HM175/18f and HM175A.2 
were compared in a tamarin model. Intravenous inoculation of the three virus preparations 
was performed as this method appears to be more sensitive than oral inoculation in 
comparing virulence (Purcell et a i ,  1984).
The replication of HAV in the tamarin model was detected and a quantitative measure of 
viral shedding in the faeces obtained by RT-PCR. This technique was useful for the direct 
comparison of the growth wild type and tissue culture adapted variants of HAV HM175 in 
tamarins. The results show that the wild type virus replicated well, producing up to 10^‘ 
HAV genome equivalents per gram of faeces. Faecal shedding was detected as early as 4 
days after inoculation of the tamarins with wild type HAV and continued for up to 54 days 
by RT-PCR. Using a molecular hybridisation technique to detect HAV RNA in marmoset 
faeces after inoculation with 2 x 10  ^CID50 of wild type HAV HM175, (Ticehurst et al., 
1987) levels of up to lO’® genomes m f' were detected. The excretion of HAV RNA 
reported by Ticehurst et al. was comparable to those obtained in the present study by 
quantitative PCR throughout the time course with faecal shedding commencing at 4 days 
post inoculation and peak titres at 1 0 - 1 2  days post inoculation followed a slow decline in 
shedding. Inoculation o f marmosets with a lower dose (10^ CID50) of the wild type HM175 
(Karron at a i ,  1988) resulted in a shorter duration of faecal shedding as detected by cDNA 
hybridisation of HAV RNA (2 weeks) and lower titres (maximum, 8.2 log genomes m f').
Initially, replication of the tissue culture adapted variant, HM175/18f, was similar to that 
of the wild type with an onset of faecal shedding in all animals detected 4 days after 
inoculation. Levels of excreted HAV RNA at 9 days post inoculation were also similar in 
the two groups with titres of 5.7 - 7.5 logio genomes g"' in animals inoculated with the wild
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type virus and 5.6 - 7.5 logio genomes g'' with HM175/18f. Subsequently however, faecal 
shedding decreased with the tissue culture adapted strain while a further increase in viral 
titre was seen with the wild type.
Lemon et al. (1991) showed that upon adaptation to growth in cell culture, antigenic 
variation may spontaneously arise in the absence of selective antibody pressure. The rapid 
decline in excretion of HM175/18f occurred at the time when anti-HAV was first detected 
in the tamarin sera, whereas in tamarin C20, inoculated with HM175/wt, the titre of virus 
in stool samples continued to increase in the presence of circulating antibodies to HAV. 
An alteration in antigenicity may have increased the susceptibility o f the HM175/18f 
variant to neutralisation and resulted in more efficient clearance from the tamarin liver. 
While HAV HM175/18f is of the single wild type serotype, several mutations have been 
found in the proposed PI region of the genome, which encodes the structural proteins, 
resulting in 3 amino acid changes (Table 6.10, Lemon et a i ,  1991). These changes do not 
appear in the immunodominant anitgenic site, which involves the residues Ser-102, Val- 
171 and Ala-176 of VPl as well as Asp-70 and Gln-74 of VP3 (Ping and Lemon, 1992). 
However, they may alter the capsid conformation such that the affinity of neutralising 
antibodies is increased resulting in more efficient neutralisation.
Table 6.10 Amino acid alterations in the PI region of HM175 pi 6 and HM175/18f
Residue Wild type 
HM175
HM175pl6 HM175/18f
VP2 (54) Lys Arg Arg
VP3 (91) Thr - Lys
VPl (271) Ser - Pro
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Figure 6.10 Replication and virulence of HAV HM I75/wt in tamarins
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Figure 6.11 Replication and virulence of HAV HM175/18f in tamarins
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No faecal shedding was seen in animals inoculated with HAV HM175A.2. This suggests 
that the adaptations required for cytopathic growth of HAV in BS-C-1 cells differ from 
those which occur when the virus clonally isolated in FRhK-4 cells. The mutations in the 
BS-C-1 cell cytopathic variant appear to completely restrict the replication of the virus in 
the animal model whereas those occurring in HM175/18f cause a reduction in the titre and 
duration of faecal shedding of the virus.
Viraemia was only demonstrated in tamarins inoculated with the wild type HM175. 
Despite the fact that viraemia occurred in tamarin C l6 infected with the wild type virus 
while levels of faecal shedding were comparable to that in the tamarins inoculated with 
HM175/18f, no viraemia was detected in the Group 2 tamarins. This may be due to the fact 
that the latter virus did not cause significant levels of liver damage as demonstrated by 
serum ALT levels and histological analysis of liver biopsies. The coincidence of viraemia 
with elevation of serum ALT in tamarins inoculated with the wild type virus also suggests 
that the presence of HAV in serum is due to leakage of the virus from damaged 
hepatocytes into the hepatic blood supply (Figure 6.10). A study of viraemia in human 
HAV infection showed detection of HAV in serum at the time of ALT elevation 
(Yotsuyanagi era/., 1993).
The duration of viraemia was shorter than the 14-21 days reported by Lemon et al. (1990) 
using a tissue culture adapted strain of HAV which demonstrated a wild type phenotype in 
an owl monkey model. However, the sensitivity of the RIFA used to detect this virus was 
1.3 log RFU ml"^  whereas the sensitivity of the RT-PCR assay used is 3.5 log genomes 
ml"\ The occurrence of peak levels of viraemia (^ 4 log RFU m l'\ 14-21 days p.i.) in the 
owl monkeys correlate well with the detection of HAV RNA in tamarins inoculated with 
HM175/wt in the present study. The duration of viraemia as detected by RT-PCR does not
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appear to correlate with duration of virus excretion, time of seroconversion or peak serum 
ALT levels as may be expected. There may however be a correlation of the time of onset 
and duration of viraemia with the initial rate of increase and peak titre of viral shedding 
(Figure 6.10).
The mechanism by which liver damage occurs in individuals infected with HAV is 
unclear. Unlike other picomaviruses, there is little evidence that HAV is directly cytotoxic 
to host cells. Excretion of virus is usually at a maximum prior to the onset of the clinical 
symptoms associated with liver damage. The formation of immune complexes involving 
HAV capsid proteins, IgM and IgG and complement protein C3d does however coincide 
with the commencement of pathological changes in the liver (Margolis et a/., 1988). 
Cytotoxic antibodies could not be demonstrated in HAV infection (Slusracrzyk et a/., 
1985; Gabriel et al., 1986) whereas in vitro studies have implicated the involvement of the 
cell mediated immune response in the destruction of infected cells (Kurane et al., 1985; 
Vallbracht et al., 1986; Baba et al., 1993). Despite appearance of antibodies to HAV while 
high levels of virus was being excreted from the liver, the extent of pathogenicity seen m 
liver biopsies taken from HM175/18f infected animals was much lower than that seen with 
the wild type. This tends to suggest that the cell mediated immune response upon 
inoculation with this cell culture adapted variant was less prolific. The absence of liver 
damage in animals inoculated with the HM175A.2 variant is probably due to the inability 
of this virus to infect and replicate to a detectable level in hepatocytes and therefore lack 
of antigen presentation to T lymphocytes. The levels of serum ALT detected in the three 
experimental groups of tamarins generally correlated with the severity of liver damage 
(Figures 6.10 and 6.11). However the absence of pathological changes in 2 of the tamarins 
in group 2 (inoculated with HM175/18f) which had raised serum ALT levels may be due 
the fact that the biopsy is only representative of a very small proportion of the whole liver.
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Analysis of material from another area of the liver may have revealed the pathogenic 
changes typical of HAV infection. Thus the use of needle biopsy in studies of HAV 
virulence is limited due to the size of specimen obtained.
Replication of HAV in hepatocytes was demonstrated by immunohistochemistry. Again, 
the failure to demonstrate HAV antigen in 1 of the group 1 animals while virus was being 
excreted is probably due to the biopsy being taken from areas of the liver in which the 
virus was not replicating. Immunofluorescent staining of liver necropsies (Mathiesen et 
al., 1980) revealed that only certain areas of the biopsy specimen contained HAV antigen. 
Viral antigen was only detected in the group 2 tamarin in which excretion of virus 
continued until the time of 21 day biopsy. However, a large area of viral antigen 
expression was also demonstrated in this animal at 70 days post inoculation when virus 
was no longer detected in the faeces suggesting that the virus had continued replicating in 
the liver at a level beneath the limits of detection by quantitative RT-PCR. In the same 
tamarin, elevated serum ALT levels continued to 49 days post inoculation compared with 
35 days in tamarins inoculated with the wild type HM175. Small pockets of viral 
replication in the liver which cannot be detected in the faeces may be responsible for the 
protracted serum ALT elevations demonstrated in tamarins by Karayiannis et al. (1990). In 
that study however, a decline in antibody titre suggested that the virus was not actively 
replicating.
The attenuation of HAV HM175 p i6, an African ^een monkey kidney cell adapted, non- 
cytopathic parent of HM175/18f, has been studied in owl monkeys (Taylor et al., 1993). In 
the owl monkey model, only 1 out of 4 inoculated animals showed significantly raised 
serum ALT levels and low levels of viraemia. Faecal shedding was only detected in this 
animal. Seroconversion occurred in 3 of the 4 monkeys however, the mean time of
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seroconversion was not until 103 days p.i.. All liver biopsies appeared normal and no HAV 
antigen was detected. Thus the HM175 variant pl6 appears to be more attenuated in the 
owl monkey model than does HM175/18f in tamarins. These results may reflect variation 
in the degree of attenuation in different primates. Karron et al. (1988), showed differences 
in growth characteristics of wild type and tissue culture adapted variants of HAV HM175 
in chimpanzees compared with marmosets. Alternatively, the additional mutations that 
occurred on further passage and clonal selection of HAV HM175/18f in FRhK-4 cells may 
have caused partial reversion to a wild type phenotype.
Tissue culture adapted strains of HAV are currently used in the production of formalm 
inactivated of HAV vaccines (Andre et al., 1992; Werzberger et a l, 1992). The attenuation 
phenotype of some tissue culture adapted strains makes the production of live attenuated 
HAV vaccines a viable strategy. HAV strain HM175A.2 was able to elicit an antibody 
response at a similar time post infection as the more pathogenic strains studied. 
Quantatitive assay of the anti-HAV antibody produced in the inoculated tamarins is 
required to determine >^4iether levels of antibody response to the different strains are 
comparable. HAV HM175 may prove useful in the development of an attenuated vaccine. 
However, much more work is required to show that the antibodies produced in response to  ^
this variant are protective and remain so over a long period of time. The stability of the 
attenuated phenotype would also need to be assessed in cell lines Wiich have been 
approved for in vitro production of live attenuated vaccines such as MRC-5 or Vero cells, 
This study has highlighted the fact that culture of HAV in different cell lines leads to a 
variation in level of attenuation. If an adequate immune response is consistently produced 
using HM175A.2 in the absence of faecal shedding there will be little concern over the 
possibility of reversion to the virulent phenotype after inoculation. However, it is possible 
that there is a very low level of faecal shedding which is below the limit of detection of the
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RT-PCR or cytopathic microtitre plate assays. Concentration of the material in a large 
volume faecal suspension by ultra centrifugation prior to analysis may clarify this point.
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VChapter? 
GENERAL DISCUSSION
The initial aim of this project was to study the elimination and inactivation of HAV in 
blood products Some viruses of major concern in blood virology are those for which 
there is no suitable cell culture based infectivity assay system, such as HCV, HBV, 
parvovirus B19 and wild type HAV. Therefore, the use of an alternative strategy for 
detection of these viruses, genome amplification, was investigated. The availability of 
tissue culture adapted strains of HAV also allowed the comparison of RT-PCR 
detection of the virus with assay of HAV infectivity in cell culture.
A relatively fast growing, tissue culture adapted strain of HAV (HM175A.2, Anderson, 
1987) which produces cytopathic effects in B-SC-1 cells and achieves titres of up to 7 
logio TCIU ml'  ^ was used to develop a cytopathic microtitre plate assay. Statistical 
analysis of several assays showed that the repeatability of this assay was acceptable for 
routine use. Use of the cytopathic microtitre plate assay facilitated the quantitation of 
HM175A.2 in spiked factor V d , tissue culture extracts and tamarin faecal samples. 
The technique could also be adapted to measuring neutralising antibody responses to 
HAV. A drawback of this assay is that it can only be used in the quantitation of viruses 
which have been ad^Tted to cytopathic growth in cell culture. It may nevertheless be 
possible to further develop this assay so that non-cytopathic wild type or vaccine strains 
may be quantitated. In a competitive assay, the non-cytopathic HAV may be incubated 
with a stock antibody preparation at a standard dilution that will completely neutralise a 
given dilution of the cytopathic virus. Any virus in the sample would bind to the 
antibody and the remaining free antibody could then be assayed by the neutralisation 
assay described in Chapter 3 with cytopathic HAV as the challenge virus. Unfortunately 
time constraints did not permit the careful optimisation of virus and antibody dilutions 
required for the development of such an assay.
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A genome amplification assay which was used to quantitate HAV RNA was also 
developed Reverse transcription and PCR amplification of replicate serial dilutions 
made the measurement of RNA fi’om non-cytopathic strains of HAV possible. The 
efficiency of this assay was assessed using in vitro transcribed RNA corresponding to 
the region of the genome that was amplified in the RT-PCR assay, which had also been 
quantitated by measurement of optical density. The titre of HAV RNA in samples could 
then be calculated in terms of genomes m l'\
The study monoclonal antibody affinity purification of HAV spiked factor VDI showed 
that the virus was not completely eliminated from the product during this process. HAV 
RNA w ^  detected in the wash buffer and additional washing steps may help to further 
eliminate the virus. However, in order to guarantee the viral safety of factor VCH, 
additional elimination or inactivation steps are required
Terminal dry heat inactivation of spiked HAV in lyophilised factor VQI was assessed in 
products of differing thermostabilities. At temperatures of 80 ^C or above, the cell 
culture infectivity of the virus was quickly abolished, A^ereas the genome continued to 
be detected by RT-PCR until the factor V d  was heated to 100 ®C for 8 hr. The use of 
temperatures as high as 100 ®C is not suitable for all factor V d  preparations due to loss 
of product activity. The necessity of complete loss of PCR positivity is also 
questionable as the detection of viral RNA by this method does not indicate the 
presence of an infectious or even complete genome. While capture of the viral RNA at 
the 3 prime end followed by purification and RT-PCR amplification of the 5’ non­
coding region showed that the majority of genomes were intact after heat treatment,
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assessment of the infectious nature of the heat treated genome is still required. An 
obvious approach to determine whether the heat treated RNA is infectious would be 
transfection of the genome into BS-C-1 cells. However, studies by van der Werf et al. 
(1986) and Samow (1989) showed that 1 pg of poliovirus RNA is required to produce 
1.5-2 X 10^  plaques in cell culture (approximately 10^  poliovirus RNA molecules 
required for the formation of 1 plaque). Assuming similar titres of HAV RNA are 
required for transfection of BS-C-1 cells, a much higher concentration of the virus 
would be required in the spiked factor VDI in order to perform transfection studies.
Titres of HAV RNA measured using the quantitative RT-PCR assay were comparable 
to that of tissue culture infectious virus in the initial spiked factor VDI samples in both 
of the thermal inactivation experiments. In order to study further the relationship 
between infectivity and PCR positivity, a time course study of HAV replication in BS- 
C-1 cells was done. Levels of viral RNA in the medium and associated wiA the cells 
were compared with tissue culture infectious virus. The titres of HAV RNA in the 
medium throughout the time course were comparable to those of infectious virus with a 
ratio of 2 genome equivalents per tissue culture infectious unit. This figure is much 
lower than the ratio of 58 genome copies per RFU previously obtained by molecular 
hybridisation of a non-cytopathic strain of HAV (HM175 pl6) and 2.4 xlO^ genome 
copies per RFU for wild type HAV HM175 (Jansen et al., 1988). However, the ratio 
reported for the variant HM175 pl6 (58:1) was determined after purification of the 
virus from lysed cells rather than from the supernatant. In this study, the ratio of 
infectious HAV HM175A.2 to HAV genomes was 19:1. The lower ratio may reflect the 
high degree of adaptation to growth in tissue culture attained by the variant HAV 
HM175A.2 over 30 passages of persistently infected cells followed by 8 ^irus passages
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and 3 rounds of plaque purification (Anderson, 1987) compared with the 16 passages in 
cell culture of HAV HM175 pl6.
Cell associated titres of HAV RNA were generally 13 log genomes ml’^  higher than 
that of infectious virus due to the presence of unencapsidated RNA, immature virus 
particles, virions containing defective HAV genomes or defective capsids containing 
functional RNA. Since the ratio of genome copies to infectious units determined for 
released virus appeared to be 2:1 in this study, only a small percentage of non- 
infectious virus particles were released. All samples were taken prior to the onset of 
visible cytopathic effect. Incubation of the cytopathic virus until cell death occurs may 
result in the release of the non-infectious viral RNA and thereby increase this ratio.
Particle to PFU ratios are usually determined by measurement of the number of 
particles of virus either by electron microscopy or optical density of a pure suspension 
of the virus and for picomaviruses, the ratios are usually between 1000 and 50 particles 
to PFU (Ruekert, 1990). However, the high titre of virus required for either of these 
methods has made this analysis difficult for HAV. Quantitative PCR could be used to 
determine the ratio of genome copies to PFU ratio of a well characterised virus such as 
poliovirus in order to elucidate the usefulness of such a ratio.
The titre of HAV RNA detected in a contaminated sample that has not been subjected 
to a viral inactivation protocol may be similar to that of infectious virus particles. 
However, these results are based on a ratio of RT-PCR determined genome equivalents 
to tissue culture infectivity and not the infectivity of the wild type virus in vivo. The
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large number of susceptible animals required to properly determine the ratio of genome 
equivalents to in vivo wild type HAV infectivity would make such a study unfeasible.
The study of replication of HAV HM175A.2 in cell culture also demonstrated the 
growth characteristics of this virus in BS-C-1 cells. By quantitating the levels of RNA 
in terms of genome equivalents per ml, the rate of HAV RNA replication could be 
compared \vith the accumulation of infectious \irus particles both associated with the 
cells and in the medium. The results showed a similar rate of uptake of this strain of 
HAV to that previously reported for poliovirus (Anderson et a l, 1987) with 90 % of the 
initial inoculum eclipsed after 1 hr. There was nevertheless a lag phase of 24 hr before 
levels of infectious virus began to rise. The cause of this long lag phase is unknown.
Comparison of levels of infectious virus with that of HAV RNA revealed that during 
the early stages of viral infection at 24 hr post infection, as much as 90 % of the 
genome may be encapsidated which may account for the slow growth of the virus and 
low yields obtained as the RNA is not available for further replication. The ability to 
quantitate the RNA so that it could be directly compared with infectious virus titres has 
therefore enabled the demonstration of the theory of Anderson and colleagues (1988) 
that the pool of RNA available for viral replication in the early stages of replication is 
low due to highly efficient encapsidation.
The quantitative RT PCR method was also used to study the growth characteristics of 
HAV HM175/18f which is less cytopathic in BS-C-1 cells. The degree to which the 
RNA of this variant was taken up from the cell culture fluid before the release of 
progeny viral RNA was lower than that of HM175A.2 indicating a slower rate of 
attachment and subsequent uncoating the rate of HM175/18f. The rate of replication of
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the HM175/18f RNA during the logarithmic growth phase was also slower than that of 
HM175A.2. The ability of HAV to cause cytopathology in BS-C-1 cells may be related 
to the rate of replication as suggested by Lemon er a/. (1991). In order to confirm this 
relationship, the rate of replication of HAV HM175/18f in FRhK-4 cells could be 
studied as this cell line exhibits greater cytopathology on infection with this strain than 
do BS-C-1 cells.
Zhang and colleagues (1995) showed that mutations in the region of wild type HAV 
RNA encoding the protein 2B and 2C resulted in a cytopathic rapidly replicating variant 
and further mutation in the F3 region, particularly 3A resulted in larger cytopathic 
plaque formation. The P2 proteins in which the mutations occur to produce cytopathic 
variants (2B and 2C) are both thought to function in transcription of the viral genome 
and interactions between these 2 proteins may occur during viral replication (Bienz et 
a l, 1990; Cho et a l, 1994; Zhang et a l, 1995). Since the cytopathology HM175/18f is 
specific to FRhK-4 cells, the fact that this virus does replicate in BS-C-1 cells tends to 
suggest that interactions of these proteins with host cell proteins may also be involved 
in the production of cytopathology. Upon passage in a ceU line, the viral proteins may 
mutate in such a way as to interact more efficiently with the proteins specific to that 
cell line. Based on the function of the corresponding protein in poliovirus (Giachetti et 
a l, 1992) the 3 A protein of HAV is thought to be involved in anchoring the genome in 
the endoplasmic reticulum by interaction with VPg and thereby aiding the synthesis of 
progeny RNA. The alteration of proteins involved in transcription may increase the rate 
of RNA replication resulting in cytopathology. Sequencing of the cytopathic variant 
HM175A.2 may help to further characterise the determinants involved in the production 
of cytopathology.
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Whilst the HAV inactivation studies were performed using tissue culture adapted 
strains of the virus* it is the inactivation of the wild type virus in blood products that is 
essential. The adaptation of HAV to growth in tissue culture involves a number of 
mutations as discussed previously. These alterations in the genome of HAV often result 
in attenuation of virulence in the tissue culture ad^ted strains and may also give rise to 
altered characteristics during inactivation or elimination protocols. The degree of 
attenuation of the two tissue culture adapted strains used in this study (HM175A.2 and 
HM175/18f) was investigated. Tamarins, which are susceptible to infection with HAV, 
were inoculated with either the wild type HAV HM175 or the tissue culture adapted 
variants and the progress of disease monitored. The wild type HM175 replicated well in 
the ànimal model and viral RNA was excreted at high levels (up t o l l  log genomes g*^ ). 
Viraemia was also demonstrated in each of the tamarins infected with this virus. 
Histological analysis and measurement of serum ALT levels showed that liver damage 
occurred in each of these tamarins.
The variant HM175/18f also replicated in the animal model but at a lower level with a 
maximum of 6.8 log HAV genomes g'^  detected in the faeces. Subsequently, the degree 
liver pathology and elevation in ALT levels in the tamarins inoculated with this variant 
were lower than with the wild type. Viraemia was not detected in these tamarins. No 
replication or pathology in the animal was detected with the cytopathic virus 
HM175A.2. The adaptation to cytopathic growth in BS-C-1 cells therefore requires 
mutations in the HAV genome which also restrict the replication of the virus to growth 
in vivo, whereas only partial attenuation is seen upon adaptation to cytopathic growth in 
FRhK-4 cells. The use of HAV strains which cause both pathogenesis in vivo and 
cytopathogenicity in tissue culture may be beneficial in determining optimal 
elimination or inactivation procedures for blood products. The development of a
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cytopathic microtitre plate assay for HM175/18f using FRhK-4 cells was not possible 
due to a lack of availability of viable cells. Such an assay would improve the suitability 
of the use of HM175/18f in further viral inactivation or elimination studies.
The detection of total anti-HAV responses in the inoculated animals appeared to be the 
same regardless of which HM175 variant used. The ability of HAV HM175A.2 to elicit 
an antibody response in tamarins with no pathogenic effects would make it a possible 
candidate strain for the production of a live attenuated vaccine. However of further 
study is required in order to determine the suitability of this strain for vaccine use. The 
immune response to HM175A.2 needs to more thoroughly characterised in terms of 
neutralisation ability. Time constraints did not permit assay of sera from inoculated 
animals in order to compare the levels of tissue culture neutralising antibody between 
experimental groups. Further long term studies are also required to determine the 
duration of neutralising antibody levels and the degree of protection achieved should be 
assessed by challenging animals inoculated with the attenuated strain with wild type 
virus. This study has shown that the adaptation of HAV to growth in different cell lines 
results in distinct characteristics in vivo. In the manufacture of vaccines, approved cell 
lines must be used such as Vero or MRC-5 cells. Therefore the virus would need to be 
carefully studied in a suitable cell line for adaptational mutations which may cause a 
reversion to the wild type phenotype.
The vaccination of patients such as haemophiliacs who receive large quantities of 
therapeutic medicines derived from human plasma has been su^ested and 
implemented in some countries following the outbreaks of hepatitis A linked to blood 
products. In the short term, while alternative viral elimination or inactivation methods 
are sought, this option is satisfactory. However, the safety of blood products must be
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assured with regard to other non-enveloped viruses such as parvovirus B19. HAV is an 
ideal virus for use in viral elimination and inactivation studies as tissue culture adapted 
strains can be quantitated both by gene amplification techniques and infectivity assay.
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APPENDICIES
APPENDIX A
Comparison of nested PCR with the single PCR method in determining end point 
dilutions.
Introduction
The variability of amplicon band intensity in the PCR titrations suggested that not all 
cDNA containing samples may give a positive result. A low efficiency of 
visualisation by ethidium bromide stained, agarose gel electrophoresis may result in 
the failure to detect amplification products from those samples containing low copy 
number of cDNA. The apparent end point dilution would in this case be lower than 
the actual end point leading to an under estimation of the concentration of cDNA.
In order to determine whether ethidium bromide stained agarose gel electrophoresis 
of amplified DNA after conventional PCR was sufficient to visualise all positive 
samples, nested PCR was performed In nested PCR, a small quantity of the product 
of conventional PCR is amplified using primers to an internal region of the amphcon. 
This method is not only useful in demonstrating specificity but also allows 
amplification of any PCR product which was not visible after the initial PCR to levels 
which can be clearly seen by ethidium bromide stained agarose gel electrophoresis.
Method
Samples: 1. HAVHM175A.2. StandardCSlOl/95.
2. HAV HM175/18f. Tamarin faecal sample (C13 dl4, see Chapter 6)
RNA was extracted from the samples using the QIAGEN QIAmp kit and reverse 
transcribed using random primers as previously described. The resulting cDNA was 
diluted as follows.
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Table 1. Dilutions of cDNA amplified by PCR
Dilution HM175/18f HM175A.2
(tamarin (PCR
faecal sample Standard
C13dl4) CSlOl/95)
1 1:10 !:!()' s
2 !:!()' : 1:10^
3 1:10^ 1:10^’
Five replicates of each dilution of cDNA (5 pi per replicate), were amplified using 
primers A7a and A8a as described in chapter 2 (p 54-55). After 40 cycles of 
amplification, Ipl of each sample was added to 49 pi nested PCR mixes containing
1.5 mM magnesium chloride, 1.2 U Amplitaq Gold (Roche) and 20 pmoles each of 
primers N1 and N2. Amplitaq Gold was used in the nested PCR as the reaction had 
previously been optimised by Dr. Saldanha using this enzyme.
Nested Primers:
N1 (HAV nt 2754-2775) ACT GCT CTT GGA GCT GTC AGA T (forward)
N2 (HAV nt 3186-3166) CTT CCT GAG CAT ACT TGA GTC (reverse)
Amplification cycles:- 
94 ®C 2 minutes
94 °C 
58 ®C 
68 °C
68 °C
30 seconds 
20 seconds 
30 seconds
7 minutes
} 30 cycles
From the remaining first amplification mix and the amplified nested PCR mixes, 18 p 
1 was run on an ethidium bromide stained 1 % agarose gel.
This comparison was repeated a total of 3 times for each sample.
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Result
Figures 1 and 2 show that the use of nested PCR did not result in amplification of 
products of the first PCR which were not previously visualised by electrophoresis. 
The titres of RNA determined by both the single and nested PCR amplifications are 
shown in Tables 2 and 3 and the mean titres in table 4.
Table 2. Results of single PCR of the PCR standard CSlOl/95 (HM17S A.2) and 
the tamarin faecal sample C13dl4 (HM175/18f).
Number positive / Total number tested Titre
Experiment 1:10 1:10^^ 1:10^ 1:10^* log 
genomes g*
HM175/18f 1 4/5 1/5 1/5 ND 5.55
2 4/5 2/5 1/5 ND 5.64
3 3/5 1/5 2/5 ND 5.59
log
genomes mT*
HM175A.2 1 ND 4/5 3/5 3/5 5.46
2 ND 4/5 4/5 1/5 5.41
3 ND 5/5 4/5 1/5 5.42
Table 3. Results of nested PCR of the PCR standard CS101/9S (HM175 A.2) and 
the tamarin faecal sample C13dl4 (HM175/18f).
Experiment
Number positive / Total number tested Titre 
log 
genomes g*
1:10 1:10^^ 1:10^ 1:10^*
HM175/18f 1 4/5 1/5 1/5 ND 5.55
2 4/5 2/5 1/5 ND 5.64
3 3/5 1/5 2/5 ND 5.59
log
genomw ml*
HM175A.2 1 ND 4/5 3/5 3/5 5.46
2 ND 4/5 4/5 1/5 5.41
3 ND 5/5 4/5 1/5 5.42
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Table 4. Mean titres obtained by single and nested PCR of the PCR standard 
CSlOl/95 (HM175 A.2) and the tamarin faecal sample C13dl4 (HM175/18f).
Mean Titre
Single PCR Nested PCR
RM175/18f (log genomes g^) 5.59 5.59
HM175A.2 (log genomes ml^) 5.43 5.43
Conclusion
The titre of HAV HM175/18f RNA determined by both single round and nested PCR 
were the same as those obtained previously by single round PCR (5.6 log genomes / 
g). This indicates that the efficiency of the single round PCR was not altered in this 
study and that it is unlikely that the use of nested PCR would have improved the 
detection of HAV RNA in the more dilute samples. The efficiency of the single 
round PCR amplification was confirmed with the HM175A.2 PCR standard 
CSlOl/95.
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Figure 1. Example nested PCR of the tamarin faecal sample C13dl4 (HAV
HM175/18f).
a. Single PCR amplification (Primers A7a and A8a)
1 2 3 4 5 6 7 8 9101112131415161718_ 19202122
b) Nested PCR (Primers N1 and N2)
1 2 3 4 5 6 7 8 9101112131415161718 19202122
Samples
1-5 cDNA diluted 1:10 18 Negative control water
6 Negative control water 19-20 Standard CS101 1:10
7-11 cDNA diluted 21^2 Standard CSl 01 1:100
12 Negative control water
13-17 cDNA diluted 1:10^
Calculation of titre
Log titre of HAV RNA = log titre (GLIM analysis) + log (100/8.8^ x 1000/3.5^) + jc 
(log genomes m f’)
= 1.04 + 3.51 + 1 
= 5.55 log genomes g *
 ^Efficiency of reverse transcription (8.8%)
^ Sample size (3 .5 pi o f a 10% suspension of the original sample in the reaction mix)
^  Dilution of faeces (10% suspension)
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Figure 2. Example nested PCR of the PCR standard CSlOl/95 (HAV
HM175A.2).
a. Single PCR amplification (Primers A7a and A8a) 
1 2 3 4 5 6 7 8 91011 12131415161718 19202122
b) Nested PCR (Primers N1 and N2)
1 2 3 4 5 6 7 8 9101112131415161718 19202122
Samples
1-5
6
7-11
12
13-17
cDNA diluted 1:10‘  ^
Negative control water 
cDNA diluted 1:10^ 
Negative control water 
cDNA diluted 1:10^^
18 Negative control water 
19-20 Standard CSlOl 1:10 
21-22 Standard CS 101 1:100
Calculation of titre
Log titre HAV RNA = log titre (GLIM analysis) + log (100/8.8^ x 1000/3.5^) 
(log genomes ml'^)
= 1.95 + 3.51
= 5.46 log genomes ml
Efficiency of reverse transcription (8.8%)
' Sample size (3.5 pi o f the original sample in the reaction mix)
-1
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APPENDIX B - Reagents
General reagents
All chemicals were obtained from Sigma Chemical Co., Poole, UK unless otherwise 
stated
PBSA
171 mM sodium chloride 
3.35 mM potassium chloride
10 mM disodium hydrogen orthophospate anhydrous 
1.84 mM potassium dihydrogen orthophosphate
6 Salt PBS
140 mM sodium chloride 
2.7 mM potassium chloride
20 mM disodium hydrogen orthophospate anhydrous
1.5 mM potassium dihydrogen orthophosphate 
1 mM calcium chloride 
0.5 mM magnesium chloride
Saline A 
137 mM sodium chloride
5.37 mM potassium chloride 
0.1 % glucose
Molecular cloning reagents
Bacterial cell culture media
SOB SOC Luria-Bertani
Broth
bactotryptone 2 % 2 % 1 %
yeast 0 .5% 0.5% a 5  94
sodium chloride 10 mM 10 mM 125 mM
potassium chloride 2.5mM 2.5 mM -
magnesium chloride* 10 mM 10 mM -
magnesium sulphate* 10 mM 10 mM -
glucose** - 20 mM -
*1 M solution autoclaved separately and added to autoclaved SOC prior to use
**2 M solution filter sterilised and added to autoclaved SOC prior to use
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AIX Luria agar plates
1.5 % (w / v) Agar in Luria Bertani 
lOOpgmr^ Ampicillin 
100 mM IPTG
60 jug ml'^ X-gal
Ethidium bromide stained agarose gels 
1 X TAB
1-2 % electrophoresis grade agarose (Ultrapure, Life Technologies)
1 pg ml'* ethidium bromide
The agarose was dissolved in Ix TAB by heating and allowed to cool to 60 °C prior to 
the addition of ethidium bromide.
50 X TAB buffer
2 M tris base
1 M glacial ascetic acid
50 mM ethylenediaminetetraacetic acid (BDTA)
10  X DNA loading buffer
50 % glycerol (molecular biology grade)
5 X TAB
0.1 % bromophenol orange
The 50 % glycerol solution was incubated at 60 °C for 30 min prior to adding acridine 
orange
TB buffer pH 8.0
10 mM tris HCl pH 8.0
1 mM ethylenediaminetetraacetic acid (BDTA)
FSB
10 mM potassium acetate
100 mM potassium chloride
45 mM manganese cloride
10 mM calcium chloride
3 mM colbalt chloride
10 % glycerol
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M olecular weight m arkers 
DNA
1 DNA molecular weight marker III (Boehringer Mannheim, Lewes, UK)
À-DNA cleaved with EcoR I and Hind III 
13 fragments 0.12-21.2 kbp
125,564,831,947, 1375, 1584, 1904, 2027, 3530, 4268, 4973, 5148, 21226 bp
2 PCR markers (Promega Corp., Southampton, UK) 
6 fragments 10-1000 bp
50, 150, 300, 500, 750, 1000 bp
RNA m arkers (Promega Corp., Southampton, UK)
9 RNA fragments 0.28-6.58 kb
281, 623, 955, 1383, 1908, 2604, 3638,4981,6583 b
PCR prim ers (5 prime non-coding region)
57 77
HA 1F 5' -GAC-TTG-ATA-CCT-CAC-CGC-CGT- 3'
312 292
HAIR 5' -AGA-CTC-CTA-CAG-CTC-CAT-GCT- 3'
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APPENDIX C - Abbreviations
ALT alanine aminotransferase
AST aspartate aminotransferase
ATP adenosine triphosphate
BCIP bromochloroindolylphosphate
BMEM buffered Eagles Minimum Essential Medium
BPL Bio Products Laboratories
cDNA complementary strand DNA (produced by reverse transcription)
CNS central nervous system
CPE cytopathic effect
CV coefficient of variation
dATP deoxyadenosine triphosphate
dCTP deoxycytidine triphosphate
dGTP deoxyguanosine triphosphate
DMSO dimethyl sulphoxide
DNA deoxyribonucleic acid
DTT dithiothreitol
dNTPs deoxynucleoside triphosophates
dTTP deoxythymidine triphosphate
EDTA ethylenediaminetetraacitic acid
PCS foetal calf serum
GE genome equivalents
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
HPLC high performance liquid chromatography
ICD Isocitrate dehydrogenase
IgG immunoglobulin G
IgM immunoglobulin M
IE interleukin
IMS industrial methylated spirit
1RES internal ribosomal entry site
ISG immune serum globulin
LD lactate dehydrogenase
MEM Eagles Minimum Essential Medium
NAD nicotinamide adenine dinucleotide
NADH reduced nicotinamide adenine dinucleotide
NBT nitro blue tetrazolamine
NIBSC National Institute for Biological Standards and Control
PBSA phosphate buffered saline A
PCR polymerase chain reaction
PFU plaque forming units
RFU radioimmunofocus forming unit
RIA radioimmunoassay
RIFA radioimmunofocus assay
RIFIT radioimmunofocus inhibition test
RNA ribonucleic acid
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RNAse ribonuclease
RSV respiratory syncytial virus
RT-PCR reverse transcription and PCR
SDS sodium dodecyl sulphate
SNBTS Scottish National Blood Transfusion Service
ssc saline sodium citrate buffer
TCID50 50% tissue culture infectious dose
TCIU tissue culture infectious unit
TNF tumour necrosis factor
UTR untranslated region
UV ultraviolet
WHO World Health Organisation
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